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1. Introduction 
Pancreatic ductal adenocarcinoma (PDAC) continues to be a devastating disease 
due to its unspecific early symptoms, poor prognosis and low survival rates in 
patients. Therefore, a timely diagnosis and effective curative therapies for PDAC 
remain a challenge to this day in the medical field. That is why this type of cancer is 
extremely interesting for scientists as well as oncologists. However, in order to 
investigate this disease further, first it is important to be aware of the anatomy and 
physiology of a healthy pancreas. 
 
1.1 The anatomy and physiology of the pancreas 
In the human organism, the pancreas is located behind the stomach, reaching from 
the duodenum to the spleen. Anatomically, this organ can be subdivided into the 
head, Caput pancreatis, which is located  within the duodenal curve on the right side, 
the body, Corpus pancreatis, and the narrow tail of the pancreas, Cauda pancreatis, 
which extends to the gastric surface of the spleen [1]. 
As in humans, in small animals the pancreas can also be divided into three parts. 
The Corpus pancreatis, which is located next to the pars cranialis duodeni, the Lobus 
pancreatis sinister, which points towards the spleen, and the Lobus pancreatis 
dexter, which is positioned in the Mesoduodenum descendens [2]. 
The pancreas consists of two separate types of glandular tissue with different 
functions: the exocrine and the endocrine pancreas. The function of the exocrine 
section is to produce pancreatic juice that flows into the duodenum and neutralizes 
the HCL from the stomach chymus with the help of production of HCO3
-. This 
digestive juice also contains the precursors of many enzymes that are necessary for 
the digestion of proteins, carbohydrates as well as fat. The endocrine pancreas, also 
known as the islets of Langerhans, produces hormones responsible for the regulation 
of the blood glucose level [3].  
 
 Introduction 
 
16 
 
These physiological processes occurring in the pancreas make it an important organ 
of the human body, but unfortunately, also a target for diseases such as pancreatic 
cancer. 
 
1.2 Tumors of the pancreas 
PDAC is a lethal malignancy with high mortality rates, for example in the USA, PDAC 
is the fourth most common cause of death related to all cancers deaths. In terms of 
cancer incidence it is ranked 11th [4, 5]. Due to medical progress, death rates for other 
common tumors such as cancers of the stomach, lungs, colon and prostate have 
decreased, whereas mortality rates of PDAC have remained the same [4, 5].  
As a result of the malignant transformation of pancreas cells, pancreatic cancer can 
occur in different regions and tissues of this organ. Cancer of the pancreas includes 
tumors of the endocrine tissue, e.g. islet cell carcinoma, as well as tumors of the 
exocrine section of the gland, for example the PDAC that constitutes approximately 
90% of all pancreatic cancers [6]. 
Tumors of the exocrine pancreatic tissue are seldom in animals; when they do occur 
they are most likely found in older cats and dogs. Most of animal tumors are of 
epithelial origin. Adenocarcinomas are the most common and are characterized by 
destructive and infiltrative tumor growth as well as an early metastasis rate in the 
peritoneum, the liver and lymphnodes of the thorax [7, 8]. Below, I will concentrate on 
the etiology and progression of PDAC. 
 
1.3 Etiology and progression of PDAC 
The etiology of PDAC still remains unknown in most aspects. There are different 
triggers discussed that can increase the risk of this disease. 
One of the environmental risk factors that is avoidable is smoking. This can increase 
the chance of getting PDAC up to 30-50 % [9]. Alcohol abuse is a second factor that 
can increase the risk of this disease [10]. Chronic pancreatitis is also determined to 
have a significant influence with a six-fold higher risk [11]. Another discussed cause 
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for PDAC is diabetes mellitus, however so far the exact mechanisms and the 
relationship between these diseases has yet to be determined and remains 
controversial [12]. Several studies also point to a hereditary component. Here, an 
autosomal dominant transmission is often considered. Patients from families with a 
history of this cancer have a predisposition to get the disease and may have at least 
two first-degree relatives that had PDAC. There are estimations that up to 4% of all 
pancreatic cancers are of hereditary origin [13, 14]. 
Due to histological and molecular observations, a multistep progression model is 
suggested for the development of PDAC [15]. The noninvasive precursor lesions in 
the pancreas, known as pancreatic intraepithelial neoplasia (PanIN) [16], share 
molecular alterations and mutations, for example in the oncogene KRAS2 or tumor-
suppressor genes BRCA2 or the TP53, which are described in invasive PDAC [17, 18]. 
Telomere shortening has been determined as an important factor in cell immortality 
and a transformation to cancer as well. This is associated with reactivation of the 
enzyme telomerase in cells with shortened telomeres [19]. Telomere shortening is 
nearly universal in all PanINs, and can result in chromosomal instability, one early 
trigger of carcinogenesis [20].  
The development of PDAC is a slow progression, taking approximately 11.7 years 
from the initiation of tumorigenesis until the first cell of a parental clone is formed, and 
another 6.8 years from the parental clone to the index metastasis [21]. Unfortunately, 
in most patients pancreatic cancer is first diagnosed in the last two years of the entire 
tumorigenic process, partially due to its slow progression, which also results in 
unspecific symptoms. 
 
1.4 Symptoms of PDAC 
Early symptoms of PDAC are disturbed digestion and weight loss. In the advanced 
stages, lesions sometimes invade retroperitoneal nerves which results in abdominal 
and back pain. Later symptoms are stearrhoe and diabetes mellitus [22, 23]. 
Clinical manifestations of the cancer of the pancreas head differ from those located in 
the tail region. The main difference is the frequency of jaundice occurrence and the 
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symptom of a palpable gallbladder hydrops [24]. Most of the tumors are located in the 
head of the pancreas, and therefore cause stricture of the intrapancreatic section of 
the common bile duct, which leads to jaundice with its typical yellow discoloration of 
the skin and sclera [23, 25]. 
Common symptoms of ductal pancreatic adenocarcinoma in small animals are weight 
loss, poor general conditions as well as anorexia. Less often are increased 
weakness, ascites, diarrhea or palpable masses in the cranial abdomen. Jaundice 
can be seen when the cancer induces an obstruction of the extrahepatic bile duct. 
Another symptom described in dogs is pancreatic insufficiency combined with 
maldigestion syndrome [8]. 
Generally, the majority of symptoms become apparent only in advanced stages of 
tumor progression, making an early diagnosis of this disease difficult. 
 
1.5 Diagnosis of PDAC 
Early diagnosis of pancreatic cancer is a decisive factor for the prognosis and the 
chance of a successful treatment. 74% of all PDAC patients die within the first year, 
and about 94% within five years after diagnosis. In cases of small tumors that were 
diagnosed at an earlier tumor stage, these percentages are lower. According to 
current statistics, PDAC has the lowest relative survival rate of all cancers [4, 5].  
Different methods are used in the diagnosis of pancreatic cancer. Nowadays, the 
most common techniques are ultrasound and computer tomography. Advantages of 
ultrasound are that it is simple to use, available and affordable. However, CT 
possesses higher sensitivity compared to ultrasound, and allows a better overview of 
the size and shape of the tumor as well as other affected organs. 
Endoscopic ultrasonography has reported a high sensitivity to also detect tumors the 
size of 10 mm, and  also can be  applied for histological examinations using fine 
needle aspiration [26]. 
Positron emission tomography with labeled fluorodeoxyglucose is another 
established noninvasive imaging method with high sensitivity for the early detection 
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of malignancies such as PDAC. The metabolism of the fluorodeoxyglucose allows an 
early diagnosis of small-sized tumors and the localization of metastasis [27]. 
In the endoscopic retrograde cholangiopancreatography, an endoscopy of the 
oesophagus, the stomach and the duodenum is performed, and both the pancreas 
and bile ducts can be visualized with the help of a contrast agent. This method has a 
high sensitivity at approximately 90%, but a notable issue is that smaller-sized tumors 
may not be identified [23, 28]. Different studies reveal that this method can also be 
used in dogs, but so far remains an exception in the diagnosis of PDAC [29].  
On a molecular level, CA19-9 is a tumor marker that increases and can frequently be 
detected in PDAC patients. This marker is used to trace the progress and 
development of the tumor. However, it is not suitable for a general screening of 
PDAC [24, 30]. 
 
1.6 Therapy of PDAC 
The therapy of PDAC is successful in few patients due to a late diagnosis of this 
cancer and its high metastatic rate. Different types of therapy are commonly used for 
PDAC patients. For the curative treatment of PDAC, surgery is the only known 
potential cure [31]. After complete removal of recognizable tumors, adjuvant therapy is 
applied to combat any unverifiable metastasis, and therefore improves the long-term 
chances of curing tumor patients. Examples for applied adjuvant therapy are 
chemotherapy, radiotherapy or immune therapy. 
Neoadjuvant therapy is defined as the preoperative intervention with the aim to 
convert unresectable tumors to resectable ones due to a volume reduction, or to 
increase the probability of complete microscopic tumor resection [32]. Examples for a 
neoadjuvant therapy are chemotherapy and radiotherapy. 
Palliative treatment is another important therapeutic approach and is considered if a 
cure seems unlikely. Since 80-90% of diagnosed tumors are unresectable due to 
local invasion or metastasis [33], the therapeutic goal here is to improve the life quality 
and overall survival of those PDAC patients. Palliative treatment includes the relief of 
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secondary symptoms caused by gastric obstruction, jaundice and pain, and is 
therefore essential for tumor patients (reviewed in[34]). 
 
1.6.1 Surgical therapy of pancreas cancer 
Surgery represents the only curative therapy for PDAC patients, but because of the 
late diagnosis, surgery is only an option in about 20% of the diagnosed tumors [35]. 
The mortality rate of this operation is relatively low at less than 5% [36]. Nevertheless, 
in patients who have undergone surgery, the median survival rate is still low and 
considered to be less than two years [35]. Approximately 30% of the patients die 
within the first year after this medical intervention [37]. Characteristics such as age, 
tumor size and grade as well as nodal and margin status of the cancer are 
considered to be prognostic factors for the survival rate of patients after resection [38, 
39]. 
There are different methods for the resection of tumors located in the head of the 
pancreas. The standard technique is the partial pancreaticoduodenectomy, according 
to Whipple and Kausch. This resection includes the removal of the head of the 
pancreas, the distal portion of the stomach, the duodenum, gall bladder and of the 
intrahepatic portion of the bile duct together with their associated lymph nodes. Other 
methods are the pylorus-preserving pancreaticoduodenectomy characterized by 
preservation of the stomach and the sphincter muscle, or a total pancreatectomy, 
which is done when the corpus of the pancreas is involved in the lesion. However, 
this method is problematic in the aspect of blood glucose level regulation [23]. 
In small animals like cats and dogs, a resection is often not to be considered because 
of already metastasizing tumors due to the late diagnosis [8]. 
Resection of PDAC can also be combined with adjuvant radiotherapy. The survival 
rate, depending on the recurrence of the tumor, has been evaluated for such 
approaches. However, local recurrence of tumors remains high in these patients [40].  
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1.6.2 Radiotherapy of PDAC 
Radiotherapy is applied on PDAC patients whose tumors are locally advanced, 
unresectable, irregular shaped and large sized. However, the appropriate dose of 
radiation for this type of tumor is difficult to dispense [41].  
The three-dimensional conformal radiotherapy is the most commonly used 
radiotherapy for the treatment of PDAC. With this technique, the profile of each 
radiation beam is adjusted to the exact shape of the tumor. The advantage of this 
method is that the relative toxicity of radiation to the normal surrounding tissue is 
reduced, since the treatment volume conforms to the shape of the tumor. This in turn 
allows for the use of a higher radiation dose specifically for the tumor tissue [42]. 
A second method used is intensity modulated radiation therapy. The distinguishing 
feature of this method is that high radiation doses can be focused on regions within 
the tumor so that the surrounding structures, especially the duodenum, receive 
minimized doses of radiation. Therefore, higher doses can be used with fewer side 
effects. This method is used for PDAC in an early stage and is locally restricted [43]. 
Often the combination of radiotherapy and chemotherapy is applied. Studies have 
revealed an advantage in the survival rate of patients for chemoradiotherapy in 
comparison to radiotherapy on its own, as well as an survival advantage for using 
chemoradiotherapy followed by chemotherapy compared to using chemotherapy 
alone (reviewed in [44]). 
 
1.6.3 Chemotherapy of PDAC 
Treatment with chemotherapeutics is of a great importance, even though it cannot 
lead to a complete cure of patients with pancreatic cancer. Rather it is used to slow 
down the tumor growth or to relieve pain. Chemotherapeutics can be administered 
before resection of tumor tissue as a neoadjuvant chemotherapy, or it can be given 
as adjuvant chemotherapy after surgery to assist the resection and lower the risk of 
recurrence, or it can be used in a palliative setting. 
Often used chemotherapeutics are gemcitabine, a pyramidine analogue, and 5-
fluorouracil (5-FU), which belongs to the group of fluorpyrimidines. 
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Gemcitabine is the current standard chemotherapeutic used for the treatment of 
metastatic or unresectable tumors of the pancreas, either as a monotherapy or in 
combination with other medication [45]. 
Early studies of gemcitabine treatment in patients with pancreatic cancer showed a 
relief in symptoms. In 1997, a clinical benefit response in 23.8% of the patients 
treated with gemcitabine as compared to 4.8% in 5-FU treated patients was 
described. Moreover, the survival rate of 12 months was only 2% in the group of 5-
FU treated patients as compared to 18% in the group of gemcitabine [45]. 
In 2001, a ESPAC 1-plus study showed that a benefit in the median survival was 
achieved in patients receiving 5-FU compared to the no chemotherapy group [46]. 
For the therapy of 5-FU combinations, clinical studies showed a survival benefit in 
humans with PDAC in comparison with no chemotherapy. However, clinical studies 
showed no difference in the survival rate between a treatment of 5-FU combination-
(5-FU, Adriamycin, Mitomycin) and 5-FU monotherapies [47]. 
To date, the very promising setting, FOLFIRINOX, is a combination of different 
chemotherapeutics that has shown to achieve a survival benefit for PDAC patients 
and is considered to be an option for patients with metastatic pancreatic cancer in 
relatively good condition. This combination therapy includes the pharmaceutics 
oxaliplatin, irinotecan, leucovorin and 5-FU. Clinical studies with FOLFIRINOX 
compared to patients treated with gemcitabine demonstrated that the median overall 
survival was 11.1 months in the first group as compared to 6.8 months in the 
gemcitabine group. Another aspect investigated was the objective response rate, 
which was higher in the FOLFIRINOX group (31.6%) as compared to the gemcitabine 
group (9.4%) [48]. 
The above mentioned therapies provide good treatment options, however many 
tumor patients develop resistances to chemo- and radiotherapy. Therefore, 
nowadays it is important to search for advanced treatment approaches. 
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1.6.4 Immune therapy 
In addition to chemotherapy or radiotherapy, immune therapy could present another 
possibility to prolong life and improve the quality of life for pancreatic cancer patients. 
This is why more than 80 immunotherapeutic trials are currently being performed for 
PDAC [49]. 
Immune therapy is intended to modify the performance of the immune system to 
improve its original ability to recognize and eliminate the body's own cancerous cells. 
This can be reached for example by recruiting and activating T cells to recognize 
tumor-specific antigens and therefore achieve a more effective response against 
PDAC to either defeat the tumor or to slow down tumor growth. Immune therapy 
includes different approaches in activating treatment with cytokines such as 
interleukins and interferons (for example interferon alpha (IFNα)), or activating 
antibodies. Another strategy is the blockade of immunological checkpoints. 
Recombinant monoclonal antibodies target tumor-specific antigens and kill the tumor 
cells through delivery of a conjugated cytotoxic agent or by direct lysis (reviewed in [50]). 
Many studies have shown that antibodies are clinically quite successful and can be 
used in diagnosis, as prognostic indicators as well as for the treatment of cancer 
(reviewed in [50]). 
IFNα is one example of immune therapies already being applied in patients suffering 
from cancers like renal cell carcinoma, malignant melanoma or chronic myeloid 
leukemia [51, 52]. IFNα, a type I interferon, is produced by various cell types such as 
monocytes, macrophages, lymphoblastoid cells, fibroblasts and plasmacytoid 
dendritic cells [53]. IFNα can manifest direct suppressive effect on tumor growth in 
vitro and in preclinical medical studies [54]. With its considerable radio- and chemo 
sensitizing effects it is able to improve the impact of other applied therapies like 
radiotherapy or chemotherapy [55, 56]. One example for such a combined therapy was 
shown in an orthotopic mouse model of PDAC. The combination of 5-FU and IFNα 
pointed out an increase in tumor infiltrating NK cells, which also showed enhanced 
cytotoxicity against Panc02 cancer cells. Furthermore, this therapy enhances the 
immunogenicity of pancreatic tumors by the higher expression of MHC class 1 
molecules [57]. Another study showed a prolonged survival when 5-FU chemotherapy 
was combined with IFNα [58]. Moreover, IFNα enhances tumor immunogenicity [59]. 
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Importantly, IFNα is considered to increase the immune response by activation of 
natural killer cells, by augmentation of the differentiation, maturation and function of 
dendritic cells, by induction of CD8+ memory cells as well as by an increase of 
macrophage activity [55, 56, 60, 61]. Although it has been shown that IFNα has 
activating characteristics, a prolonged survival rate has yet to be achieved. 
Moreover, generally the use of immune stimulatory approaches have so far not been 
as promising as expected [50]. The possible reasons for this are described in detail in 
1.8.4. and were previously mentioned as so-called immunological checkpoint 
molecules. 
Immunological checkpoint molecules are inhibitory pathways that fulfill two main 
purposes: they help generate and maintain self-tolerance due to elimination of T cells 
specific for self-antigens, and they restrain the amplitude of T cells to prevent a 
stronger response against foreign pathogens than is necessary. However, they can 
be contra productive for a successful development of anti-tumor immunity. One 
immunological checkpoint is conveyed by the cytotoxic-T-lymphocyte-associated 
protein 4 (CTLA-4) counter-regulatory receptor, which is expressed by activated T 
cells [62]. Another important immunological checkpoint is the molecule B7-H1, which is 
one of the ligands for the PD-1 receptor. B7-H1 is an immunological molecule that is 
expressed on different cell types, like DC, macrophages etc. and is known to have 
suppressive functions on T cells [63]. Moreover, B7-H1 could be found on tumor cells 
and some types of immune suppressive cells. 
Taking together, the immune system can be an attractive therapeutic target in 
pancreatic cancer. However to improve the results of immunotherapy, it is necessary 
to gain a more detailed understanding of the immune system as a whole, covering its 
activation and suppressive aims. 
 
1.7 The immune system 
The immune system represents a complex network composed of several organs, 
different cell types as well as a variety of cytokines and molecules. 
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This system protects the body from damage by infectious agents and other harmful 
substances through a variety of effector cells and molecules, and can be divided into 
the innate and the adaptive system. The innate immune response is always 
immediately available to combat a wide range of pathogens, but does not respond to 
specific pathogens and does not lead to long lasting immunity. The adoptive system 
provides a specific response which requires the recognition of specific "non-self" 
antigens that develop during a lifetime and confers protective immunity to reinfection 
with the same pathogen. 
Taken together, the immune system fulfills several main tasks. It provides 
immunological recognition carried out by lymphocytes and white blood cells, as well 
as immune effector functions, achieved by the complement system of blood proteins, 
antibodies and lymphocytes allowing an elimination of the infection. Beyond that, it is 
involved in processes of immune regulation, such as the ability of self-regulation to 
protect the body from allergies and autoimmune diseases. Furthermore, the immune 
system provides immunological memory, which protects the individual against 
recurring disease and allows for the development of an immediate and stronger 
response against a causing pathogen [64].  
 
1.8 Cells of the immune system 
All cells of the immune system derive from pluripotent hematopoietic stem cells of the 
bone marrow, and then develop into mature cells of either the lymphoid or the 
myeloid lineages. The myeloid lineage comprises most of the cells of the innate 
immune system such as macrophages, granulocytes or dendritic cells, whereas the 
lymphoid lineage is composed of natural killer cells of innate immunity and 
lymphocytes of the adaptive immune system [64]. In following, the cell compartments 
most relevant for this work are described here in detail.  
 
1.8.1 Lymphocytes 
Lymphocytes belong to the leukocytes and are an important component of the 
adaptive immune response. They can be divided into two groups: B lymphocytes (B 
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cells) and T lymphocytes (T cells). Lymphocytes originate in the bone marrow. While 
B lymphocytes mature in the bone marrow as well, precursor T lymphocytes migrate 
for their maturation to the thymus. Mature lymphocytes circulate in the lymph and 
blood, and large numbers of these cells are found in lymphoid tissues or organs. 
Cells that have not yet been activated by antigens represent naive lymphocytes, 
whereas antigen-activated, differentiated and entirely functional cells are known as 
effector lymphocytes. B cells convert into plasma cells after binding of an antigen to a 
B-cell receptor. This plasma cell is the effector form of B cells, which produces and 
secretes antibodies. T cells activated by a specific antigen, differentiate into effector 
T cells and proliferate. Various types of effector T lymphocytes have been described 
that can functionally be associated with either killing, activation or regulation [64]. 
The expression of specific cell surface receptors and functional specialization 
enables additional classification of T lymphocytes. All of them have a TCR/CD3 
complex, crucial for their activation, with a corresponding antigen-MHC 
conglomerate, but only one group of the cells expresses the CD4 molecule (T helper 
cells) whereas the other fraction is characterized by CD8 expression (Cytotoxic T 
cells) [64].  
CD4+ T lymphocytes are also called T helper cells since they have a function of 
assisting and activating other effector cells in the immune system [65]. Two major 
subsets of T helper cells have been described in detail. The first group, Type 1 helper 
cells (TH1), is known to produce IL-2, interferon-gamma (IFN-ɣ) and tumor necrosis 
factor-beta (TNF-ß) and acts in cancer, delayed-type hypersensitivity reactions and 
also activates infected macrophages to become more efficient in killing pathogens or 
cancer cells. Whereas the Type 2 helper cells (TH2) express IL-4, IL-5, IL-6 and IL-
10 and function in stimulating of B cells by antibody production and secretion (reviewed 
in [66]). 
CD8+ T cells fulfill the task of killing infected cells as well as cancer cells. They 
recognize modified cells by binding to their MHC-I-molecule [64] and kill the cells by 
production of perforin and granzymes, which leads to apoptosis of infected cells [67]. 
Furthermore, they secrete IFNɣ, which increases the expression of MHC I molecules 
on other cells [68]. 
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Whereas most cells in a tumor environment or when fighting infection die due to an 
apoptosis, a small proportion differentiates into memory cells. T lymphocytes have 
the ability to differentiate into two different subsets of memory cells: T effector 
memory cells (Tem) and T central memory cells (Tcm), which also can differentiate into 
T effector cells (Teff) after renewed antigen contact and then provide long lasting 
immunity [64, 69, 70]. In the process of T cell activation, an important role is played by 
antigen-presenting cells (APC). One of the most potent APC are dendritic cells. 
1.8.2 Dendritic cells (DC) 
Dendritic cells (DC) arise from lymphoid and myeloid progenitor cells in the bone 
marrow, serve as a messenger between innate and adaptive immunity and represent 
the most efficient inducers of a T cell response. Immature dendritic cells migrate from 
the bone marrow through the bloodstream to enter tissues, and they have the ability 
to phagocyte pathogens. Should they encounter invading microorganisms, they 
mature into cells that are able to migrate to the lymph nodes and to activate 
lymphocytes by presenting pathogen antigens on their surface [64]. The activation 
capacity of DC depends on the expression of the co-stimulatory molecules B7.1 
(CD80) and B7.2 (CD86). These membrane-bound molecules are widely expressed 
on antigen-presenting cells and can interact with the T cell counter receptors CD28 
und CTLA-4 [71, 72]. Additionally, DC can express regulatory molecules, such as B7-
H1, which gives added input to their stimulation capacity.  
There are at least two major groups in which dendritic cells can be categorized: the 
conventional myeloid dendritic cells (cDC), which are involved in antigen presentation 
and activation of naïve T cells, and plasmacytoid dendritic cells (pDC), which are not 
that important for activating naïve Tcells but can produce high amounts of Class I 
interferon [64, 73]. 
Human plasmacytoid and myeloid DC can be characterized as followed: CD11c-/low 
CD123+ CD45RA+ HLA-DR+ and CD11chighCD11blow cells [74]. Plasmacytoid dendritic 
cells in mice are described as CD45R/B220+ CD11c int/low CD11b- whereas 
conventional DC are characterized by the CD11b+ CD11chigh expression [75].  
Thus, the complexity and variety of specific cell populations enables a fast and 
effective immune response, whenever it is necessary. 
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1.8.3. Natural killer cells 
Natural killer cells (NK cells) develop in the bone marrow from the common myeloid 
lymphoid progenitor and circulate in the blood. NK cells are able to kill other cells by 
releasing cytotoxic granules containing cytotoxic granzymes and pore-forming protein 
perforin. Killing is triggered by germline-encoded receptors and therefore NK cells are 
classified as part of the innate immune system because of those invariant receptors. 
Several interferons and cytokines are able to activate NK cells, for example IFNα, 
IFNβ or IL-12 [64] . 
  
 
1.8.4. Immune regulation 
Both the strength and efficiency of the immune response have to be controlled. 
Mechanisms of immune regulation ensure that pathogens can be effectively 
combated without causing autoimmunity and tissue damage. Immune regulation can 
be viewed at different levels, for example on molecular levels and the levels of 
different cytokines and mediators as well as on the cellular level, which is for example 
represented by regulatory T cells (Treg) and myeloid derived suppressor cells 
(MDSC). 
 
1.8.4.1 Regulatory T cells (Treg) 
Regulatory T cells (Treg) can be divided into two subsets: naturally occurring Treg 
(nTreg), and adaptive or inducible Treg (iTreg) (reviewed in [76]). Treg have a capability 
to reduce the immune response by suppressing other cells of the immune system, 
either by direct cell-cell contact or through the production of suppressive cytokines, 
for example restraining the differentiation of naïve T cells to T helper cells [64]. 
nTreg constitute 5-10% of the total CD4+ T cell population in healthy humans as well 
as in mice. These cells are produced in the thymus, then enter the peripheral blood 
circulation and are found in the lymph nodes and the spleen [77]. Treg are the part of 
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CD4-compartment and express the α-chain of the IL-2 receptor (CD25) as well as the 
transcription factor Forkhead-Box-Protein P3 (Foxp3) [25, 64, 78]. 
While in mice Foxp3 represent an unique marker for Treg, in humans the Foxp3 is 
not limited to Treg but is also expressed by activated CD4+ effector T cells [79-81]. 
iTreg differentiate from naïve FoxP3- CD4+ T cells due to the impact of IL-10 but also 
from activated effector T cells [76, 82] undergoing anergy, and can be found in 
increased numbers in some cancers, for example in melanoma or renal cell 
carcinoma [83]. 
Other characteristic surface markers or mediators characteristic for Treg include co-
stimulatory and co-inhibitory molecules like CD28 or cytotoxic T lymphocyte antigen 4 
(CTLA-4), PD-1 as well as several Toll-like receptors and a variety of 
immunosuppressive cytokines such as IL-10 or transforming growth factors (TGF)-ß 
[84-86]. 
Due to their immunosuppressive function, Treg are involved in tumorogenic 
processes. An enrichment of Treg in the tumor environment has been demonstrated 
in several types of cancer, resulting in a suppression of the immune response due to 
the inhibitory effect of released cytokines like TGF-ß and IL-10, or due to direct cell 
contact with the target cell [87-90]. Furthermore, an accumulation of Treg correlates 
with poor prognosis for patients (tumor growth and survival rates) [91, 92]. 
In a PDAC model in mice, it was shown that a tumor environment favors the 
accumulation of regulatory T cells [90]. In this process several mechanisms are 
involved, to include conversion of non-regulatory T cells into Treg or the activation of 
naïve Treg [93, 94]. 
 
1.8.4.2  Myeloid derived suppressor cells (MDSC) 
Another important group of immunoregulatory cells involved in cancer progression 
are myeloid derived suppressor cells (MDSC). MDSC is a heterogeneous group of 
cells that consists of myeloid progenitor cells and immature myeloid cells (IMC) from 
the bone marrow. In healthy individuals IMC quickly differentiate into mature 
granulocytes, macrophages or dendritic cells, but in pathological situations such as 
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infectious diseases, trauma, sepsis or cancer the differentiation into mature cells can 
be blocked, resulting in expansion of MDSC [95]. In humans, MDSC express the 
myeloid marker CD33 but lack the expression of lymphoid markers and some 
markers of maturation, like the MHC-II-molecule HLA-DR [96, 97]. In mice, they are 
characterized by the co-expression of the myeloid-cell lineage differentiation antigen 
Gr-1 and CD11b [98]. Based on the expression of the two epitopes of Gr-1, Ly-6G and 
Ly-6C, the MDSC in mice can be further divided more precisely into two subsets: the 
granulocytic MDSC (gMDSC, CD11b+LY6G+LYC6low) and the monocytic MDSC 
(mMDSC, CD11b+LY6G-LY6Chigh) [99]. 
During pathological situations such as in cancer, the activation of IMCs enhances the 
expression of immune suppressive factors like the reactive oxygen species (ROS), 
arginase 1 (ARG1) and inducible nitric oxide synthase (iNOS), leading to 
augmentation of nitric oxide (NO) production [95]. iNOS plays an important role in the 
MDSC suppressive pathways [100]. One mechanism requires the synergistic 
interaction with ARG1 and the production of super-oxide and NO by iNOS, and a 
second one depends completely on iNOS [101]. 
Previously, L-arginine was known to be the major target of the suppressive activity of 
MDSC. This substrate is metabolized by two enzymes, iNOS and ARG1. Arginase 1 
increases the L-arginine catabolism, which causes a shortage of L-arginine in the 
tumor microenvironment and therefore inhibits T cell proliferation by decreasing their 
expression of the CD3 ζ chains [102] and by inducing T cell apoptosis [103]. 
Nowadays, additional mechanisms of MDSC-provided immune suppression are 
described. One is the production of ROS by MDSCs which can cause oxidative 
stress [104], DNA damage in immune cells of the tumor environment, recruitment of 
MDSCs to the tumor site and preventing the maturation of immature MDSC into DC 
[95, 105, 106].  
Another strategy is the expansion of regulatory T cells. MDSC are able to promote 
the clonal expansion of nTreg as well as the conversion of naïve CD4+ T cells into 
iTreg [107]. 
Both described subsets of MDSC use different mechanisms to suppress T cell 
function: granulocytic MDSC express high levels of ROS and very small amounts of 
NO, whereas monocytic MDSC express high levels of NO and only a little ROS. 
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However, despite their different mechanisms the suppressive capacity of both 
subsets is equal [99].  
Lately, MDSC were also described in dogs as an immunosuppressive cell population 
with the markers CD11blow/CADO48Alow. This population was increased in the 
peripheral blood of tumor-bearing dogs [108]. This population has a 
polymorphonuclear granulocytic character and equates the granulocytic subset of 
MDSC in humans or mice [109]. Beyond that, it is specified that in dogs with advanced 
or metastatic cancer, the fraction of putative MDSC is higher than in healthy dogs or 
in dogs with early-stage, non-metastatic tumors [109] . 
The MDSC can also express several surface molecules such as CD115, CD124 or 
CD80 [99]. Beyond that, as well as some other cells, they can express the important 
immunoregulatory molecule B7-H1 [99]. 
 
1.8.4.3 The B7-H1 molecule 
On a molecular level, the immune suppression is regulated by numbers of 
immunosuppressive molecules, one of them is B7-H1. 
B7-H1 (PD-L1, CD274) is a member of the B7 family. This molecule together with B7-
DC (PD-L2, CD273) acts as a ligand for the programmed death-1 receptor (PD-1). 
PD-1 is induced on monocytes, B cells and T cells during activation and plays a role 
in regulating peripheral tolerance and autoimmunity [63, 110] . 
B7-H1 expression was described on T cells, B cells, DC and macrophages as well as 
on parenchymal cells, including pancreatic islet cells and vascular endothelial cells 
[111]. In contrast, B7-DC is nearly only expressed on the surface of dendritic cells and 
macrophages [110]. Both ligands are considered to participate mainly in the negative 
regulation of the immune system by linking to PD-1 [110].  
As it was demonstrated, B7-H1 can also be expressed on tumor cells, and B7-H1 
promotes tumor growth and induces apoptosis of PD-1 expressing T cells in the 
tumor environment [112]. It is also suggested that the interaction of PD-1/PD-L1 
causes the conversion of Helper 1 T cells into regulatory T cells, which could be an 
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explanation for the increased number of Treg in the tumoral environment where B7-
H1 is strongly expressed [113]. 
Moreover, the engagement of B7-H1 with PD-1 receptors on activated T cells 
promotes the production of IL-10 [112], which has immunosuppressive effects due to 
the inhibition of the IFNɣ and IL-2 cytokines [114, 115]. The expression of B7-H1 in 
cancers like carcinomas of the lung, breast, stomach, kidney and pancreas is 
associated with rapid tumor progession, poor prognosis and higher mortality [116-120]. 
In patients with PDAC, the expression of B7-H1 correlates with the stage of a tumor 
and serum level of the tumor marker CA 19-9 [121]. Additionally, cytokines, like IFNɣ 
can induce negative feedback loops and upregulate the expression of B7-H1 in 
pancreatic cancer tissue; and the concentration of IFNɣ in the pancreatic tumor 
environment correlates with expressed levels of B7-H1 [120]. Together with the data 
received in our group that another activating cytokine can also upregulate B7-H1 
expression [122, 123]+[unpublished observation], this allows one to assume that some 
activating immune therapy approaches could be in part restricted due to undesirable 
B7-H1 expression. 
 
1.9. The goal of this thesis 
In summary, the immune system plays an important role in cancer development and 
progression, also in PDAC. The complicated network of different immunological 
mechanisms can shift the balance in the direction of suppression or attenuation of an 
immune response. Therefore, the analysis of immune cells, their regulatory 
molecules and the understanding of crosslinks between the different cells, as well as 
advanced knowledge about immunological checkpoints are of great importance for 
the development of new treatment approaches of pancreatic cancer. Because of that, 
the aim of this thesis is to analyze the precise role of the B7-H1 expression on cells 
of the immune system with the main focus on MDSC in the context of anti-tumor 
immunity in PDAC. In order to achieve this aim, different experiments in vitro as well 
as in vivo were carried out using a mouse orthotopic model of pancreatic cancer 
using C57BL/6 Wild Type (WT) mice and transgene B7-H1 knockout (KO) mice. 
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2. Material and Methods 
 
2.1 Material 
 
2.1.1 Mice 
In the experiments, two types of mice age 8-12 weeks were used. The C57BL/6 WT 
mice were purchased by Charles River, Sulzbach. The B7-H1 KO mice were 
originally created by Dong and colleagues by homolog recombination in embryonic 
stem cells in a C57/Bl6 background [124] and kindly provided by Dr. Linda Diehl and 
Prof. Percy Knolle. Both types of mice were kept in the animal facility of University 
Heidelberg (IBF, Heidelberg) under specific pathogen-free (SPF) conditions. 
Homozygous B7-H1 KO mice were checked for the KO genotype stability in regular 
intervals. Experiments with animals were carried out after approval by the authorities 
(Regierungspraesidium Karlsruhe).  
 
 
2.1.2 Pancreascarcinoma cells 
The syngeneic ductal pancreatic carcinoma cell line Panc02 was used for the tumor 
cell implantation [125]. 
 
 
2.1.3 Pharmaceutical products 
Pharmaceutical products Manufacturer 
Mouse Interferon Alpha A R&D Systems® 
Isofluran Baxter (Isofluran) Baxter  GmbH 
Ketanest S 25mg/ml (Ketamin) Pfizer AG 
Rimadyl® ad us. vet., Injection 
solution(Carprofen) 
Pfizer AG 
Rompun 2% (Xylazin) Bayer 
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5-FU 50 mg/ml (5 Fluorouracil) medac GmbH 
Tab.2.1.3. 1 Pharmaceutical products 
 
2.1.4 Anti-mouse Antibodies for the flow cytometry 
 
Specifity Conjugate Clone Isotype 
End 
volume in 
µl * 
Manufacturer 
CD62L APC MEL-14 
Rat (Fischer) 
IgG2a, κ 
1 
BD 
Pharmingen 
CD25 APC 3C7 
Rat (Outbred 
OFA) IgG1, λ 
1.5 
BD 
Pharmingen 
CD11c APC HL3 
Armenian 
Hamster IgG1, λ2 
1 
BD 
Pharmingen 
CD115 APC AFS98 Rat IgG2a, κ 1 eBioscience 
Gr-1 
APC- 
Cy 7 
RB6-
8C5 
Rat IgG2b, κ 0.25 
BD 
Pharmingen 
CD3e 
APC- 
Cy 7 
145-
2C11 
Armenian 
Hamster IgG1, κ 
2 
BD 
Pharmingen 
CD44 FITC IM7 Rat IgG2b, κ 0.5 
BD 
Pharmingen 
FoxP3 FITC FJK-16s Rat IgG2a, κ 1 eBioscience 
CD80 FITC 16-10A1 
Armenian 
Hamster IgG2, κ 
1 
BD 
Pharmingen 
F4/80 FITC BM8 Rat IgG2a, κ 1 eBioscience 
Purified 
Arginase-1 
N/A** 
19/Argin
-ase1 
Mouse IgG1 2 
BD 
Pharmingen 
Ig for 
Arginase-1 
FITC N/A** Goat Ig 0,5 
BD 
Pharmingen 
CD45R/ 
B220 
Pacific 
Blue 
RA3-
6B2 
Rat IgG2a, κ 1 
BD 
Pharmingen 
CD45RB PE 16A Rat IgG2a, κ  1 
BD 
Pharmingen 
CD44 PE IM7 Rat IgG2b, κ 1,25 
BD 
Pharmingen 
I-A[b] PE 
AF6-
120.1 
Mouse (BALB/c) 
IgG2a, κ 
0.5 
BD 
Pharmingen 
CD 274 
(B7-H1) 
PE MIH5 Mouse IgG1 3 eBioscience 
CD 273 
(B7-DC) 
PE TY25 Rat IgG2a, κ 3 eBioscience 
Ly-6G PE 1A8 
Rat (LEW/N) 
IgG2a, κ 
0.5 
BD 
Pharmingen 
CD62L PE MEL-14 
Rat(F344) IgG2a, 
κ 
1 
BD 
Pharmingen 
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CD69 PE H1.2F3 
Armenian 
Hamster IgG1, λ3 
3 
BD 
Pharmingen 
CD86 PE-Cy 7 GL1 
Rat (Louvain) 
IgG2a, κ 
1 
BD 
Pharmingen 
CD8a 
PerCP- 
Cy 5.5 
53-6.7 
Rat (LOU/Ws1/M) 
IgG2a, κ 
1 
BD 
Pharmingen 
CD69 
PerCP- 
Cy 5.5 
H1.2F3 
Armenian 
Hamster IgG1, λ3 
1.5 
BD 
Pharmingen 
CD11b 
PerCP- 
Cy 5.5 
M1/70 Rat (DA) IgG2b, κ 1 
BD 
Pharmingen 
FoxP3 
PerCP- 
Cy 5.5 
FJK-16s Rat IgG2a ,κ 2,5 eBioscience 
CD4 V450 RM4-5 Rat (DA) IgG2a, κ 1 BD Horizon 
Ly-6C V450 AL-21 Rat IgM, κ 0.1 BD Horizon 
CD45 V500 30-F11 
Rat (LOU/Ws1/M) 
IgG2b, κ 
2 BD Horizon 
CFSE FITC N/A** N/A** 0,5 µM eBioscience 
CD16/ 
CD32 
N/A** 93 Rat IgG2a, λ 2 eBioscience 
CD28 
Functional
Grade 
Purified 
N/A** 37.51 
Golden Syrian 
Hamster IgG 
2 µl/ml 
medium 
eBioscience 
CD3 
Functional
Grade 
Purified 
N/A** 17A2 Rat IgG2b, κ 
1 µl/ml 
medium 
eBioscience 
Tab.2.1.4. 1 Anti-mouse antibodies for flow cytometry 
* volume pro 2x106 cells/50 µl 
** N/A not applicable 
 
2.1.5 Laboratory Equipment 
Laboratory Equipment Manufacturer 
Bio Vortex V1 Lab-4 you 
Counting chamber Neubauer Improved neoLab Laborbedarf GmbH 
Digital Timer neoLab 
Flow cytometer (FACS) Canto II Becton Dickinson 
Freezer -20°C Liebherr 
Freezer -80°C Thermo Scientific 
GASTIGHT Syringe 25µl Hamilton Company 
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Incubator HeraCell Heraeus 
Wash stations Millipore GmBH 
Luminex® 100/200 System Bio-Rad 
Multipette® plus Eppendorf 
Optical microscope Axiostarplus Zeiss 
Optical microscope Axiovert 25 Zeiss 
Pipette Proline Biohit GmbH 
Pipettes Pipetman Gilson 
Pipetus®-akku Hirschmann Laborgeräte 
Refrigerator 4°C Liebherr 
Scale EW600-2M Kern & Sohn GmbH 
Sterile bench HeraSafe Heraeus 
Vortex Genie 2 Scientific Industries 
Zentrifuge 5810 R Eppendorf 
Tab.2.1.5 1 Laboratory Equipment 
2.1.6 Laboratory consumables 
 
Laboratory consumables Manufacturer 
aluminum foil Roth GmbH 
cell scraper 25 cm Sarstedt 
cell strainer (100 µm, 40 µm) Becton Dickinson 
Combitips Plus (0.1 ml, 0.5 ml, 2.5 ml, 5 ml)   Eppendorf 
Costar® Stripette (5 ml, 10 ml, 25 ml) Corning Incorporated 
Eppendorf Tubes 1,5 ml Eppendorf 
FACS Tubes 5 ml Becton Dickinson 
 Falcon Tubes (15 ml, 50 ml) Becton Dickinson 
Millex sterile filter 33 mm Diameter Millipore 
Microlance Needle 26G x1/2 Becton Dickinson 
Polysorb™ USP 5-0 Covidien AG 
Staple remover Fine Science Tools 
Surgical Skin StaplersReflex 7 mm Fine Science Tools 
Suture Slip Reflex 7 mm Fine Science Tools 
Syringe 50 ml B.Braun 
 Material and Methods  
 
37 
 
Syringe 5 ml Becton Dickinson 
Syringe 1 ml B.Braun 
Transferpipettes 3 ml Becton Dickinson 
Well Plates (6-well, 96-well) Becton Dickinson 
Tab.2.1.6. 1 Laboratory consumables 
 
2.1.7 Laboratory solutions 
Laboratory solutions Manufacturer 
Collagenase III Biochrom AG 
Collagenase IV Biochrom AG 
DNAse I Roche 
Dulbecco`s PBS Solution (10x) PAA Laboratories GmbH 
EDTA 0.5 M; pH 8.0 SERVA Electrophoresis GmbH 
Foxp3 Staining Buffer Set eBioscience 
HBSS Buffer PAA Laboratories GmbH 
Hyaluronidase Linaris GmbH 
H-Insulin Aventis Pharma AG 
RBC Lysis Buffer(10x) BioLegend 
RPMI 1640 PAA Laboratories GmbH 
Trypan Blue 0.5 % Biochrom AG 
Tab.2.1.7. 1 Laboratory solutions 
 
 
 
 
2.1.8 Media and Buffers 
 
2.1.8.1 Buffers for the flow cytometry 
Stain Buffer: 
- 1x PBS buffer solution  + 2 mM EDTA  
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Fixation buffer for intracellular FACS-Staining: 
- 1:4 Dilution of Fixation/Permeabilization Concentrate (eBioscience) + 
Fixation/Permeabilization Diluent (eBioscience) 
Wash buffer for intracellular FACS-Staining ("Perm-Wash"): 
- 1:10 Dilution of  Permeabilization Buffer (eBioscience) + distilled H20 
 
2.1.8.2 Medium, buffer and solutions for the cell culture 
Wash buffer for the cell culture: 
- PBS buffer (1x), sterile 
Medium for the cell culture: 
- RPMI 1640 + 10 % Fetal Calf Serum (heat-inactivated at 56°C for 30 min)  
Interferon stock solution 
- Mouse IFNα stock solution was purchased from R&D Systems® and was used 
for the treatment of cultures in a concentration of 1000U/ml. 
5-FU stock solution 
- The original stock solution was purchased from Medac. For the treatment of 
cultures it was used in a concentration of 65 µg/ml. 
 
CFSE stock solution 
- The CFSE (Carboxyfluorescein Succinimidyl Ester) Proliferation Dye was from 
eBioscience, and originaly reconstituted to 10 mM with DMSO. For the titration 
the concentrations of 0.25 µM, 0.5 µM and 1.0 µM were tested. The most 
suitable concentration of 0.5 µM was used for cell labeling.  
Digestion solution 
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- The components of this solution are: 0.05 mg/ml DNAse I, 0.24 mg/ml 
Collagenase III, 0.56 mg/ml Collagenase IV, 0.2 mg/ml Hyaloronidase, 0.08 
U/ml H-Insulin in HBSS Buffer. Aliquots were made and stored at -20°C. 
 
2.1.8.3 Buffer for MACS 
MACS Buffer 
- 1x PBS buffer solution + 0.5 % bovine serum albumin + 2 mM EDTA 
 
2.1.9 Software 
Software Manufacturer 
Bio-Plex Manager 4.0 Bio-Rad 
EndNote X6 Thompson Reuters 
FlowJo (Version 7.6.1) Diva Tree Star 
GraphPad PRISM (Version 5) GraphPad Software 
Tab.2.1.9. 1 Software 
 
 
 
2.2 Methods 
2.2.1 Orthotopic mouse model 
Mice were anesthetized by inhalation anesthesia. For the induction, Isoflurane in the 
concentration of 5 Vol% was used together with 95 Vol% of oxygen. The 
maintenance of the status was achieved by using 3.5 Vol% Isoflurane and 96.5 Vol% 
of oxygen. Bepanthen eye ointment was used to protect the eyes from desiccation. 
Also 50 µl Rimadyl (5 mg/kg s.c., 1:10 diluted with 0.9 % NaCl) was injected 
preoperatively for pain relief/analgesia. 
Tumor cells (Panc02) in a concentration of 2x107/ml were diluted in PBS and a 
volume of 5 µl was injected using a GASTIGHT Syringe (25 µl). The mice were 
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fixated in dorsal position, then the abdomen and substernal region were shaved, 
disinfected with alcohol and cut open in the linea alba to prevent heavy bleeding. 
After dislocation of the pancreas, Panc02 cells were implanted. Following the 
implantation a forceps was used to clamp the point of injection for 30 seconds and 
then the pancreas was located back to its original position. 
After those steps, the abdomen was stitched in two-layers by continuous sutures. For 
both sutures an absorbable polyfil needle-thread combination (Polysorb 5-0 rounded 
needle) was used. Besides that, the skin was also stapled with clamps that were 
removed 10 days after the surgery.  
 
2.2.2 Treatment of the mice with IFNα, with 5-FU or with the combination of   
IFNα+5-FU 
For treatment, the mice received therapeutics at Day 5, 7 and 9 after the surgery. 
The mice were injected intraabdominally with 50 µl of either IFNα or 5-FU. The group 
of mice which got the combined therapy received 50 µl of IFNα and 50 µl of 5-FU. 
The injection solution of IFNα was diluted to a concentration of 2x105/ml. For the 5-
FU treatment the concentration of 14 mg/ml was prepared. 
After four weeks the mice were killed by cervical dislocation. In cases of acute 
suffering incompatible with animal health and welfare, the mice were killed 
beforehand. Criteria for this were a bad general state of health like scrubby hair, 
hypothermia or refusing the food intake, apathy, icterus, ascites or an abnormal 
posture as well as a high loss of weight. 
 
2.2.3 Preparation of tumors and spleens, collecting blood samples 
Four weeks after the implantation of Panc02 cells, the mice were killed by cervical 
dislocation. If serum was needed, the mice were first anesthetized by Ketamin-
Xylazin and blood samples were taken directly by heart puncture. Afterwards, the 
mice were killed by cervical dislocation. 
Spleens and tumors were dissected and kept in PBS for further use. The size of 
pancreatic tumors was determined using a slide vernier caliper. 
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Additionally, the abdomen was examined for the presence of metastasis in the liver, 
intestines and peritoneum as well as any adhesions or abnormalities. The size of the 
metastasis was graded from + to +++. 
After they were allowed to clot, the blood samples were centrifuged at 6000 g for 25 
min. The clear serum supernatant was centrifuged again at 9300 g for 10 min. 
Afterwards the serum was frozen at -20°C until it was analyzed by Luminex 
approach. 
 
Fig.2.2.3. 1 Photos of blood sample collection, dissection and measuring of organs 
 
2.2.4 Preparation of a single-cell suspension 
To prepare a single-cell suspension from spleen and tumor, tissue was pressed 
through a 100 µm cell strainer and flushed with 10 ml of PBS to collect as many cells 
as possible. Then the samples were centrifuged at 4°C, 400 g, 5 min and the 
supernatant was discarded. After adding 1 ml of erythrolysis buffer, the samples were 
resuspended and incubated for 2 min. As a result, the erythrocytes were destroyed 
and an unspecific binding to antibodies was prevented. Following this incubation 
time, 10 ml of PBS was added to stop erythrolysis. After another centrifugation step 
(4°C, 400 g, 5 min) the cells were resuspended in 10 ml of PBS and flowed through a 
40 µm cell strainer. The tumor samples passed through the 40 µm cell strainer twice, 
since tumor cells are generally more likely to generate clumps. Subsequent to 
another centrifugation, the cell number was detected by using trypan blue and a 
Neubauer counting chamber. Finally the cell concentration was adjusted to the 
requested concentration of 2x106 cells/50 µl [126]. 
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2.2.5 Flow cytometry 
Flow cytometry is a method that can be used to determine cells based on their 
characteristics of size (FSC- Forward Scatter), granularity (SSC- Side Scatter) and 
intensity of antibody-bound fluorescence. Flow cytometry is also called FACS 
(“Fluorescence activated cell sorting”) and is based on an antigen-antibody reaction 
using fluorescence conjugated antibodies. The cells are excited by a laser and the 
emitted signals are transformed into an electrical signal that can be recorded and 
analyzed. 
Prior to the measurement of the samples, compensation was made to minimize the 
overlap of fluorescence spectra, produced by different types of fluorescence. The 
principle of this compensation is to measure the single fluorescence-coupled 
antibodies separately, to calculate the overlap and to compensate for it. 
 
2.2.5.1 Immunophenotyping 
The splenocytes and tumor cells were stained with different antibody combinations in 
several panels to enable a detailed look at the individual cell populations. In tumor-
bearing mice, CD45 was used to differentiate between tumor cells (CD45-) and 
tumor-infiltrating leucocytes (CD45+). CD4/CD8 panel: CD4/CD8 T cells as well as 
their subsets, naïve T cells (CD62L+CD44-), effector T cells (CD62L-CD44-), central 
memory T cells (CD62L+CD44+), and effector memory T cells (CD62L-CD44+) were 
analyzed. DC panel: in this panel the following subsets, conventional DC 
(CD11chighCD11b+, cDC) and plasmacytoid DC (CD11cintCD45R+, pDC) were 
characterized, and the expression of MHC-II molecules (I-A[b]) or B7-H1 molecules 
(B7-H1) on their surface was investigated. The activation state of the dendritic cells 
was verified by the expression of CD80 and CD86 costimulatory molecules. For the 
analysis of suppressive cell population, the Treg panel was used as well as the 
MDSC panel. Treg panel: in the Treg panel the T regulatory cells were gated as 
Foxp3+CD25+ within the CD4 T cell population. MDSC panels: in the panels for 
MDSC it was first gated on total MDSC (CD11b+Gr-1+) and this population was 
further divided in two subsets. The granulocytic MDSC are characterized as Ly-
6ClowLy-6G+ and the monocytic MDSC as Ly-6ChighLy-6G-. To test functional status of 
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MDSC, the expression of Arginase-1 (Arg-1) and inducible Nitric Oxide Synthase 
(iNOS) was examined. 
 
2.2.5.2 Extracellular staining 
First, the cells were incubated for 10 min with 1 µl of anti-CD16/CD32 in order to 
inhibit unspecific binding of antibodies by the Fc-receptors. Afterwards, 50 µl of the 
cell suspension was plated in 96-well plates, the appropriate antibodies for cell 
surfaces molecules were added to each well and incubated for 15 min at 4°C in the 
dark. After this incubation the samples were washed twice with 200 µl of stain buffer. 
In between and afterwards the samples were centrifuged and the supernatant was 
discarded. After the washing steps the cells were resuspended in 100 µl stain buffer 
and then transferred to FACS tubes already containing 300 µl stain buffer. The tubes 
were stored on ice until they were analyzed on the BD Canto II Flow cytometer. 
 
2.2.5.3 Intracellular staining 
For intracellular staining it is necessary that the cells are fixated and permeabilisated 
so the antibodies are able to bind to the intracellular antigen. First, extracellular 
staining with non-conjugated antibodies was performed and the cells were fixed with 
1 ml of the Fixation/Permeabilisation Buffer. The samples were then incubated for at 
least 3 hours at 4°C avoiding light. Afterwards, two washing steps with 2 ml of 
Permeabilisation Buffer were performed. The centrifuge was set at 4°C, 400 g, 5 min. 
After those washing steps the intracellular and also the conjugated extracellular 
antibodies were pipetted to the samples. The reason for this is that conjugated 
extracellular antibodies are more instable than non-conjugated and therefore could 
easily fall apart throughout the fixation. Finally, after two more washing steps with 
Permeabilisation Buffer, the cells were resuspended in 300 µl of stain buffer and 
analyzed on the BD FACS Canto II.  
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2.2.6 Treatment of splenocytes in culture 
After preparation of a single-cell suspension of the spleen cells, they were 
resuspended in the medium (RMPI 1640+10% FCS) in the concentration of 2x106 
cells/ml. Afterwards, the cells were plated using a 6-well plate with 5ml per well and 
incubated at 37°C for 1 hour in order to allow them to recover before treatment. After 
this the cultures were treated either with IFNα in the concentration of 1000 U/ml or 5-
FU in the concentration of 65 µg/ml or the combination of IFNα+5-FU. Some of the 
wells were left as vehicle controls with 5 µl PBS. After an incubation time of 24 hours 
at 37°C in the incubator, the cells were harvested by using a gentle scraper. Finally, 
the cells were prepared for FACS staining following the usual staining protocol. 
 
2.2.7 Investigation of MDSC suppressive activity 
In order to investigate whether the MDSC have a suppressive effect on the 
proliferation of splenocytes, these cells had been cocultured in different 
constellations. CFSE (Carboxyfluorescein succinimidyl ester) labeled splenocytes 
from either WT or B7-H1 KO mice were plated with or without the activation with 
CD3/CD28. Afterwards, MDSC from WT or B7-H1 KO mice were added to the 
splenocytes. 
2.2.7.1 CFSE cell labeling of splenocytes 
In order to trace proliferative capacity of splenocytes, they were labeled with CFSE. 
CFSE is a marker for proliferation and cell tracking and is able to cross the intact cell 
membranes. The cell division can be seen because only half of the fluorescence 
intensity is found in the next cell generation. 
CFSE in the optimized concentration of 0.5 µM was added to the single cell 
suspension of splenocytes, then the samples were incubated for 10 min at room 
temperature protected from light. To stop the labeling process, first 5 volumes of 
complete cold medium was added and the samples were incubated on ice for 
another 5 min. Afterwards, the samples were washed 3 times with a cold medium. 
The washing steps were always carried out as followed: 4°C, 400 g, 5 min. After this, 
the splenocytes were put in cell culture. 
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2.2.7.2. Digestion of tumors 
Digestion solution (see 2.1.8.2.) was used to digest the tumors and therefore reduce 
their stickiness, in particular of the more necrotic tumor regions. First, the isolated 
tumors were cut into small pieces and incubated in 5 ml of the digestion solution at 
37°C in the water bath with the shaker function. Afterwards, the tumors were treated 
in the usual way using the FACS protocol.  
 
2.2.7.3 Magnetic activated cell sorting (MACS) 
The MACS separation was used to isolate the MDSC from the tumor cell suspension 
according to manufacturer instructions. The basic principle of MACS is that specific 
cell fractions can be magnetically labeled due to the expression of specific receptors. 
Thus, during the isolation procedure positive cells will remain on the column due to 
the magnetic field while the negative cells flow through. Afterwards, the positive cells 
can be removed with a plunger. The MDSC subpopulations are characterized by the 
differential expression of Ly-6G and Ly-6C cell surface. In our case first Gr-1highLy-
6G+ cells can be magnetically labeled by Anti-Ly-6G-Biotin antibody and Anti-Biotin 
MicroBeads. Therefore, the first flow through is pre-enriched in Gr-1dimLy-6G- cells. 
Afterwards, this first flow through is magnetically labeled with Anti-Gr-1-Biotin 
antibodies and Streptavidin MicroBeads, which allows for isolating Gr-1dimLy-6G- cells 
by positive selection. 
The samples for isolation were prepared as a single-cell suspension. After the first 
centrifugation step (4°C, 300 g, 10 min) the cells were resuspended in MACS buffer. 
Then, a FcR Blocking Reagent was added. Afterwards, the samples were vortexed 
and incubated in the refrigerator for 10 min. Anti-Ly-6G-Biotin antibody was added, 
the cells were mixed again and incubated in the refrigerator for another 10 min. Then 
the cells were washed with MACS buffer and centrifuged at 4°C, 300 g, 10 min. The 
supernatant was discarded and the cells were resuspended in an appropriate amount 
of buffer. Afterwards, Anti-Biotin MicroBeads were added to the samples, followed by 
an incubation step of 15 min at 4°C. After another washing step, the cells were 
centrifuged and resuspended in MACS buffer in order to pass through the column. 
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The LS Column was first placed in the magnetic field of the MACS Seperator and 
rinsed with MACS buffer. The cell suspension ran through the column and the flow-
through was collected. After three washing steps, all flow through were combined 
with the flow through of unlabeled cells and this suspension of unlabeled cells (pre-
enriched of Gr-1dimLy-6G-) were labeled in a second step. 
The positive cells from the column were removed from the outside magnetic field 
using the MACS buffer and a plunger. 
To increase the purity of Gr-1highLy-6G+ cells, the cells were allowed to pass through 
once more using a new column.  
In the second step, the cells from the first flow through were labeled with Anti-Gr1-
Biotin antibody and incubated for 10 min. Afterwards, the samples were washed with 
MACS buffer, and after another centrifugation, the supernatant was discarded. After 
resuspending the cells in MACS buffer, Streptavidin Micro Beads were added. 
Another 10-min incubation step and one washing step followed. Finally, the cells 
were resuspended in an appropriate amount of MACS buffer. 
For this isolation, an MS Column was used. The cell suspension was applied on the 
column and washed three times with buffer. Then the Gr-1dimLy-6G- cells were 
flushed out of the column by using the plunger. 
Again to increase the purity of Gr-1dimLy-6G- cells they were run through a new 
second column. 
 
2.2.7.4 Coculture 
For the cocultures, 96-well round bottom plates were used. The CFSE labeled 
splenocytes were seeded in a concentration of 2x105/200 µl Medium and the MDSC 
in a concentration of 2x105/50 µl Medium. To activate the cells, CD3 antibody           
(1 µl/ml) and CD28 antibody (2 µl/ml) were used as activation stimuli and were added 
to the appropriate wells 1 hour after the cells were plated. 
After an incubation time of 72 hours at 37°C, the medium supernatant was collected 
and stored at -20°C until it was analyzed by the Luminex approach. The cells were 
harvested and the cell concentration was adjusted to 2x106/50 µl. Afterwards, the 
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cells were stained with appropriate antibodies and their fluorescence was measured 
by flow cytometry on the BD FACS Canto II.  
 
2.2.8 Luminex (Bioplex) assay 
Samples of collected sera and culture supernatants were analyzed by Luminex assay 
for the presence of the following cytokines: IL-6, IFNɣ, IL-10, IL-1ß, IL-2 and VEGF 
by 6plex with magnetic beads and TGF-ß1 with non-magnetic beads.  
According to the manufacturer instructions, the samples were centrifuged at 800 g for 
5 min to allow debris to deposit at the bottom of the Eppendorf tube.  
The plates were first prewashed with wash buffer and shacked off for 10 min at room 
temperature followed by removing the buffer using a magnetic (for magnetic beads) 
or the vacuum (for non-magnetic beads) wash stations. 
Afterwards, the following reagents were added: Assay buffer to background and 
sample wells, serum matrix to background, standard and control wells, standard to 
the appropriate standard wells and the quality controls to the control wells. Then the 
samples were added to the relevant wells. The samples used for the TGF-ß1 
detection were treated with HCL and NaOH prior to plating. Finally, the appropriate 
beads were added to each well. The plate was sealed and placed on the plate shaker 
at 4°C overnight. 
On the next day, all contents were removed and the plates washed twice with buffer. 
Afterwards, the Detection antibody was added to each well for 1 hour. The secondary 
antibody, Streptavidin-Phycoerythrin was directly added to each well and incubated 
for another 30 min. After two washing steps, Sheath fluid was added to each well and 
the plates were measured by the Luminex® 100/200 System.  
 
2.2.9 Statistical analysis 
All statistical analyses were performed using GraphPad Prism Version 5.01. 
Distributions of continuous variables were described by standard error of mean, 
SEM, median, 25% and 75% percentiles, and were presented as box-and-whiskers 
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plots or as column bar graphs. D’Agostino and Pearson omnibus normality tests were 
conducted to estimate the distribution of data. The null hypothesis (mean values were 
equal) versus the alternative hypothesis (mean values were not equal) was tested for 
more than two groups by one-way ANOVA with the Dunnett’s post-hoc test, and for 
two groups by unpaired, two-tailed t-test for normal distributed variants or by the 
Mann-Whitney test for nonparametric distributed data. Survival analysis was done 
with Kaplan-Meyer curves and statistically analyzed with the Log-rank test. All 
statistical tests were two-tailed. The significance level was α=5%. 
 
 Results 
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3.  Results 
 
3.1 Effects of chemo (5-FU) - and immunotherapy (IFNα) on the 
constellation of leukocyte subsets and on the expression of B7-
H1/B7-DC molecules on splenocytes of healthy WT and B7-H1 KO 
mice in in vitro cultures 
 
In this experiment series we wanted to investigate whether 5-FU and IFNα could 
directly influence the frequency and phenotype of leukocytes subsets in healthy WT 
and B7-H1 KO mice. Moreover, we wanted to examine if this could be also 
accompanied by a direct effect on B7-H1 or B7-DC expression in the different 
leukocytes subpopulations of WT and B7-H1 KO mice respectively. To achieve this, 
we isolated splenocytes of healthy WT and B7-H1 KO mice and treated them in a 
culture with either 5-FU, IFNα or the combination of IFNα+5-FU. After incubation for 
24 hours, we collected the cells, analyzed them by flow cytometry and compared WT 
and B7-H1 KO mice in terms of the constellation of different immune cells as well as 
the expression of the B7-H1/B7-DC molecules. 
 
3.1.1 Analysis of CD4+/CD8+ T cells 
First, we took a look at the frequency of lymphocytes in all live cells. In all treatment 
groups as well as in the control group, the percentage of lymphocytes was 
significantly lower in WT mice than in B7-H1 KO mice (Fig.3.1.1.1 A). By looking at 
WT and B7-H1 KO separately, no significant difference was seen between controls 
and the therapy groups, neither in WT nor B7-H1 KO mice (Fig.3.1.1.1 B,C). 
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Fig.3.1.1. 1 Quantification of lymphocytes from WT and B7-H1 KO mice in control groups 
(without treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-
FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
standard error of mean (SEM) (n = 16; *p<0.05, **p<0.01; control group vs. treatment groups; two-way 
(A) and one-way (B,C) ANOVA) 
 
 
In a second step, we determined the frequency of T cell populations, CD4+ T cells 
and CD8+ T cells, out of CD3+ cells. The performed gating strategy for the CD4/CD8 
panel in this in vitro experiment is shown in Fig.3.1.1.2., the FACS data (dot-plot, 
histogram) represent one typical result out of four independent experiments. 
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Gating Strategy for CD4+/CD8+ T cells 
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Fig.3.1.1. 2 Gating strategy for CD4
+
/CD8
+
 T cells in splenocytes using flow cytometry. 
Lymphocytes were gated out using FSC/SSC dot plot. Next, the CD3
+
cells were selected and the 
CD4
+
/CD8
+
 T cells were gated out from CD3
+
 cells. Furthermore, the CD4
+
/CD8
+
 T cells were divided 
into naïve T cells (Tnaive), effector T cells (Teff), effector memory cells (Tem) and central memory 
cells (Tcm). The activation status of different subpopulations was determined by analyzing the 
expression of the CD69 early activation marker. All positive gates were set according to FMO controls. 
 
Concerning the CD4+ T cells, a significantly higher frequency of CD4+ T cells out of 
CD3+ cells was seen in the treatment groups of 5-FU and IFNα+5-FU in WT 
compared to B7-H1 KO mice. In control and IFNα treated groups, only a tendency 
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towards an increase in CD4+ T cells was seen (Fig.3.1.1.3 A). No significant 
difference was determined between control and treatment groups for both WT and 
B7-H1 KO mice, when investigated separately (Fig.3.1.1.3 B,C). 
 
Fig.3.1.1. 3 Quantification of CD4
+ 
T cells from WT and B7-H1 KO mice in control groups 
(without treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-
FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; *p<0.05; control group vs. treatment groups; two-way (A) and one-way (B,C) ANOVA) 
 
We also looked at the activation status of CD4+ T cells by analyzing the expression of 
the CD69 early activation marker. WT and B7-H1 KO showed no significant 
difference in their activation status when compared with each other (Fig.3.1.1.4 A). 
By looking at WT mice in detail, the expression of CD69 was higher in IFNα and 
IFNα+5-FU treatment groups as compared to the control. Between control and the 5-
FU treatment group, no significant difference was recognized (Fig.3.1.1.4 B). In B7-
H1 KO, a significant increase of CD69 expression was found in the treatment groups 
of IFNα and IFNα+5-FU compared with control (Fig.3.1.1.4 C). Considering the MFI 
(mean fluorescent intensity) for CD69 on CD4+ T cells, a significant difference was 
found between WT and B7-H1 KO in the treatments with IFNα and IFNα+5-FU 
(Fig.3.1.1.4 D). In WT mice, a significantly lower CD69 MFI was recorded in the 
group of IFNα+5-FU compared to control (Fig.3.1.1.4 E). However, in cells of B7-H1 
KO mice no significant difference was seen (Fig.3.1.1.4 F). 
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Fig.3.1.1. 4 Quantification of CD69 expression on CD4
+
T cells from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD69
+
 CD4
+
 T cells together with the MFI of CD69 was analyzed by flow cytometry. Data from four 
independent experiments are presented as column bar graphs with SEM (n = 16; 
*p<0.05,**p<0.01,***p<0.001; control group vs. treatment groups; two-way (A,D) and one-way 
(B,C,E,F) ANOVA ) 
 
Next, we examined the individual subsets of CD4+ T cells (Tnaive, Teff, Tem, Tcm) 
and their activation status based on CD69 expression. In WT mice, the percentage of 
naïve cells was significantly higher in the control as well as in all treatment groups 
compared to B7-H1 KO (Fig.3.1.1.5 A). Between the treatments and control in the 
WT group, no significant change in percentage of Tnaive could be shown (Fig.3.1.1.5 
B). For the B7-H1 KO mice in the groups of IFNα and IFNα+5-FU, a significant 
increase in percentages of Tnaive was registered compared with the control group 
(Fig.3.1.1.5 C). 
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Fig.3.1.1. 5 Quantification of naïve CD4
+
T cells from WT and B7-H1 KO mice in control groups 
(without treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-
FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; **p<0.01, ***p<0.001; control group vs. treatment groups; two-way (A) and one-way 
(B,C) ANOVA) 
 
The second subset we analyzed was the population of effector T cells (Teff) out of all 
CD4+ T cells. The statistical analysis showed a tendency towards higher percentages 
of Teff in the B7-H1 KO groups in comparison to WT (Fig.3.1.1.6 A). By looking at 
WT groups separately, no significant difference was seen between control and 
treatment groups (Fig.3.1.1.6 B). For B7-H1 KO groups, a significant increase in Teff 
frequency was found in the 5-FU group compared to control (Fig.3.1.1.6 C). 
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Fig.3.1.1. 6 Quantification of effector CD4
+
T cells from WT and B7-H1 KO mice in control 
groups (without treatment, co) and after the treatment of splenocytes in in vitro cultures with 
IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; *p<0.05; control group vs. treatment groups; two-way (A) and one-way (B,C) ANOVA) 
 
 
Contemplating the activation status of CD4+ Teff cells, no significant difference was 
measured between WT and B7-H1 KO mice (Fig.3.1.1.7 A). Analyzing the different 
treatments of WT compared to control, significantly higher percentages of CD69+ Teff 
were achieved in the groups of IFNα and IFNα+5-FU (Fig.3.1.1.7 B). Also in the 
groups of B7-H1 KO mice, significantly higher frequencies of activated Teff were 
found after treatment with IFNα and IFNα+5-FU compared to control (Fig.3.1.1.7 C). 
For the MFI of CD69 on Teff, no significant difference was seen between WT and B7-
H1 KO mice (Fig.3.1.1.7 D). Furthermore, no significant change in the value of CD69 
MFI was found between treatment groups and control by looking at WT and B7-H1 
KO mice separately (Fig.3.1.1.7 E,F). 
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Fig.3.1.1. 7 Quantification of CD69 expression on effector CD4
+
T cells from WT and B7-H1 KO 
mice in control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD69
+
 effector CD4
+
 T cells together with the MFI of CD69 was analyzed by flow cytometry. Data 
from four independent experiments are presented as column bar graphs with SEM (n = 16; 
*p<0.05,**p<0.01; control group vs. treatment groups; two-way (A,D) and one-way (B,C,E,F) ANOVA) 
 
 
For the subset of effector memory cells (Tem) within the CD4+ T cell population, we 
observed significantly higher percentages of Tem in B7-H1 KO compared to WT 
mice, both in the control and in all treatment groups (Fig.3.1.1.8 A). Between the 
treatment groups of WT mice, no significant difference was determined for the 
frequency of CD4+ Tem (Fig.3.1.1.8 B). Within the groups of B7-H1 KO mice, 
significantly lower percentages of Tem were found in the treatment groups of IFNα 
and IFNα+5-FU compared to control (Fig.3.1.1.8 C). 
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Fig.3.1.1. 8 Quantification of effector memory CD4
+
T cells from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; *p<0.05, ***p<0.001; control group vs. treatment groups; two-way (A) and one-way (B,C) 
ANOVA) 
 
The analysis of CD69+ cells out of CD4+ Tem revealed a tendency to lower 
percentages in all four groups of WT as compared to B7-H1 KO (Fig.3.1.1.9 A). 
When looking at the WT groups in detail, significantly higher levels of CD69+Tem 
were observed in IFNα and IFNα+5-FU groups compared to controls (Fig.3.1.1.8 B). 
In the B7-H1 KO, a significant increase of CD69 expression was found after the 
treatment with IFNα and IFNα+5-FU compared to control (Fig.3.1.1.9 C). The 
analyzed MFI of CD69 revealed no significant difference between control and 
treatment groups of WT and B7-H1 KO (Fig.3.1.1.9 D). By looking at WT and B7-H1 
KO separately, significantly higher values of CD69 MFI were determined for the 
groups of IFNα and IFNα+5-FU compared to controls in both WT and B7-H1 KO mice 
(Fig.3.1.1.9 E,F). 
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Fig.3.1.1. 9 Quantification of CD69 expression on effector memory CD4
+
T cells from WT and 
B7-H1 KO mice in control groups (without treatment, co) and after the treatment of splenocytes 
in in vitro cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD69
+
 effector memory CD4
+
 T cells together with the MFI of CD69 was analyzed by flow 
cytometry. Data from four independent experiments are presented as column bar graphs with SEM (n 
= 16; *p<0.05,**p<0.01,***p<0.001; control group vs. treatment groups; two-way (A,D) and one-way 
(B,C,E,F) ANOVA) 
 
 
The last analyzed fraction of CD4+ T cells were the central memory cells (Tcm). The 
percentages of this cell population were significantly higher in the control and all 
therapy groups in B7-H1 KO compared to WT mice (Fig.3.1.1.10 A). In WT, the 
differences between control and treatment groups were not of significance 
(Fig.3.1.1.10 B), whereas in B7-H1 KO mice, significantly lower frequencies of Tcm 
were determined for all treatment groups compared to control (Fig.3.1.1.10 C). 
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Fig.3.1.1. 10 Quantification of central memory CD4
+
T cells from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; *p<0.05, **p<0.01; control group vs. treatment groups; two-way (A) and one-way (B,C) 
ANOVA) 
 
As indicated by investigation of CD69 expression, the activation status of Tcm cells 
was similar between the groups of WT and B7-H1 KO mice (Fig.3.1.1.11 A). By 
looking at WT in detail, significantly higher percentages of activated cells were 
determined for IFNα and IFNα+5-FU groups compared to control (Fig.3.1.1.11 B). In 
B7-H1 KO, such a significant increase in frequency of activated cells was also found 
in the treatment groups of IFNα and IFNα+5-FU compared to control (Fig.3.1.1.11 C). 
The statistical analysis showed no significant difference between WT and B7-H1 KO 
for the different treatments in respect of CD69 MFI (Fig.3.1.1.11 D). Besides, in WT, 
no significant difference between control and treated groups was determined for the 
MFI of CD69 (Fig.3.1.1.11 E). Instead, for groups of B7-H1 KO mice, significant 
differences in the values of CD69 MFI were seen between control and IFNα, IFNα+5-
FU groups (Fig.3.1.1.11 F). 
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Fig.3.1.1. 11 Quantification of CD69 expression on central memory CD4
+
T cells from WT and 
B7-H1 KO mice in control groups (without treatment, co) and after the treatment of splenocytes 
in in vitro cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD69
+
 central memory CD4
+
 T cells together with the MFI of CD69 was analyzed by flow cytometry. 
Data from four independent experiments are presented as column bar graphs with SEM (n = 
16;**p<0.01,***p<0.001; control group vs. treatment groups; two-way (A,D) and one-way (B,C,E,F) 
ANOVA) 
 
Afterwards, we took a closer look at the CD8+ T cells. For this cell population, gated 
out of CD3+ lymphocytes, the comparison between WT and B7-H1 KO groups 
showed no significant difference between the control and treatment groups of both 
mouse strains (Fig.3.1.1.12 A). In WT, no significant difference in CD8+ T cell 
frequency was seen between control and treatment groups (Fig.3.1.1.12 B), whereas 
in the B7-H1 KO groups, a significant decrease was found in 5-FU treated cells 
compared to the control (Fig.3.1.1.12 C). 
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Fig.3.1.1. 12 Quantification of CD8
+ 
T cells from WT and B7-H1 KO mice in control groups 
(without treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-
FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; *p<0.05; control group vs. treatment groups; two-way (A) and one-way (B,C) ANOVA) 
 
Next we analyzed the activation status of CD8+ T cells by measuring the expression 
of the CD69 early activation marker. The comparison between WT and B7-H1 KO 
showed no significant difference for the controls and treatment groups (Fig.3.1.1.13 
A). In both, WT and B7-H1 KO groups, significantly higher frequencies of CD69+ 
CD8+ T cells were observed after IFNα and IFNα+5-FU treatment compared to the 
control (Fig.3.1.1.13 B,C). The MFI of CD69 revealed significantly lower values in the 
control and 5-FU treatment group of B7-H1 KO compared to the same groups of WT 
(Fig.3.1.1.13 D). For the control and treatment groups of WT mice, no significant 
difference in the value of CD69 MFI was determined (Fig.3.1.1.13 E). Between 
control and IFNα treatment group of B7-H1 KO, a significant increase in CD69 MFI 
was found after the treatment (Fig.3.1.1.13 F). 
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Fig.3.1.1. 13 Quantification of CD69 expression on CD8
+ 
T cells from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD69
+
 CD8
+
 T cells together with the MFI of CD69 was analyzed by flow cytometry. Data from four 
independent experiments are presented as column bar graphs with SEM (n = 16;**p<0.01,***p<0.001; 
control group vs. treatment groups, two-way (A) and one-way (B,C) ANOVA) 
 
Afterwards, we looked at the four subsets of CD8+ T cells in more detail: Tnaive, Teff, 
Tem and Tcm as well as their activation status were analyzed. We observed 
significantly lower percentages of naïve CD8+ T cells in all four groups of B7-H1 KO 
compared to WT cells (Fig.3.1.1.14 A). By looking at WT and B7-H1 KO separately, 
no significant differences in the frequency of naïve CD8+ T cells were seen between 
the treatments and control in both WT and B7-H1 KO groups (Fig.3.1.1.14 B,C).  
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Fig.3.1.1. 14 Quantification of naïve CD8
+ 
T cells from WT and B7-H1 KO mice in control groups 
(without treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-
FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; ***p<0.001; control group vs. treatment groups; two-way (A) and one-way (B,C) ANOVA) 
 
Assessing the percentage of Teff out of the CD8+ T cell population, we detected a 
tendency towards higher values of these cells in all of the B7-H1 KO groups 
compared to WT (Fig.3.1.1.15 A). By looking at WT and B7-H1 KO separately, 
increased CD8+ Teff frequencies were observed in the group of 5-FU compared to 
control in both WT and B7-H1 KO (Fig.3.1.1.15 B,C). 
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Fig.3.1.1. 15 Quantification of effector CD8
+ 
T cells from WT and B7-H1 KO mice in control 
groups (without treatment, co) and after the treatment of splenocytes in in vitro cultures with 
IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; *p<0.05, **p<0.01; control group vs. treatment groups; two-way (A) and one-way (B,C) 
ANOVA) 
 
 
The analysis of the activation status of Teff revealed significantly higher frequencies 
of CD69+ cells in all groups of B7-H1 KO cells compared to WT groups (Fig.3.1.1.16 
A). For WT, increased percentages of CD69+ Teff were measured in IFNα and 
IFNα+5-FU treatment groups compared to control (Fig.3.1.1.16 B). In B7-H1 KO 
groups, significantly higher percentages of CD69+ cells were found after IFNα 
treatment compared to control, whereas the CD69 expression was significantly lower 
in the group of 5-FU treatment in comparison to control (Fig.3.1.1.16 C). The MFI of 
CD69 expression on CD8+Teff had lower values in B7-H1 KO groups compared to 
WT groups. This result is highly significant for all samples, except for controls where 
only a tendency was determined (Fig.3.1.1.16 D). Between the control and therapy 
groups of WT, no significant difference in CD69 MFI was found (Fig.3.1.1.16 E). For 
the groups of B7-H1 KO cells, significant increase in MFI values were registered in 
IFNα and IFNα+5-FU treatment groups compared to the control (Fig.3.1.1.16 F). 
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Fig.3.1.1. 16 Quantification of CD69 expression on effector CD8
+ 
T cells from WT and B7-H1 KO 
mice in control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD69
+
 effector CD8
+
 T cells together with the MFI of CD69 was analyzed by flow cytometry. Data 
from four independent experiments are presented as column bar graphs with SEM (n = 16; 
*p<0.05,**p<0.01,***p<0.001; control group vs. treatment groups; two-way (A,D) and one-way 
(B,C,E,F) ANOVA) 
 
 
As far as Tem, we saw significantly higher Tem frequencies in the groups of B7-H1 
KO compared to WT groups (Fig.3.1.1.17 A). When looking at the WT in detail, 
significantly higher percentages of CD8+ Tem were measured in the treatment group 
of 5-FU compared to the control (Fig.3.1.1.17 B). In the B7-H1 KO groups, no 
significant differences in percentages of Tem were seen between the control and 
treatment groups (Fig.3.1.1.17 C). 
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Fig.3.1.1. 17 Quantification of effector memory CD8
+ 
T cells from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; *p<0.05, **p<0.01,***p<0.001; control group vs. treatment groups; two-way (A) and one-
way (B,C) ANOVA) 
 
When analyzing the expression of CD69 on Tem, no significant difference in the 
frequency of CD69+ Tem was determined between cells of all WT and B7-H1 KO 
groups (Fig.3.1.1.18 A). In both WT and B7-H1 KO mice, a significant increase in 
activated CD8+ Tem cells was measured in the treatment groups of IFNα and 
IFNα+5FU compared to the controls (Fig.3.1.1.18 B,C). The MFI of CD69 showed a 
significantly higher value in the 5-FU WT group compared to the same group of B7-
H1 KO cells (Fig.3.1.1.18 D). In WT, significantly higher values in CD69 MFI were 
seen in the group of 5-FU treatment compared to the control (Fig.3.1.1.18 E). 
Whereas in the groups of B7-H1 KO, no significant difference in CD69 MFI was noted 
between the control and treatment groups (Fig.3.1.1.18 F). 
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Fig.3.1.1. 18 Quantification of CD69 expression on effector memory CD8
+ 
T cells from WT and 
B7-H1 KO mice in control groups (without treatment, co) and after the treatment of splenocytes 
in in vitro cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD69
+
 effector memory CD8
+
T cells together with the MFI of CD69 was analyzed by flow cytometry. 
Data from four independent experiments are presented as column bar graphs with SEM (n = 16; 
*p<0.05,***p<0.001; control group vs. treatment groups; two-way (A,D) and one-way (B,C,E,F) 
ANOVA) 
 
Tcm were the last analyzed subset of CD8+ T cells. The comparison between WT 
and B7-H1 KO groups showed significantly higher frequencies of CD8+ Tcm in the 
controls, IFNα and IFNα+5-FU groups of B7-H1 KO. In the treatment group of 5-FU, 
a tendency towards higher percentages was found in cells of B7-H1 KO mice 
(Fig.3.1.1.19 A). In the WT groups, no significant difference between the treatments 
and the control was observed (Fig.3.1.1.19 B). In the B7-H1 KO group, IFNα 
treatment significantly increased the percentages of Tcm, and 5-FU significantly 
decreased Tcm frequencies compared to the control (Fig.3.1.1.19 C). 
effector memory cells
co IFNa 5-FU IFNa + 5-FU
0
2
4
6
WT
KO
***
**
***
**
%
 o
f
C
D
8
+
T
 c
e
ll
s
wild-type
co IFNa 5-FU IFNa + 5-FU
0.0
0.5
1.0
1.5
*
e
ff
e
c
to
r
m
e
m
o
ry
C
D
8+
T
 c
e
ll
s
,
%
 o
f
C
D
8
+
 T
 c
e
ll
s
B7-H1 KO
co IFNa 5-FU IFNa + 5-FU
0
2
4
6
e
ff
e
c
to
r 
m
e
m
o
ry
 C
D
8
+
T
 c
e
ll
s
,
%
 o
f
C
D
8
+
 T
 c
e
ll
s
CD69
+
co IFNa 5-FU IFNa + 5-FU
0
10
20
30
40
WT
KO
%
 o
f
e
ff
/m
e
m
C
D
8
+
T
 c
e
ll
s
wild-type
co IFNa 5-FU IFNa + 5-FU
0
10
20
30
40 ***
***
C
D
6
9
, 
%
 o
f
e
ff
/m
e
m
C
D
8+
T
 c
e
ll
s B7-H1 KO
co IFNa 5-FU IFNa + 5-FU
0
10
20
30
40
*** ***
C
D
6
9
, 
%
 o
f
e
ff
/m
e
m
C
D
8
+
T
 c
e
ll
s
CD69
+
of eff/mem CD8
+
T cells
co IFNa 5-FU IFNa + 5-FU
0
1000
2000
3000
4000
WT
KO
***
M
F
I
wild-type
co IFNa 5-FU IFNa + 5-FU
0
1000
2000
3000
4000
*
C
D
6
9
 M
F
I 
o
f
e
ff
/m
e
m
C
D
8+
T
 c
e
ll
s B7-H1 KO
co IFNa 5-FU IFNa + 5-FU
0
500
1000
1500
2000
2500
C
D
6
9
 M
F
I 
o
f
e
ff
/m
e
m
C
D
8+
T
 c
e
ll
s
A                                                              B                                                            C
A                                                              B                                                            C
D                                                               E                                                              F
 
 Results 
 
  
 
69 
 
 
Fig.3.1.1. 19 Quantification of central memory CD8
+ 
T cells from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; **p<0.01,***p<0.001; control group vs. treatment groups; two-way (A) and one-way (B,C) 
ANOVA) 
 
When analyzing the activation status of CD8+ Tcm, significantly higher percentages 
of CD69+ Tcm were found in the IFNα and IFNα+5-FU treatment groups of B7-H1 KO 
compared to those groups of WT. For controls and 5-FU groups, a tendency towards 
decreased cell numbers was seen in the B7-H1 KO group compared to WT 
(Fig.3.1.1.20 A). Taking a closer look at the WT and B7-H1 KO separately, 
significantly higher percentages of CD69+ Tcm were observed in the groups of IFNα 
and IFNα+5-FU compared to controls in both WT and B7-H1 KO mice (Fig.3.1.1.20 
B,C). The statistical analysis of the MFI of CD69 on Tcm revealed no significant 
difference between the groups of WT and B7-H1 KO cells (Fig.3.1.1.20 D). Also 
between the treatment groups and the control of either WT or B7-H1 KO, no 
significant change in values of CD69 MFI was determined (Fig.3.1.1.20 E,F).   
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Fig.3.1.1. 20 Quantification of CD69 expression on central memory CD8
+ 
T cells from WT and 
B7-H1 KO mice in control groups (without treatment, co) and after the treatment of splenocytes 
in in vitro cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD69
+
 central memory CD8
+
 T cells together with the MFI of CD69 was analyzed by flow cytometry. 
Data from four independent experiments are presented as column bar graphs with SEM (n = 16; 
**p<0.01,***p<0.001; control group vs. treatment groups; two-way (A) and one-way (B,C) ANOVA) 
 
 
Taken together, our main findings for the CD4+/CD8+ T cells were higher frequencies 
of lymphocytes in spleens of B7-H1 KO mice compared to WT mice. Furthermore, in 
spleens of B7-H1 KO mice we found higher ratios of Tem and Tcm throughout all 
treatments compared to spleens of WT mice. In the treatment groups of IFNα and 
IFNα+5-FU, higher concentrations of activated CD69+ cell populations were found 
throughout the entire experiment series in both mouse strains, WT and B7-H1KO. 
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3.1.2 Analysis of regulatory T cells (Treg) 
After analyzing the CD4+ and CD8+ T cells, we decided to next take a detailed look at 
an important subset of the CD4+ T cells, the regulatory T cells (Treg). As well we 
analyzed their non-regulatory counterparts, Tcon and activated Tcon. The gating 
strategy for these cell populations is presented in Fig.3.1.2.1. The FACS data (dot-
plot) represent one typical result out of four independent experiments. 
 
Fig.3.1.2. 1 Gating strategy for regulatory T cells and Tcon in splenocytes using flow 
cytometry. 
The first gate was set on lymphocytes using FSC/SSC dot plot; afterwards CD4
+
Tcells were 
determined. Out of this cell population Treg, Tcon, activated Tcon were determined using CD25 and 
FoxP3 expression. 
 
The percentages of Treg out of all CD4+ T cells were significantly higher in all 
treatment groups and in the control of B7-H1 KO mice compared to WT groups 
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(Fig.3.1.2.2 A). Analyzing WT and B7-H1 KO groups separately, no significant 
difference in frequencies of Treg was found between control and treatment groups, 
neither in WT nor in B7-H1 KO (Fig.3.1.2.2 B,C). 
 
 
Fig.3.1.2. 2 Quantification of Treg from WT and B7-H1 KO mice in control groups (without 
treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-FU and 
IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; *p<0.05, **p<0.01; control group vs. treatment groups; two-way (A) and one-way (B,C) 
ANOVA) 
 
For the Tcon population out of CD4
+
 T cells, no significant differences in frequencies 
were seen between WT and B7-H1 KO groups (Fig.3.1.2.3 A). Also by taking a 
detailed look at WT and B7-H1 KO groups, in both there were no significant 
differences in the percentages of Tcon measured between the control and treatment 
groups (Fig.3.1.2.3 B,C). 
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Fig.3.1.2. 3 Quantification of Tcon from WT and B7-H1 KO mice in control groups (without 
treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-FU and 
IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; control group vs. treatment groups; two-way (A) and one-way (B,C) ANOVA) 
 
 
Analyzing the frequencies of activated Tcon out of all CD4+ T cells, no significant 
difference was determined between the groups of WT and B7-H1 KO (Fig.3.1.2.4 A). 
In WT, between the control and treatment groups, no significant difference in the 
frequency of activated Tcon was seen (Fig.3.1.2.4 B). The analysis of the groups of 
B7-H1 KO splenocytes revealed no significant change in percentages of activated 
Tcon between the therapies and the control (Fig.3.1.2.4 C). 
 
Fig.3.1.2. 4 Quantification of activated Tcon from WT and B7-H1 KO mice in control groups 
(without treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-
FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards the cells were stained with fluorescence labeled specific antibodies and analyzed by 
flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; control group vs. treatment groups; two-way (A) and one-way (B,C) ANOVA 
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To summarize, our analysis of the Treg population revealed higher frequencies of 
Treg in spleens of B7-H1 KO mice compared to WT spleens, independent of the 
applied therapy. 
 
3.1.3 Analysis of dendritic cells (DC) 
Another analyzed cell population were the dendritic cells (DC) with their two subsets, 
conventional DC (cDC) and plasmacytoid DC (pDC). The gating strategy for the DC 
panel is shown in Fig.3.1.3.1. The FACS data (dot-plot, histogram) represent one 
typical result out of four independent experiments. 
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Fig.3.1.3. 1 Gating strategy for dendritic cells in splenocytes using flow cytometry. 
The first gate was set on all live leukocytes cells using FSC/SSC dot plot. Then the two subsets of DC, 
conventional DC (cDC) and plasmacytoid DC (pDC), were gated according to the expression of 
CD11c and either CD11b or CD45R markers. The I-Ab antibody was used to define the maturation 
status of cDC and pDC. Mature cDC and pDC were further analyzed for the expression of CD80 and 
CD86 costimulatory as well as the expression of B7-H1/B7-DC regulatory molecules. All positive gates 
were set according to FMO controls. 
 
First, we analyzed the percentages of cDC out of all live cells. By comparing WT and 
B7-H1 KO groups to each other, we saw that no significant difference in percentages 
of cDC occurred (Fig.3.1.3.2 A). Furthermore, we showed that in both WT and B7-H1 
KO mice, significantly lower frequencies of cDC were measured in the IFNα 
treatment group compared to control (Fig.3.1.3.2 B,C). When looking at the pDC, no 
significant differences in percentages of pDC were found between the groups of WT 
and B7-H1 KO (Fig.3.1.3.2 D). In WT, no significant change in frequencies of pDC in 
the treatment groups compared to control was determined (Fig.3.1.3.2 E). Also in the 
groups of B7-H1 KO, the difference in pDC ratio between the treated groups and the 
control was of no significance (Fig.3.1.3.2 F). 
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Fig.3.1.3. 2 Quantification of cDC and pDC from WT and B7-H1 KO mice in control groups 
(without treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-
FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; *p<0.05; control group vs. treatment groups; two-way (A,D) and one-way (B,C,E,F) 
ANOVA) 
 
 
Furthermore, we analyzed the maturation status of cDC and pDC with the help of the 
I-Ab antibody. In the cDC population, the analysis of the maturation status revealed 
no significant difference between WT and B7-H1 KO throughout all groups 
(Fig.3.1.3.3 A). In WT and B7-H1 KO on their own, no significant difference was seen 
between the treatment groups compared to controls in both WT and B7-H1 KO mice 
(Fig.3.1.3.3 B,C). The analysis of the maturation status of the pDC population 
revealed no significant change in percentages between WT and B7-H1 KO groups 
throughout all treatments (Fig.3.1.3.3 D). Also between control and treatment groups 
of either WT or B7-H1 KO mice, no significant difference in the frequency of mature 
pDC was determined (Fig.3.1.3.3 E,F). 
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Fig.3.1.3. 3 Quantification of mature cDC and pDC from WT and B7-H1 KO mice in control 
groups (without treatment, co) and after the treatment of splenocytes in in vitro cultures with 
IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; control group vs. treatment groups; two-way (A,D) and one-way (B,C,E,F) ANOVA) 
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separately, we saw a significant increase in CD80 MFI values in all treatment groups 
of WT compared to the control group (Fig.3.1.3.4 E). In the groups of B7-H1 KO 
mice, significantly higher values were observed between control and 5-FU, IFNα+5-
FU treatment groups (Fig.3.1.3.4 F). 
 
 
Fig.3.1.3. 4 Quantification of CD80 expression on mature cDC from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD80
+
 mature cDC together with the MFI of CD80 was analyzed by flow cytometry. Data from four 
independent experiments are presented as column bar graphs with SEM (n = 16; 
*p<0.05,**p<0.01,***p<0.001; control group vs. treatment groups; two-way (A,D) and one-way 
(B,C,E,F) ANOVA) 
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B7-H1 KO groups, no significant change in frequencies of the CD86+ mature cDC 
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was determined between treatment groups and controls (Fig.3.1.3.5 B,C). The 
analysis of CD86 MFI revealed no significant difference in all subgroups between the 
groups of WT and B7-H1 KO (Fig.3.1.3.5 D). However, in the groups of WT mice, 
significantly higher values of CD86 MFI were measured in the groups of IFNα and 
IFNα+5-FU compared to the control (Fig.3.1.3.5 E). In B7-H1 KO groups, a significant 
increase of the CD86 MFI was revealed after the treatment of the cells with IFNα and 
IFNα+5-FU compared to the control (Fig.3.1.3.5 F). 
 
 
Fig.3.1.3. 5 Quantification of CD86 expression on mature cDC from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD86
+
 mature cDC together with the MFI of CD86 was analyzed by flow cytometry. Data from four 
independent experiments are presented as column bar graphs with SEM (n = 16; 
*p<0.05,**p<0.01,***p<0.001; control group vs. treatment groups; two-way (A,D) and one-way 
(B,C,E,F) ANOVA) 
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As presented in Fig.3.1.3.6 A, a tendency towards higher percentages of CD80+ 
mature pDC was seen in all subgroups of WT compared to those of B7-H1 KO 
groups. The groups of WT and B7-H1 KO, when investigated separately, showed no 
significant difference between control and treatment groups, neither in WT nor in B7-
H1 KO (Fig.3.1.3.6 B,C). Concerning the MFI of CD80 on mature pDC, we found no 
significant difference in values when we compared WT groups toB7-H1 KO groups 
(Fig.3.1.3.6 D). In the groups of WT mice, no significant changes in the values of the 
CD80 MFI were determined between treatment groups and control (Fig.3.1.3.6 E). In 
the B7-H1 KO groups on their own, significantly higher CD80 MFI values were found 
for IFNα and IFNα+5-FU groups compared to the control (Fig.3.1.3.6 F). 
 
 
Fig.3.1.3. 6 Quantification of CD80 expression on mature pDC from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD80
+
 mature pDC together with the MFI of CD80 was analyzed by flow cytometry. Data from four 
independent experiments are presented as column bar graphs with SEM (n = 16; *p<0.05; control 
group vs. treatment groups; two-way (A,D) and one-way (B,C,E,F) ANOVA) 
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For the frequencies of CD86+ cells among mature pDC, no significant difference was 
seen between the groups of WT and B7-H1 KO mice (Fig.3.1.3.7 A). Beyond that, in 
WT and B7-H1 KO groups on their own, no significant difference in frequencies of 
CD86+ mature pDC was determined between the single treatment groups and the 
control in both the WT and B7-H1 KO groups (Fig.3.1.3.7 B,C). The analysis of CD86 
MFI on mature pDC revealed significantly lower values in cells of B7-H1 KO for the 
groups of IFNα, 5-FU and IFNα+5-FU compared to those groups of WT. For the 
control of WT and B7-H1 KO, a tendency towards lower values in B7-H1 KO was 
observed (Fig.3.1.3.7 D). In WT, the MFI of CD86 was significantly increased after 
IFNα and IFNα+5-FU treatment compared to control (Fig.3.1.3.7 E). In B7-H1 KO, 
significantly higher intensity values of CD86 MFI were found in the group of IFNα 
treatment compared to control (Fig.3.1.3.7 F).  
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Fig.3.1.3. 7 Quantification of CD86 expression on mature pDC from WT and B7-H1 KO mice in 
control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of CD86
+
 mature cDC together with the MFI of CD86 was analyzed by flow cytometry. Data from four 
independent experiments are presented as column bar graphs with SEM (n = 16; *p<0.05,***p<0.001; 
control group vs. treatment groups; two-way (A,D) and one-way (B,C,E,F) ANOVA) 
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by DC. Therefore, the next aspect we were interested in was the expression of B7-H1 
regulatory molecules on mature cDC and pDC in the cells of WT mice, respectively 
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treatment groups and the control (Fig.3.1.3.8 B). When assessing the B7-DC 
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(Fig.3.1.3.8 C). The MFI of B7-DC expression on mature cDC was increased in the 
group of 5-FU compared to the control (Fig.3.1.3.8 D). 
 
Fig.3.1.3. 8 Quantification of B7-H1/B7-DC expression on mature cDC from WT and B7-H1 KO 
mice in control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of B7-H1/B7-DC
+
 mature cDC together with the MFI of B7-H1/B7-DC was analyzed by flow cytometry. 
Data from four independent experiments are presented as column bar graphs with SEM (n = 16; 
*p<0.05,**p<0.01; control group vs. treatment groups; one-way (A-D) ANOVA) 
 
Analysis of the B7-H1/B7-DC expression on mature pDC is demonstrated in 
Fig.3.1.3.9. In WT mice, no significant difference in the frequency of B7-H1+ mature 
pDC between control and treatments groups was registered (Fig.3.1.3.9 A). The 
analysis of the MFI of B7-H1 expression on mature pDC, showed that the values 
were not significantly different between the controls and therapy groups (Fig.3.1.3.9 
B). In the groups of B7-H1 KO mice, we determined no significant differences in the 
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B7-DC expression on mature pDC between the control and treatment groups 
(Fig.3.1.3.9 C). For the B7-DC MFI values, we saw no significant differences between 
treatment groups and control (Fig.3.1.3.9 D). 
 
Fig.3.1.3. 9 Quantification of B7-H1/B7-DC expression on mature pDC from WT and B7-H1 KO 
mice in control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The frequency 
of B7-H1/B7-DC
+
 mature pDC together with the MFI of B7-H1/B7-DC was analyzed by flow cytometry. 
Data from four independent experiments are presented as column bar graphs with SEM (n = 
16;control group vs. treatment groups; one-way (A-D) ANOVA) 
 
Taken together, the data of the examined DC cell populations did not show 
significant differences in the frequencies of cDC, pDC, as well as their activation 
status between spleens of healthy WT or B7-H1 KO mice. Beyond that, the analysis 
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mature cDC in spleens of B7-H1 KO mice after the IFNα, IFNα+5-FU treatment 
compared to the control.  
 
3.1.4 Analysis of Gr-1+CD11b+ cells 
The last analyzed cell population in this in vitro experiment was the population of Gr-
1+CD11b+ cells, which corresponds to myeloid derived suppressor cells (MDSC) in 
tumor-bearing mice. 
The gating strategy for this panel is shown in Fig.3.1.4.1. FACS data (dot-plot, 
histogram) represent one typical result out of four independent experiments. 
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Fig.3.1.4. 1 Gating strategy for Gr-1
+
CD11b
+
 cell population in splenocytes using flow 
cytometry. 
The first gate was set on leukocytes using FSC/SSC dot plot; afterwards, the Gr-1
+
CD11b
+
 cell 
population was gated. From this population furthermore the expression of the molecule B7-H1 in WT, 
B7-DC in B7-H1 KO was analyzed using histograms. All positive gates were set according to FMO 
controls. 
 
First, we analyzed the frequency of Gr-1+CD11b+ cells out of all leukocytes. When 
comparing the groups of WT and B7-H1 KO mice with each other, only for the group 
with the 5-FU treatment, could a significant difference be seen with decreased 
percentages of Gr-1+CD11b+ cells in the 5-FU group of B7-H1 KO mice (Fig.3.1.4.2 
A). If we just looked at the treatment groups of WT, no significant difference was 
determined between the different treatment groups and control (Fig.3.1.4.2 B). For 
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the groups of B7-H1 KO, there were also no significant differences seen between the 
control and treatment groups (Fig.3.1.4.2 C). 
 
 
Fig.3.1.4. 2 Quantification of Gr-1
+
CD11b
+
 cells from WT and B7-H1 KO mice in control groups 
(without treatment, co) and after the treatment of splenocytes in in vitro cultures with IFNα, 5-
FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies and analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs with 
SEM (n = 16; **p<0.01; control group vs. treatment groups; two-way (A) and one-way (B,C) ANOVA) 
 
 
We furthermore determined the MFI of B7-H1 respectively of B7-DC expression on 
Gr-1+CD11b+cells. In groups of WT mice, the MFI of B7-H1 did not show a significant 
difference in values between control and treated groups (Fig.3.1.4.3 A). For the 
groups of B7-H1 KO mice, no significant differences in values of the MFI of B7-DC on 
Gr-1+CD11b+cells were seen between control and treatment groups (Fig.3.1.4.3 B). 
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Fig.3.1.4. 3 Quantification of B7-H1/B7-DC MFI of Gr-1
+
CD11b
+
 cells from WT and B7-H1 KO 
mice in control groups (without treatment, co) and after the treatment of splenocytes in in vitro 
cultures with IFNα, 5-FU and IFNα+5-FU. 
Freshly isolated splenocytes were put in a culture and treated with IFNα, 5-FU and IFNα+5-FU for 24 
hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies. The MFI of B7-
H1
+
/B7-DC
+
 Gr-1
+
CD11b
+
 cells was analyzed by flow cytometry. Data from four independent 
experiments are presented as column bar graphs with SEM (n = 16;control group vs. treatment 
groups; one-way (A,B) ANOVA) 
 
Summarizing the data of Gr-1+CD11b+ cell population, in cultures of spleens of 
healthy WT and B7-H1 KO mice, only in the treatment group of 5-FU a significantly 
lower ratio of Gr-1+CD11b+ cells was seen in spleens of B7-H1 KO mice compared to 
those of WT mice. 
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3.2 In vivo Effects of chemo (5-FU) - and immunotherapy (IFNα) on 
the constellation of leukocyte subsets and the expression of B7-
H1/B7-DC molecules in tumor-bearing WT and B7-H1 KO mice 
 
Since we have seen that chemotherapy can affect the constellation of leukocyte 
subsets in healthy mice, in this experiment series we wanted to examine whether 5-
FU and IFNα could directly influence the constellation of immune cells in tumor-
bearing WT and B7-H1 KO mice. Furthermore, we wanted to investigate if this could 
also be accompanied by a direct effect of 5-FU and IFNα on B7-H1 or B7-DC 
expression on the different leukocyte subpopulations of WT and B7-H1 KO mice 
respectively. To achieve this, we treated tumor-bearing WT and B7-H1 KO mice with 
either IFNα, or 5-FU alone or in the combination of IFNα+5-FU on Day 5, 7 and 9 
after Panc02 implantation. One group was kept untreated and used as the control. 
After a period of four weeks, the mice were killed and the spleens and tumors 
eviscerated. With the help of flow cytometry, we analyzed and compared treated WT 
and B7-H1 KO mice in terms of the constellation of different immune cells as well as 
the expression of B7-H1/B7-DC molecules. 
 
3.2.1 Analysis of CD4+/CD8+ T cells 
The performed gating strategy for CD4/CD8 Panel is shown in Fig.3.2.1.1. The FACS 
data (dot-plot, histogram) represent one typical result out of four independent 
experiments.
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and 
          
Fig.3.2.1.1 Gating strategy for CD4
+
/CD8
+
 T cells in spleens and tumors using flow cytometry. 
Lymphocytes were gated out using FSC/SSC dot plot. Afterwards, we marked CD45
+
 cells to 
discriminate tumor cells (CD45
-
) and tumor-infiltrating leukocytes (CD45
+
). The CD3
+
 cells were 
determined and the CD4
+
/CD8
+
 T cells were gated out ofCD3
+
 cells. Furthermore, the CD4
+
/CD8
+
 
Tcells were divided into naïve T cells (Tnaive), effector T cells (Teff), effector memory cells (Tem) and 
central memory cells (Tcm). The activation status of different subpopulations was determined by 
analyzing the expression of CD69 early activation marker. All positive gates were set according to 
FMO controls. 
 
First, we analyzed the frequency of CD8+ T cells out of all CD3+ lymphocytes within 
the splenocytes of tumor-bearing mice. The analysis of WT and B7-H1 KO groups in 
comparison showed significantly higher percentages of CD8+ Tcells in the treatment 
groups of 5-FU and IFNα+5-FU in B7-H1 KO mice compared to those groups of WT 
mice (Fig.3.2.1.2 A). In WT spleens, no significant difference in the ratio of CD8+ T 
cells was observed between control and treatment groups (Fig.3.2.1.2 B). However, 
in B7-H1 KO spleens, significantly increased percentages of CD8+ T cells were 
measured in the group of IFNα+5-FU compared to the control (Fig.3.2.1.2 D). 
When taking a detailed look at the tumors of WT mice, significantly higher 
frequencies of CD8+ T cells were found in mice treated with IFNα compared to the 
control mice (Fig.3.2.1.2 C).  
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Here and further on in this experiment series, the B7-H1 effect on the tumor growth 
was so strong that we had nearly no visible tumors from the B7-H1 KO mice so we 
could isolate tumor-infiltrating cells and take a more detailed look. The only available 
tumor material was used for MDSC characterization, described later on (3.4.1). 
 
 
Fig.3.2.1.2 Quantification of CD8
+
 T cells in spleens and tumors from tumor bearing WT and B7-
H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as the control. Four weeks after surgery, the mice were killed 
and the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD8
+
 T cells out of CD3
+
 lymphocytes was 
analyzed by flow cytometry. Data from four independent experiments are presented as column bar 
graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: 
n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p0.05, ***p<0.001; control group vs. treatment 
groups; two-way (A) and one-way (B,C,D) ANOVA) 
 
The activation status of CD8+ T cells from spleens and tumors was determined by the 
expression of the CD69 early activation marker. When comparing the groups of WT 
splenocytes with those of B7-H1 KO, no significant difference was seen throughout 
all four groups (Fig.3.2.1.3 A). When we looked at the groups of WT and B7-H1 KO 
spleens in detail, no significant difference was registered between the control and the 
treatment groups in both the WT and B7-H1 KO groups (Fig.3.2.1.3 B,D). 
The analysis of WT tumors showed no significant difference between control and 
treatment groups in respect of proportion of CD69+ CD8+ T cells (Fig.3.2.1.3 C). 
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The measured MFI of CD69 on CD8+ T cells of the spleens reached significantly 
higher values in all four groups of WT compared to groups of B7-H1 KO tumor-
bearing mice (Fig.3.2.1.3 E). Alone in the WT and B7-H1 KO groups, the analyzed 
MFI of CD69 revealed no significant difference between the treatment groups and the 
control (Fig.3.2.1.3 F,H). 
In the tumors of WT mice, no significant difference in CD69 MFI was observed 
between control and treatment groups (Fig.3.2.1.3 G). 
 
 
Fig.3.2.1.3 Quantification of CD69 expression on CD8
+
 T cells in spleens and tumors from 
tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as the control. Four weeks after surgery, the mice were killed 
and the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD69
+
 CD8
+
 T cells out of CD3
+
 
lymphocytes together with the MFI of CD69 was analyzed by flow cytometry. Data from four 
independent experiments are presented as column bar graphs and box plots with SEM ((spleens: n = 
9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-
FU);  ***p<0.001; control group vs. treatment groups; two-way (A,E) and one-way (B,C,D,F,G,H) 
ANOVA) 
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Next, we analyzed the four subsets of CD8+ T cells, Tnaive, Teff, Tem, and Tcm. The 
CD8+ Tnaive in spleens achieved lower percentages in the B7-H1 KO groups 
compared to the WT groups. For the controls, as well as for the therapies with IFNα 
and IFNα+5-FU, this difference is of significance. In the group of 5-FU, a tendency 
towards lower percentages of Tnaive was found in spleens of B7-H1 KO mice 
compared to those of WT mice (Fig.3.2.1.4 A). Analyzing splenocytes of treated WT 
and B7-H1 KO tumor-bearing mice separately, a significant decrease of Tnaive was 
found in the treatment of IFNα+5-FU compared to control in spleens of both the WT 
and B7-H1 KO tumor-bearing mice (Fig.3.2.1.4 B,D). 
The analysis of WT tumors demonstrated no significant difference in percentages of 
Tnaive between control and treatment groups (Fig.3.2.1.4 C). 
 
 
Fig.3.2.1.4 Quantification of naïve CD8
+
 T cells in spleens and tumors from tumor-bearing WT 
and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as the control. Four weeks after surgery, the mice were killed 
and the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of naïve CD8
+
 T cells was analyzed by flow 
cytometry. Data from four independent experiments are presented as column bar graphs and box plots 
with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 
for IFNα; 5-FU; IFNα+5-FU);**p<0.01, ***p<0.001; control group vs. treatment groups; two-way (A) 
and one-way (B,C,D) ANOVA) 
 
Considering the Teff population of CD8+ T cells in spleens, in all four groups 
significantly increased frequencies of Teff were found in the groups of B7-H1 KO 
mice compared to groups of WT mice (Fig.3.2.1.5 A).  
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By looking at CD8+ Teff of spleens in WT mice in detail, significantly lower 
frequencies were determined for the groups of IFNα,5-FU and IFNα+5-FU in 
comparison to the control (Fig.3.2.1.5 B). In the spleens of B7-H1 KO tumor-bearing 
mice, no significant differences in the ratio of Teff were recognized between the 
control and the treatment groups (Fig.3.2.1.5 D). 
The analysis of tumors of WT mice revealed significantly lower percentages of Teff in 
the groups of IFNα and IFNα+5-FU compared to the control (Fig.3.2.1.5.C). 
 
 
Fig.3.2.1.5 Quatification of effector CD8
+
 T cells in spleens and tumors from tumor-bearing WT 
and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of effector CD8
+
 T cells was analyzed by flow 
cytometry. Data from four independent experiments are presented as column bar graphs and box plots 
with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 
for IFNα; 5-FU; IFNα+5-FU); *p<0.05, **p<0.01, ***p<0.001; control group vs. treatment groups; two-
way (A) and one-way (B,C,D) ANOVA) 
 
The proportion of CD69+ Teff was significantly higher in all four groups of B7-H1 KO 
spleens compared to WT spleens (Fig.3.2.1.6 A). As one can see in Fig.3.2.1.6 B, in 
WT spleens we found that all treatment groups achieved significantly higher 
frequencies of CD69+ cells as compared to the control. In spleens of B7-H1 KO tumor 
bearing mice, a significant increase in the percentage of CD69+ Teff was seen 
between the control and the IFNα+5-FU treatment group (Fig.3.2.1.6 D). 
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In the analysis of the tumors of WT mice, it was observed that the treatment group of 
IFNα has significantly less CD69+ Teff compared to the control group (Fig.3.2.1.6 C). 
The measured MFI of CD69 expression on Teff showed significantly higher values in 
WT spleens in all four groups compared to the same B7-H1 KO groups (Fig.3.2.1.6 
E). No significant changes in CD69 MFI were observed when comparing the control 
to treatment groups of either WT or B7-H1 KO tumor-bearing mice separately 
(Fig.3.2.1.6 F,H). 
In tumors of WT mice, no significant differences in the MFI of CD69 were seen 
between the control and treatment groups (Fig.3.2.1.6 G). 
 
 
Fig.3.2.1.6 Quantification of CD69 expression on effector CD8
+
 T cells in spleens and tumors 
from tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD69
+
 CD8
+
 effector T cells together with 
the MFI of CD69 was analyzed by flow cytometry. Data from four independent experiments are 
presented as column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-
FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05, **p<0.01, 
***p<0.001; control group vs. treatment groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
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The analysis of the frequency of Tem out of all CD8+ T cells in spleens revealed 
highly significant greater percentages in all groups of B7-H1 KO mice compared to 
the ones of WT tumor-bearing mice (Fig.3.2.1.7 A). In WT spleens, IFNα+5-FU 
treatment induced significantly higher frequencies of Tem compared to the control 
(Fig.3.2.1.7 B). Whereas in groups of B7-H1 KO, no significant difference in 
frequencies of Tem was seen between the therapies and the control (Fig.3.2.1.7 D). 
For the Tem, out of all CD8+ T cells in WT tumors, we found a significant increase in 
percentages in the IFNα+5-FU treated WT mice compared to the control mice 
(Fig.3.2.1.7 C).   
 
 
Fig.3.2.1.7 Quantification of effector memory CD8
+
 T cells in spleens and tumors from tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of effector memory CD8
+
 T cells was analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs and 
box plots with SEM ((spleens: n = 9 for co, and3 n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for 
co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05,***p<0.001; control group vs. treatment groups; two-
way (A) and one-way (B,C,D) ANOVA) 
 
When analyzing the frequency of CD69+ cells, out of all the CD8+ Tem in the spleens 
of WT and B7-H1 KO tumor-bearing mice, significantly lower percentages were seen 
in B7-H1 KO spleens in the control and 5-FU treatment groups compared to those 
groups of WT mice. In IFNα and IFNα+5-FU treatment groups, no significant 
difference was observed between WT and B7-H1 KO mice (Fig.3.2.1.8 A).  
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The analysis of either WT or B7-H1 KO spleens showed no significant increases or 
decreases in percentages between control and treatment groups in both mouse 
strains, WT and B7-H1 KO (Fig.3.2.1.8 B,D). 
Between treatment groups and the control of WT tumors, no significant difference in 
the frequency of CD69+ Tem was determined (Fig.3.2.1.8 C). 
As we looked at the values of CD69 MFI of CD8+ Tem in spleens, lower values were 
determined for the groups of B7-H1 KO compared to WT tumor-bearing mice. For 
IFNα, 5-FU and IFNα+5-FU treatments, this result was statistically significant, 
whereas the comparison between the controls of WT and B7-H1 KO tumor-bearing 
mice showed a tendency towards lower values (Fig.3.2.1.8 E). In WT mice, the 
comparison between control and treatment groups revealed no significant difference 
in CD69 MFI (Fig.3.2.1.8 F). In B7-H1 KO groups, the difference in CD69 MFI 
between the treatment groups and the control was of no significance (Fig.3.2.1.8 H).  
Analyzing WT tumors, no significant difference in the values of CD69 MFI of CD8+ 
Tem was seen between the control and treatment groups (Fig.3.2.1.8 G). 
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Fig.3.2.1.8 Quantification of CD69 expression on effector memory CD8
+
 T cells in spleens and 
tumors from tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD69
+
 effector memory CD8
+
 T cells 
together with the MFI of CD69 was analyzed by flow cytometry. Data from four independent 
experiments are presented as column bar graphs and box plots with SEM ((spleens: n = 9 for co, and 
n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05, 
**p<0.01; control group vs. treatment groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
Analyzing the cell fraction of Tcm out of CD8+ T cells, no significant difference was 
seen between WT and B7-H1 KO spleens throughout all four groups (Fig.3.2.1.9 A). 
In spleens of WT tumor-bearing mice, a significant increase of Tcm frequencies was 
registered in the groups of IFNα and IFNα+5-FU treatment compared to the control 
(Fig.3.2.1.9 B).  In the B7-H1 KO spleens, a significant increase in the frequency of 
Tcm was detected after treatment with IFNα+5-FU compared to the control 
(Fig.3.2.1.9 D). 
The analysis of Tcm in WT tumors showed significantly higher percentages of Tcm in 
the treatment group of 5-FU compared to the control group (Fig.3.2.1.9 C). 
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Fig.3.2.1.9 Quantification of central memory CD8
+
 T cells in spleens and tumors from tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of central memory CD8
+
 T cells was analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs and 
box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, 
n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05,**p<0.01, ***p<0.001; control group vs. treatment groups; 
two-way (A) and one-way (B,C,D) ANOVA) 
 
Examining the activation status of CD8+ Tcm, a tendency towards lower percentages 
of CD69+CD8+ Tcm was recorded in B7-H1 KO mice compared to WT mice 
throughout all groups (Fig.3.2.1.10 A). When analyzing the spleens of WT and B7-H1 
KO tumor-bearing mice in detail, no significant change in percentages in CD69
+
CD8
+ 
Tcm was observed between the control and the treatment groups, neither in spleens 
of WT mice nor the B7-H1 KO mice (Fig.3.2.1.10 B,D). 
Tumors of WT mice showed an increase in activated Tcm in the group of 5-FU 
treatment compared to the control recorded by the increase of CD69+ cells 
(Fig.3.2.1.10 C). 
The analysis of CD69 MFI of CD8+ Tcm revealed similar values in groups of WT and 
B7-H1 KO spleens (Fig.3.2.1.10 E). The comparison between control and treatment 
groups of either WT and B7-H1 KO spleens demonstrated no significant difference in 
the MFI of CD69 (Fig.3.2.1.10 F,H). 
For the MFI of CD69 on Tcm in WT tumors, we determined no significant difference 
in values between the control and treatment groups (Fig.3.2.1.10 G).  
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Fig.3.2.1.10 Quantification of CD69 expression on central memory CD8
+
 T cells in spleens and 
tumors from tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD69
+
 central memory CD8
+
 T cells 
together with the MFI of CD69 was analyzed by flow cytometry. Data from four independent 
experiments are presented as column bar graphs and box plots with SEM ((spleens: n = 9 for co, and 
n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU);   **p<0.01; 
control group vs. treatment groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
After we finished the analysis of CD8+ cells and their subsets, we followed the same 
procedure to analyze the CD4+ T cells as well as their activation status and subsets. 
The gating strategy is shown above in Fig.3.2.1.1. First, we investigated the 
percentages of CD4+ T cells out of CD3+ lymphocytes in spleens. No significant 
difference in the ratio of CD4+ T cells was seen between the groups of WT and B7-H1 
KO spleens (Fig.3.2.1.11 A). In the WT and B7-H1 KO groups on their own, no 
significant change in frequencies was found in both mouse strains between the single 
treatments compared to the controls (Fig.3.2.1.11 B,D). 
For the tumors of WT mice, we determined significantly lower percentages of CD4
+
 T 
cells for the group of IFNα treatment compared to control (Fig.3.2.1.11 C). 
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Fig.3.2.1.11 Quantification of CD4
+
 T cells in spleens and tumors from tumor-bearing WT and 
B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD4
+
 T cells was analyzed by flow 
cytometry. Data from four independent experiments are presented as column bar graphs and box plots 
with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 
for IFNα; 5-FU; IFNα+5-FU);   *p<0.05; control group vs. treatment groups; two-way (A) and one-way 
(B,C,D) ANOVA) 
 
Analysis of the activation status of the CD4+ T cell population revealed no significant 
difference in the ratio of CD69+ cells between groups of WT and B7-H1 KO spleens 
(Fig.3.2.1.12 A). When analyzing the single treatments compared to the control, in 
both WT and B7-H1 KO splenocytes no significant difference in the ratio of CD69+ 
cells was seen (Fig.3.2.1.12 B,D). 
The percentage of CD69+ cells out of CD4+ Tcells in tumors of WT mice was not 
significantly different between the control and the single treatments (Fig.3.2.1.12 C). 
For the MFI of CD69, no significant difference in values was found between the 
subgroups of WT and B7-H1 KO spleens (Fig.3.2.1.12 E). Furthermore, between the 
control and treatments of either WT or B7-H1 KO spleens, no significant difference in 
CD69 MFI was determined (Fig.3.2.1.12 F,H).  
For WT tumors, no significant difference between the control and treatment group 
was measured determining the CD69 MFI of CD4+ Tcells (Fig3.2.1.12 G). 
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Fig.3.2.1.12 Quantification of CD69 expression on CD4
+
 T cells in spleens and tumors from 
tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD69
+
 CD4
+
 T cells together with the MFI 
of CD69 was analyzed by flow cytometry. Data from four independent experiments are presented as 
column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-
FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); control group vs. treatment groups; two-
way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
In the analysis of Tnaive out of CD4+ T cells in spleens, significantly higher 
frequencies were seen in the group of controls in WT compared to B7-H1 KO tumor-
bearing mice. The comparison of the treatment groups between WT and B7-H1 KO 
spleens indicated no significant difference (Fig.3.2.1.13 A). Looking at the single 
treatment groups in spleens of WT mice, significantly lower percentages of Tnaive 
were measured between control and 5-FU treatment and even lower for IFNα+5-FU 
treatment (Fig.3.2.1.13 B). In the spleens of B7-H1 KO mice, significantly lower 
frequencies of CD4+ Tnaive were registered in the groups of 5-FU andIFNα+5-FU 
treatment compared to control (Fig.3.2.1.13 D). 
As one can see in the analysis of WT tumors, a significantly higher percentage of 
Tnaive was found in WT mice treated with IFNα compared to control (Fig.3.2.1.13 C). 
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Fig.3.2.1.13 Quantification of naïve CD4
+
 T cells in spleens and tumors from tumor-bearing WT 
and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of naïve CD4
+
 T cells was analyzed by flow 
cytometry. Data from four independent experiments are presented as column bar graphs and box plots 
with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 
for IFNα; 5-FU; IFNα+5-FU); *p<0.05,**p<0.01, ***p<0.001; control group vs. treatment groups; two-
way (A) and one-way (B,C,D) ANOVA) 
 
The analysis of Teff out of CD4+ T cells demonstrated a significant difference 
between the controls of WT and B7-H1 KO spleens, with higher percentages of CD4+ 
Teff in the B7-H1 KO group (Fig.3.2.1.14 A). Between the single treatments and the 
control of WT spleens, frequencies of Teff were similar to each other (Fig.3.2.1.14 B). 
When comparing the treatment groups of B7-H1 KO spleens to the control, a 
significant increase in percentage of Teff was found after therapy with IFNα and 
IFNα+5-FU (Fig.3.2.1.14 D). 
By taking a closer look at the tumors of WT mice, we have seen significantly higher 
ratios of Teff in the group of 5-FU treatment compared to control (Fig.3.2.1.14 C). 
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Fig.3.2.1.14 Quantification of effector CD4
+
 T cells in spleens and tumors from tumor-bearing 
WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of effector CD4
+
 T cells was analyzed by flow 
cytometry. Data from four independent experiments are presented as column bar graphs and box plots 
with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 
for IFNα; 5-FU; IFNα+5-FU); *p<0.05,**p<0.01; control group vs. treatment groups; two-way (A) and 
one-way (B,C,D) ANOVA) 
 
The activation status of CD4+ Teff, investigated by measuring of CD69 expression, 
was not significantly different between WT and B7-H1 KO spleens throughout all four 
groups (Fig.3.2.1.15 A). The analysis of both the WT and B7-H1 KO spleens 
revealed no significant difference between controls and treatment groups 
(Fig.3.2.1.15 B,D). 
Furthermore, in tumors of WT mice, no significant difference in the percentages of 
Teff was found between treated mice and the control group (Fig.3.2.1.15 C).  
The measurements of the CD69 MFI of CD4+ Teff in spleens showed no significant 
difference between WT and B7-H1 KO spleens in all four groups (Fig.3.2.1.15 E). 
When looking at WT and B7-H1 KO groups in more detail, no significant difference in 
CD69 MFI was found between control and treatment groups, in both the WT and B7-
H1 KO spleens (Fig.3.2.1.15 F,H). 
Nearly equal values of CD69 MFI of CD4+ T cells were observed for the treatment 
groups of WT tumors compared to the control group (Fig.3.2.1.15 G). 
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Fig.3.2.1.15 Quantification of CD69 expression on effector CD4
+
 T cells in spleens and tumors 
from tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD69
+
 effector CD4
+
 T cells together with 
the MFI of CD69 was analyzed by flow cytometry. Data from four independent experiments are 
presented as column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-
FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); control group vs. treatment 
groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
Next, we examined the cell fraction of Tem out of CD4+ T cells. Between WT and B7-
H1 KO spleens, higher cell frequencies were found in the spleens of B7-H1 KO 
tumor- bearing mice in all four groups. For controls, IFNα and 5-FU treatments were 
used, whose result was of a statistical significance (Fig.3.2.1.16 A). In WT spleens, a 
significant increase in the frequency of Tem was found in the groups of 5-FU and 
IFNα+5-FU compared to the control (Fig.3.2.1.16 B). In spleens of B7-H1 KO tumor-
bearing mice, a significant increase in Tem was observed in the group of IFNα+5-FU 
treatment compared to control (Fig.3.2.1.16 D). 
When analyzing the tumors of WT mice, no significant difference in the frequency of 
Tem was seen between the control group and treatment groups (Fig.3.2.1.16 C). 
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Fig.3.2.1.16 Quantification of effector memory CD4
+
 T cells in spleens and tumors from tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of effector memory CD4
+
 T cells was analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs and 
box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, 
n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05,**p<0.01, ***p<0.001; control group vs. treatment groups; 
two-way (A) and one-way (B,C,D) ANOVA) 
 
Determining the expression of CD69 on Tem, a tendency towards lower ratios of 
CD69+ Tem was found in the groups of B7-H1 KO spleens compared to WT groups. 
Between the groups of 5-FU treatments, this result was significant (Fig.3.2.1.17 A). 
When analyzing the treatments for the WT and B7-H1 KO groups on their own, the 
observed proportion of CD69+ cells showed no significant difference between the 
treatments compared to controls, in the spleens of both the WT and B7-H1 KO 
tumor-bearing mice (Fig.3.2.1.17 B,D). 
In the tumors of WT mice, no significant difference in the ratio of CD69+ Tem was 
seen between the treatment groups and the control (Fig.3.2.17 C). 
Afterwards, we took a closer look at the MFI of CD69 of Tem in the spleens of WT 
and B7-H1 KO tumor-bearing mice. No significant difference was seen in the 
comparison of WT and B7-H1 KO spleens to each other (Fig.3.2.1.17 E) as well as 
between the single groups compared to the control of either WT or B7-H1 KO 
spleens (Fig.3.2.1.17 F,H). 
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 Analyzing the MFI of CD69 of Teff in WT tumors, no significant difference was 
observed between the control and the treatment groups (Fig.3.2.1.17 G). 
 
 
Fig.3.2.1.17 Quantification of CD69 expression on effector memory CD4
+
 T cells in spleens and 
tumors from tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD69
+
 effector memory CD4
+
 T cells 
together with the MFI of CD69 was analyzed by flow cytometry. Data from four independent 
experiments are presented as column bar graphs and box plots with SEM ((spleens: n = 9 for co, and 
n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU);*p<0.05; 
control group vs. treatment groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
The analysis of Tcm out of CD4+ T cells in spleens of tumor-bearing mice revealed 
highly significant differences between WT and B7-H1 KO spleens in all four groups, 
with higher percentages of CD4+ Tcm in the B7-H1 KO groups compared to WT 
groups (Fig.3.2.1.18 A). In groups of WT spleens alone, significantly higher cell 
frequencies of Tcm were measured in the group of IFNα+5-FU treatment compared 
to the control (Fig.3.2.1.18 B). Between treatment groups and the control of B7-H1 
KO spleens, no significant difference in Tcm percentages was seen (Fig.3.2.1.18 D). 
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By analyzing the tumors of WT mice, significantly higher percentages of CD4+ Tcm 
were found in the group of IFNα+5-FU treated animals in comparison to control 
animals (Fig.3.2.1.18 C). 
 
 
Fig.3.2.1.18 Quantification of central memory CD4
+
 T cells in spleens and tumors from tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of central memory CD4
+
 T cells was analyzed 
by flow cytometry. Data from four independent experiments are presented as column bar graphs and 
box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, 
n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05,***p<0.001; control group vs. treatment groups; two-way 
(A) and one-way (B,C,D) ANOVA) 
 
When determining the activation status of CD4+ Tcm, no significant difference in 
percentages of CD69+ Tcm was found between the spleens of WT and B7-H1 KO 
tumor-bearing mice in all treatments and the control group. A tendency towards lower 
percentages was determined for the control and IFNα and 5-FU treatments in 
spleens of B7-H1 KO mice compared to the same groups of WT mice (Fig.3.2.1.19 
A). When we looked at the single groups of either WT or B7-H1 KO, no significant 
difference in the ratio of Tcm was found between the treatments and the control, in 
the spleens of both WT and B7-H1 KO tumor-bearing mice (Fig.3.2.1.19 B,D). 
The analysis of tumors of WT mice revealed no statistical difference in the frequency 
of Tcm between the treated and control mice (Fig.3.2.1.19 C). 
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In the analysis of the MFI of CD69 of Tcm, one can see significantly lower values 
measured in the groups of IFNα, 5-FU and IFNα+5-FU treatment for the spleens of 
B7-H1 KO mice compared to WT spleens (Fig.3.2.1.19 E). In comparison of the 
treatment groups to the control, the values were not of a significant difference, in both 
groups of WT and B7-H1 KO spleens (Fig.3.2.1.19 F,H). 
Furthermore, no significant difference in the MFI of CD69 was observed in WT 
tumors between the control and treatment groups (Fig.3.2.1.19 G). 
 
 
Fig.3.2.1.19 Quantification of CD69 expression on central memory CD4
+
 T cells in spleens and 
tumors from tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD69
+
 central memory CD4
+
 T cells 
together with the MFI of CD69 was analyzed by flow cytometry. Data from four independent 
experiments are presented as column bar graphs and box plots with SEM ((spleens: n = 9 for co, and 
n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU);  *p<0.05, 
**p<0.01; control group vs. treatment groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
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Summarizing the data of CD4+/CD8+ T cells, we observed higher frequencies of 
CD4+/CD8+ Tem and Tcm in spleens of B7-H1 KO compared to those of WT tumor-
bearing mice. 
 
3.2.2 Analysis of Myeloid derived suppressor cells (MDSC) 
Since the MDSC play an important role in the establishment and development of 
tumors, we wanted to know which impact the application of different therapies has on 
the constellation of these cells in presence and absence of B7-H1. In Fig.3.2.2.1, the 
gating strategy for MDSC is shown. The FACS data (dot-plot, histogram) represent 
one typical result out of four independent experiments. 
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Fig.3.2.2. 1 Gating strategy for Myeloid derived suppressor cells (MDSC) in spleens and tumors 
from tumor-bearing WT and B7-H1 KO mice using flow cytometry. 
First, lymphocytes were gated using FSC/SSC dot plot. Afterwards, we gated on CD45
+
 cells, and out 
of this cell population, Gr-1
+
CD11b
+
 MDSC were marked. The two subsets of MDSC, granulocytic and 
monocytic MDSC were gated according to the expression of Ly-6G and Ly-6C. For the functional 
status, the iNOS and Arginase subsets were determined from total MDSC as well as from both 
subsets using histograms. Furthermore, the expression of the B7-H1/B7-DC molecules was analyzed 
for all MDSC as well as for the two subsets using histograms. All positive gates were set according to 
FMO controls. 
 
 
First, we determined the frequency of MDSC out of all leukocytes in spleens of WT 
and B7-H1 KO tumor-bearing mice. A tendency towards lower frequencies of MDSC 
for all treatment groups and the controls was determined in B7-H1 KO spleens 
compared to WT spleens. Between the groups of IFNα+5-FU treatment, this 
difference was statistically significant (Fig.3.2.2.2 A). In spleens of WT mice, no 
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significant difference between the treatment groups and control was observed 
(Fig.3.2.2.2 B). In contrast, in the spleens of B7-H1 KO mice, a significant increase in 
the percentage of MDSC was measured for IFNα and IFNα+5-FU treatment groups 
compared to control (Fig.3.2.2.2 D). 
Furthermore, in the tumors of WT mice, a significantly higher percentage of MDSC 
was found after IFNα+5-FU treatment in comparison to the control (Fig.3.2.2.2 C). 
 
 
Fig.3.2.2. 2 Quantification of MDSC in spleens and tumors from tumor-bearing WT and B7-H1 
KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of MDSC was analyzed by flow cytometry. 
Data from four independent experiments are presented as column bar graphs and box plots with SEM 
((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-
FU; IFNα+5-FU);  *p<0.05; control group vs. treatment groups; two-way (A) and one-way (B,C,D) 
ANOVA) 
 
Afterwards, we examined the percentages of granulocytic MDSC (gMDSC) and 
monocytic MDSC (mMDSC) out of total MDSC in spleens of WT and B7-H1 KO mice. 
Between WT and B7-H1 KO spleens, a significantly higher percentage of gMDSC 
was found in the B7-H1 KO IFNα group compared to this group of WT spleens. For 
the other groups no significant difference was seen (Fig.3.2.2.3 A). By looking at the 
spleens in more detail, in the groups of WT spleens a significant decrease in 
frequency of gMDSC was seen in 5-FU treated animals compared to control animals 
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(Fig.3.2.2.3 B). In the B7-H1 KO spleens, an increase of gMDSC was observed in the 
group of IFNα treatment compared to the control group (Fig.3.2.2.3 D).  
The analysis of tumors from WT mice showed no significant difference in the ratio of 
gMDSC between untreated and treated mice (Fig.3.2.2.3 C). 
 
 
Fig.3.2.2. 3 Quantification of gMDSC in spleens and tumors from tumor-bearing WT and B7-H1 
KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of gMDSC was analyzed by flow cytometry. 
Data from four independent experiments are presented as column bar graphs and box plots with SEM 
((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-
FU; IFNα+5-FU); *p<0.05; control group vs. treatment groups; two-way (A) and one-way (B,C,D) 
ANOVA) 
 
When assessing the monocytic MDSC subpopulation out of the total MDSC in 
spleens of WT and B7-H1 KO tumor-bearing mice, significantly decreased ratios of 
mMDSC were found in B7-H1 KO spleens in the group of IFNα treatment compared 
to the corresponding group of WT spleens (Fig.3.2.2.4 A). When comparing the 
single groups of WT spleens to each other, a significantly lower frequency of mMDSC 
was found in the group of IFNα+5-FU compared to the control group (Fig.3.2.2.4 B). 
In spleens of B7-H1 KO mice, significantly lower percentages of mMDSC were 
registered in the treatment groups of IFNα, 5-FU and IFNα+5-FU compared to control 
(Fig.3.2.2.4 D). 
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In the tumors of WT animals, no significant difference in the frequency of mMDSC 
was observed between control and the treatment groups (Fig.3.2.2.4 C). 
 
 
Fig.3.2.2. 4 Quantification of mMDSC in spleens and tumors from tumor-bearing WT and B7-H1 
KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of mMDSC was analyzed by flow cytometry. 
Data from four independent experiments are presented as column bar graphs and box plots with SEM 
((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-
FU; IFNα+5-FU); *p<0.05, **p<0.01; control group vs. treatment groups; two-way (A) and one-way 
(B,C,D) ANOVA) 
 
Furthermore, we analyzed the functional status of MDSC and their two subsets. 
Therefore, we examined the iNOS as well as the Arginase expression of these cell 
populations, starting with the analysis of iNOS production in total MDSC, gMDSC and 
mMDSC. In total MDSC, one can see similar iNOS levels between the subgroups of 
WT andB7-H1 KO spleens (Fig.3.2.2.5 A). In the analysis of the single groups of WT 
spleens, a significantly lower percentage of iNOS+ cells was seen in the group of 
IFNα+5-FU treatment compared to the control (Fig.3.2.2.5 B). Between the single 
treatments and the control in B7-H1 KO spleens, no significant difference in the ratio 
of iNOS+ MDSC was observed (Fig.3.2.2.5 D). 
The comparison of treatment groups to the control of WT tumors showed no 
significant difference in iNOS+ MDSC (Fig.3.2.2.5 C). 
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For the MFI of iNOS+ MDSC, a significantly lower value was determined for the B7-
H1 KO IFNα treatment group compared to the corresponding WT group. For the 
other groups, the MFI of iNOS+ MDSC revealed a tendency towards lower values in 
groups of B7-H1 KO spleens compared to groups of WT spleens (Fig.3.2.2.5 E). No 
significant differences in the iNOS MFI were measured when we compared the 
treatment groups of either WT or B7-H1 KO spleens to the respective control group 
(Fig.3.2.2.5 F,H). 
The comparison of treatment groups with the control in WT tumors revealed no 
significant difference in the values of iNOS MFI as seen in Fig.3.2.2.5 G. 
 
 
Fig.3.2.2. 5 Quantification of iNOS expression of MDSC in spleens and tumors from tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of iNOS
+
 MDSC together with the MFI of 
iNOS was analyzed by flow cytometry. Data from four independent experiments are presented as 
column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-
FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU);***p<0.001; control group vs. treatment 
groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
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In spleens of WT and B7-H1 KO mice, similar frequencies of iNOS+ gMDSC were 
determined in all four groups (Fig.3.2.2.6 A). By looking at WT and B7-H1 KO 
spleens separately, no significant difference was observed between the control group 
compared to the treatments, in spleens of both the WT and B7-H1 KO tumor-bearing 
mice (Fig.3.2.2.6 B,D). 
Beyond that, no significant change in percentages of iNOS+ gMDSC was found for 
the treatment groups in tumors of WT mice compared to the control group 
(Fig.3.2.2.6 C).  
For the MFI of iNOS+ gMDSC, a significantly lower value was observed in the group 
of IFNα treatment in B7-H1 KO spleens compared to WT spleens. In the other 
groups, no significant difference was seen between the groups of WT spleens 
compared to those of B7-H1 KO spleens (Fig.3.2.2.6 E). Comparing the groups of 
either WT or B7-H1 KO spleens separately, no significant difference in the MFI of 
iNOS was seen between control and treated animals, in both WT and B7-H1 KO 
spleens (Fig.3.2.2.6 F,H). 
In the tumors of WT mice, we found no significant difference in the iNOS MFI 
between the control group and treatment groups (Fig.3.2.2.6 G). 
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Fig.3.2.2. 6 Quantification of iNOS expression of gMDSC in spleens and tumors from tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of iNOS
+
 gMDSC together with the MFI of 
iNOS was analyzed by flow cytometry. Data from four independent experiments are presented as 
column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-
FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU);  *p<0.05; control group vs. treatment 
groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
When looking at the iNOS+ mMDSC in spleens of WT and B7-H1 KO tumor-bearing 
mice in comparison, no significant difference was seen throughout all four groups 
(Fig.3.2.2.7 A). The detailed analysis of WT as well as B7-H1 KO spleens, revealed 
no significant difference in the frequency of iNOS+ mMDSC between the control and 
treated mice (Fig.3.2.2.7 B,D). 
In WT tumors, the change in percentage of iNOS+ mMDSC between the control and 
treatment groups was of no statistical significance (Fig.3.2.2.7 C). 
As one can see in the Fig.3.2.2.7 E, the MFI of iNOS+ mMDSC demonstrated no 
significant difference between all groups of WT spleens compared to B7-H1 KO 
spleens. In the spleens of WT tumor-bearing mice, a significantly lower MFI of iNOS 
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was determined for the group of 5-FU treated animals compared to control animals 
(Fig.3.2.2.7 F). The analysis of iNOS MFI in B7-H1 KO spleens showed no significant 
difference between the control and treatment groups (Fig.3.2.2.7 H). 
For the MFI of iNOS in WT tumors, no significant difference in values was found 
between the control and treatment groups (Fig.3.2.2.7 G). 
 
 
Fig.3.2.2. 7 Quantification of iNOS expression of mMDSC in spleens and tumors from tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of iNOS
+
 mMDSC together with the MFI of 
iNOS was analyzed by flow cytometry. Data from four independent experiments are presented as 
column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-
FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); **p<0.01; control group vs. treatment 
groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
After we finished the analysis of iNOS expression, we next analyzed the Arginase 
expression in total MDSC, as well as their subsets. No difference in Arg+ MDSC was 
seen between WT and B7-H1 KO tumor-bearing mice for all four groups when we 
compared spleens of WT to the B7-H1 KO spleens (Fig.3.2.2.8 A). When comparing 
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the single-treatment groups of either WT or B7-H1 KO spleens to the control groups 
separately, no significant difference in the frequency of Arg+ MDSC was determined 
in the spleens from both the WT and B7-H1 KO tumor-bearing mice (Fig.3.2.2.8 B,D). 
The analysis of WT tumors showed no significant difference in the ratio of Arg+ 
MDSC between the control group and the treatment groups (Fig.3.2.2.8 C). 
 
The measured MFI of Arg+ MDSC in spleens showed significantly lower values in the 
group of IFNα+5-FU treated animals of B7-H1 KO spleens compared to WT spleens. 
For the other groups, a tendency towards lower intensities was found in B7-H1 KO 
spleens compared to WT spleens (Fig.3.2.2.8 E). Between the control and treatment 
groups in spleens from both the WT and B7-H1 KO mice, we did not see a significant 
difference in the values of Arg MFI (Fig.3.2.2.8 F,H).  
In the groups of WT tumors, no significant difference in the Arg MFI was registered 
when we compared the control group to the treatment groups (Fig.3.2.2.8 G). 
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Fig.3.2.2. 8 Quantification of Arg expression of MDSC in spleens and tumors from tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of Arg
+
 MDSC together with the MFI of Arg 
was analyzed by flow cytometry. Data from four independent experiments are presented as column 
bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; 
tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05; control group vs. treatment groups; 
two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
When we took a detailed look at the Arginase expression in gMDSC in spleens of WT 
and B7-H1 KO tumor-bearing mice in comparison, similar percentages were 
determined for all four groups (Fig.3.2.2.9 A). Within the single groups of WT and B7-
H1 KO spleens, no significant difference in the ratio of Arg+ gMDSC was seen 
between the controls and applied therapies in spleens of WT as well as B7-H1 KO 
tumor-bearing mice (Fig.3.2.2.9 B,D). 
When analyzing WT tumor groups, no statistically significant difference was revealed 
after applied treatments compared to the control (Fig.3.2.2.9 C). 
For the MFI of Arg, significantly lower values were determined in the B7-H1 KO group 
of IFNα+5-FU treatment compared to the respective WT group (Fig.3.2.2.9 E). The 
comparison of the single groups of either WT or B7-H1 KO spleens showed no 
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significant difference in Arg MFI between the controls and treatment groups, in both 
mouse strains (Fig.3.2.2.9 F,H). 
In the analysis of WT tumors, one can see a significant increase in the value of Arg 
MFI in the 5-FU treatment group compared to the control group (Fig.3.2.2.9 G). 
 
 
Fig.3.2.2. 9 Quantification of Arg expression of gMDSC in spleens and tumors from tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of Arg
+
 granulocytic MDSC together with the 
MFI of Arg was analyzed by flow cytometry. Data from four independent experiments are presented as 
column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-
FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU);  *p<0.05; control group vs. treatment 
groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
The analysis of MDSC demonstrated lower frequencies of total MDSC in all four 
groups in the spleens of B7-H1 KO compared to WT spleens of tumor-bearing mice.  
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3.2.3 Analysis of B7-H1/B7-DC expression on MDSC 
We also analyzed the expression of the regulatory molecules B7-H1 on total MDSC, 
as well as on the MDSC subsets in WT spleens and tumors. Additionally, we were 
interested whether different treatments can have an impact on the expression of B7-
H1 on MDSC. In WT spleens as well as in WT tumors, no significant difference in the 
frequency of B7-H1+ MDSC was seen between control groups and treatment groups 
(Fig.3.2.3.1 A,B). 
When determining the MFI of B7-H1 of total MDSC, a significantly lower value was 
observed in WT spleens in the group IFNα+5-FU treatment compared to the control 
(Fig.3.2.3.1 C). The measured MFI of B7-H1 on total MDSC of WT tumors showed no 
significant difference between the control group and the treatment groups (Fig.3.2.3.1 
D). 
 
 
Fig.3.2.3. 1 Quantification of B7-H1 expression on MDSC in spleens and tumors from tumor-
bearing WT mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of B7-H1
+
 MDSC together with the MFI of B7-
H1 was analyzed by flow cytometry. Data from four independent experiments are presented as box 
plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 
4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05; control group vs. treatment groups; one-way (A,B,C,D) 
ANOVA) 
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Next, we examined the percentage of B7-H1+ cells out of gMDSC in spleens and 
tumors of WT mice. No significant difference in the frequency of B7-H1+ gMDSC was 
found between the single treatment groups and the control group, neither in spleens 
nor in tumors from WT mice (Fig.3.2.3.2 A,B). 
The analyzed MFI of B7-H1 did not point out a significant difference between control 
mice and treated mice, in both the spleens and tumors of WT mice (Fig.3.2.3.2 C,D). 
 
 
Fig.3.2.3. 2 Quantification of B7-H1 expression on gMDSC in spleens and tumors from tumor-
bearing WT mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of B7-H1
+
 gMDSC together with the MFI of 
B7-H1 was analyzed by flow cytometry. Data from four independent experiments are presented as box 
plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 
4-6 for IFNα; 5-FU; IFNα+5-FU); control group vs. treatment groups; one-way (A,B,C,D) ANOVA) 
 
For the expression of B7-H1 molecule on mMDSC, we found no significant change in 
frequencies of B7-H1+ mMDSC in WT spleens of treated animals compared to control 
animals (Fig.3.2.3.3 A). In WT tumors, the difference in the ratio of B7-H1+ mMDSC 
between the control group and treatment groups is of no statistical significance 
(Fig.3.2.3.3 B). 
Analyzing the measured B7-H1 MFI of mMDSC, no significant difference between the 
control group and treatment groups was determined for both the spleens and tumors 
of WT mice (Fig.3.2.3.3 C,D). 
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Fig.3.2.3. 3 Quantification of B7-H1 expression on mMDSC in spleens and tumors from tumor-
bearing WT mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of B7-H1
+
 mMDSC together with the MFI of 
B7-H1 was analyzed by flow cytometry. Data from four independent experiments are presented as box 
plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 
4-6 for IFNα; 5-FU; IFNα+5-FU); control group vs. treatment groups; one-way (A,B,C,D) ANOVA) 
 
Furthermore, we looked at the B7-DC expression on total MDSC and MDSC subsets 
in spleens of B7-H1 KO mice. In the analysis of B7-DC expression on total MDSC, no 
significant difference in percentages of B7-DC+ MDSC was seen between the control 
and treatment groups (Fig.3.2.3.4 A). The MFI of B7-DC of total MDSC was not 
significantly different between the control group and the treatment groups (Fig.3.2.3.4 
B). 
For the B7-DC expression on gMDSC, similar percentages were found in all 
treatment groups compared to the control group (Fig.3.2.3.4 C). The MFI of B7-DC 
on this cell population showed no statistically difference between the control and 
treatment groups (Fig.3.2.3.4 D). 
For mMDSC, we found no significant difference in frequencies of B7-DC+ mMDSC 
between the control and treatment groups in spleens of B7-H1 KO mice (Fig.3.2.3.4 
E). Furthermore, for the B7-DC MFI of mMDSC, similar values were registered for the 
treatment groups compared to the control group (Fig.3.2.3.4 F). 
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Fig.3.2.3. 4 Quantification of B7-DC expression on MDSC, gMDSC and mMDSC in spleens from 
tumor-bearing B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens were stained with fluorescence 
labeled specific antibodies. The frequencies of B7-DC
+
 MDSC, gMDSC and mMDSC together with the 
MFI of B7-DC were analyzed by flow cytometry. Data from four independent experiments are 
presented as box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; 
tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); control group vs. treatment groups; one-way 
(A,B,C,D,F,G,) ANOVA) 
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Summarizing the data concerning the regulatory molecules B7-H1/B7-DC in spleens 
and tumors of tumor-bearing WT and B7-H1 KO mice, no significant difference in the 
expression of this molecule was seen between the control and treated mice.  
 
3.2.4 Analysis of regulatory T cells (Treg) 
Another suppressive cell population we analyzed in detail was the population of Treg. 
We examined Treg, as well as Tcon and activated Tcon, in spleens of WT and B7-H1 
KO mice (control and treated with IFNα, 5-FU, IFNα+5-FU) as well as in WT tumors. 
Our gating strategy is presented below in Fig.3.2.4.1. The FACS data (dot-plot, 
histogram) represent one typical result out of four independent experiments. 
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Fig.3.2.4. 1 Gating strategy for regulatory T cells in spleens and tumors using flow cytometry. 
The first gate was set on lymphocytes using FSC/SSC dot plot; afterwards CD4
+ 
T cells were marked. 
Out of this cell population of regulatory T cells (Treg), Tcon, activated Tcon and CD25
-
FoxP3
+, 
the 
cells were determined using CD25 and FoxP3 expression. 
 
First, we looked at the frequencies of Treg out of all CD4+ T cells in spleens from WT 
and B7-H1 KO tumor-bearing mice. When comparing the groups of splenocytes of 
treated WT and B7-H1 KO tumor-bearing mice, no significant difference in Treg 
frequencies was found for all four groups (Fig.3.2.4.2 A). By taking a detailed look at 
the single groups of WT or B7-H1 KO spleens, no significant difference in the ratio of 
Treg was observed between the control group and the treatment groups in the 
spleens from both the WT and B7-H1 KO tumor-bearing mice (Fig.3.2.4.2 B,D). 
The comparison of the treatment groups to the control of WT tumors, showed no 
significant difference in the percentages of Treg (Fig.3.2.4.2 C). 
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Fig.3.2.4. 2 Quantification of Treg in spleens and tumors from tumor-bearing WT and B7-H1 KO 
mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of Treg was analyzed by flow cytometry. Data 
from four independent experiments are presented as column bar graphs and box plots with SEM 
((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-
FU; IFNα+5-FU); control group vs. treatment groups; two-way (A) and one-way (B,C,D) ANOVA) 
 
Analyzing the proportion of Tcon out of the CD4+ T cells in spleens of WT and B7-H1 
KO tumor-bearing mice, one can see similar percentages of Tcon between WT and 
B7-H1 KO spleens throughout all groups (Fig.3.2.4.3 A). By looking at the groups of 
WT spleens alone, we registered a significant decrease in the frequency of Tcon in 
the groups of IFNα and IFNα+5-FU treatment compared to the control (Fig.3.2.4.3 B). 
In B7-H1 KO spleens, a significantly lower percentage of Tcon was seen in the group 
of 5-FU treatment compared to the control (Fig.3.2.4.3 D). 
The analysis of WT tumors revealed a significant increase in Tcon ratio in the group 
of IFNα+5-FU treatment compared to the control group (Fig.3.2.4.3 C). 
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Fig.3.2.4. 3 Quantification of Tcon in spleens and tumors from tumor-bearing WT and B7-H1 KO 
mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of Tcon was analyzed by flow cytometry. Data 
from four independent experiments are presented as column bar graphs and box plots with SEM 
((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-
FU; IFNα+5-FU); *p<0.05,**p<0.01, ***p<0.001; control group vs. treatment groups; two-way (A) and 
one-way (B,C,D) ANOVA) 
 
Furthermore, the percentages of activated Tcon (CD25+) in WT and B7-H1 KO 
tumor-bearing mice were determined. The measured differences in frequencies of 
activated Tcon were not significant between all groups from the WT and B7-H1 KO 
spleens (Fig.3.2.4.4 A). In WT spleens in detail, no significant difference in the ratio 
of activated Tcon was seen in the treatment groups compared to the control group 
(Fig.3.2.4.4 B). For spleens of B7-H1 KO mice, a significantly lower percentage of 
activated Tcon was observed in the group of IFNα treatment compared to the control 
group (Fig.3.2.4.4 D). 
The tumors of WT mice showed no significant difference in the percentages of Tcon 
between the control and treatment groups (Fig.3.2.4.4 C).  
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Fig.3.2.4. 4 Quantification of activated Tcon in spleens and tumors from tumor-bearing WT and 
B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of activated Tcon was analyzed by flow 
cytometry. Data from four independent experiments are presented as column bar graphs and box plots 
with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 4-6 
for IFNα; 5-FU; IFNα+5-FU); *p<0.05; control group vs. treatment groups; two-way (A) and one-way 
(B,C,D) ANOVA) 
 
Taken together, the analysis of Treg revealed no large impact in our different 
therapies on the frequencies of Treg in WT and B7-H1 KO tumor-bearing mice. 
Furthermore, no significant differences were observed when we compared the 
frequencies of Treg between WT and B7-H1 KO tumor-bearing mice. 
 
 
3.2.5 Analysis of dendritic cells (DC) 
The last major cell population we analyzed was the population of DC with their 
subsets of conventional DC (cDC) and plasmacytoid DC (pDC). Furthermore, we 
took a closer look at their maturation status, analyzed the expression of the 
costimulatory molecules CD80/CD86 as well as the expression of the regulatory 
molecules B7-H1/B7-DC. The gating strategy for our DC panel is shown in 
Fig.3.2.5.1. The FACS data (dot-plot, histogram) represent one typical result out of 
four independent experiments. 
Spleen
co IFNa 5-FU IFNa + 5-FU
0
2
4
6
WT
KO
T
re
g
, 
%
 o
f 
C
D
4
+
 c
e
ll
s
Spleen
co IFNa 5-FU IFNa  + 5-FU
0
2
4
6
T
re
g
, 
%
 o
f 
C
D
4
+
 c
e
ll
s
Tumor
co IFNa 5-FU IFNa  + 5-FU
0
10
20
30
40
50
T
re
g
, 
%
 o
f 
C
D
4
+
 c
e
ll
s
Spleen
co IFNa 5-FU IFNa  + 5-FU
0
2
4
6
8
T
re
g
, 
%
 o
f 
C
D
4
+
 c
e
ll
s
Spleen
co IFNa 5-FU IFNa + 5-FU
0
20
40
60
80
100
WT
KO
T
c
o
n
, 
%
 o
f 
C
D
4
+
c
e
ll
s
Spleen
co IFNa 5-FU IFNa  + 5-FU
70
80
90
100
***
**
T
c
o
n
, 
%
 o
f 
C
D
4
+
c
e
ll
s
Tumor
co IFNa 5-FU IFNa  + 5-FU
0
20
40
60
80
100 *
T
c
o
n
, 
%
 o
f 
C
D
4
+
c
e
ll
s
Spleen
co IFNa 5-FU IFNa  + 5-FU
70
75
80
85
90
*
T
c
o
n
, 
%
 o
f 
C
D
4
+
c
e
ll
s
Spleen
co IFNa 5-FU IFNa + 5-FU
0.0
0.2
0.4
0.6
0.8
1.0
WT
KO
a
c
ti
v
a
te
d
 T
c
o
n
, 
%
 o
f 
C
D
4
+
T
 c
e
ll
s Spleen
co IFNa 5-FU IFNa  + 5-FU
0.0
0.2
0.4
0.6
0.8
1.0
 a
c
ti
v
a
te
d
 T
c
o
n
, 
%
 o
f 
C
D
4
+
c
e
ll
s
Tumor
co IFNa 5-FU IFNa  + 5-FU
0
2
4
6
8
10
a
c
ti
v
a
te
d
 T
c
o
n
, 
%
 o
f 
C
D
4
+
T
 c
e
ll
s Spleen
co IFNa 5-FU IFNa  + 5-FU
0.0
0.2
0.4
0.6
0.8
1.0
*
 a
c
ti
v
a
te
d
 T
c
o
n
, 
%
 o
f 
C
D
4
+
c
e
ll
s
A                                                              B                                                            C                                                              D
A                                                              B                                                            C                                                              D
A                                                              B                                                           C                                                               D
WT B7-H1 KO
WT B7-H1 KO
WT B7-H1 KO
 
 Results 
 
  
 
135 
 
 
 
 
 Results 
 
  
 
136 
 
 
 
 
 
 
 
 
 
 
 
 Results 
 
  
 
137 
 
or 
 
Fig.3.2.5. 1 Gating strategy for dendritic cells in spleens and tumors using flow cytometry. 
The first gate was set on CD45
+
 cells, and out of those, all the living cells were gated using FSC/SSC 
dot plot. Then the two subsets of DC, conventional DC (cDC) and plasmacytoid DC (pDC), were gated 
according to the expression of CD11c and either CD11b or CD45R markers. The I-Ab antibody was 
used to define the maturation status of cDC and pDC. Mature cDC and pDC, and further analyzed for 
the expression of CD80 and CD86 as well as the expression of B7-H1/B7-DC molecules. All positive 
gates were set according to FMO controls. 
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In the DC panel, we started with the analysis of the cDC cell population. WT and B7-
H1 KO spleens from tumor-bearing mice in comparison showed no significant 
difference in the frequency of cDC between all four groups of both mouse strains 
(Fig.3.2.5.2 A). When looking at WT spleens in detail, no significant difference in 
percentage of cDC was seen between the control group and the treatment groups 
(Fig.3.2.5.2 B). In B7-H1 KO mice, significantly lower percentages of cDC were found 
in the groups of IFNα and IFNα+5-FU treatments compared to the control group 
(Fig.3.2.5.2 D). 
In WT tumors, a significant decrease of cDC portion was determined in the IFNα+5-
FU group compared to the control group (Fig.3.2.5.2 C) 
After we analyzed the frequency of the cDC population, we also determined the 
maturation status of this cell fraction. For spleens from WT and B7-H1 KO tumor-
bearing mice in comparison, similar values were reached between WT and B7-H1 
KO throughout all treatments and the controls (Fig.3.2.5.2 E). In WT spleens, the 
treatment groups compared to the control in WT showed a significant decrease in 
percentage of mature cDC in the 5-FU and IFNα+5-FU treated animals (Fig.3.2.5.2 
F). For the groups of B7-H1 KO spleens, we found no significant difference in the 
ratio of mature cDC between the treatments and the control (Fig.3.2.5.2 H).  
In tumors of WT animals, significantly lower frequencies of mature cDC were found in 
the group of IFNα treatment compared to the control (Fig.3.2.5.2 G). 
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Fig.3.2.5. 2 Quantification of cDC and their maturation status in spleens and tumors from 
tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequencies of cDC and mature cDC were analyzed by 
flow cytometry. Data from four independent experiments are presented as column bar graphs and box 
plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 
4-6 for IFNα; 5-FU; IFNα+5-FU);  *p<0.05, **p<0.01; control group vs. treatment groups; two-way (A,E) 
and one-way (B,C,D,F,G,H) ANOVA) 
 
After we determined the frequencies of mature cDC, we analyzed the costimulatory 
molecules CD80 and CD86, starting with the expression of CD80 molecule. In the 
groups of IFNα, 5-FU and IFNα+5-FU treatments, a significantly increased 
expression of the D80 molecule, revealed by the determined percentages, was seen 
in spleens of B7-H1 KO compared to WT mice (Fig.3.2.5.3 A). When looking at the 
WT spleen groups in more detail, no significant difference in percentage of CD80+ 
mature cDC was seen between the treatment groups compared to the control, 
(Fig.3.2.5.3 B). Instead, in the spleens of B7-H1 KO mice a significant increase in the 
portion of CD80+, mature cDC was found in the groups of IFNα and 5-FU treatment 
compared to the control (Fig.3.2.5.3 D). 
The analysis of CD80 molecule expression in WT tumors revealed no significant 
difference between the single treatments compared to the control (Fig.3.2.5.3 C). 
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The measured MFI of CD80 molecule showed highly significant lower values in the 
spleens of B7-H1 KO compared to spleens from WT tumor-bearing mice in all four 
groups (Fig.3.2.5.3 E). In the WT spleens, no significant difference in CD80 MFI was 
registered between control and treatment groups (Fig.3.2.5.3 F). In B7-H1 KO 
spleens, significantly higher values in the MFI of CD80 were found in the groups of 
IFNα and 5-FU treatment compared to control (Fig.3.2.5.3 H). 
In tumors of WT mice, a significant increase in the value of CD80 MFI was recorded 
in the IFNα treated mice, whereas in the group of 5-FU treatment, a significant 
decrease in the value was seen compared to the control group (Fig.3.2.5.3 G). 
 
 
Fig.3.2.5. 3 Quantification of CD80 expression on mature cDC in spleens and tumors from 
tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD80
+
 mature cDC together with the MFI of 
CD80 was analyzed by flow cytometry. Data from four independent experiments are presented as 
column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-
FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU);  *p<0.05, **p<0.01; control group vs. 
treatment groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
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Next, we determined the differences in mature cDC that express CD86 molecules, 
between WT and B7-H1 KO spleens as well as between the single treatments 
compared to the control in both mouse strains. Significantly higher percentages of 
CD86 molecule expression were found in B7-H1 KO spleens in the groups of IFNα, 
5-FU, and IFNα+5-FU compared to those groups of WT spleens from tumor-bearing 
mice (Fig.3.2.5.4 A). Between the treatment groups and the control of WT spleens, 
no significant difference in CD86+ mature cDC was seen (Fig.3.2.5.4 B), whereas in 
the B7-H1KO spleens a significant increase in percentage of CD86+ mature cDC was 
found in IFNα treated animals compared to untreated ones (Fig.3.2.5.4 D). 
In the WT tumors, no significant difference in frequencies was determined between 
the treatment groups and the control group analyzing CD86+ mature cDC (Fig.3.2.5.4 
C). 
As one can see in the analysis of the MFI of CD86 on mature cDC, significantly lower 
values were observed in B7-H1 KO spleens compared to WT spleens in all four 
groups (Fig.3.2.5.4 E). Between the single groups in spleens of treated WT and B7-
H1 KO tumor-bearing mice, no significant difference in values of CD86 MFI was 
found between the control and the treatment groups in spleens from both the WT and 
B7-H1 KO mice (Fig.3.2.5.4 F,H). 
Furthermore, for WT tumors, no significant difference was measured for the MFI of 
CD86 when we compared treatment groups to the control (Fig.3.2.5.4 G). 
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Fig.3.2.5. 4 Quantification of CD86 expression on mature cDC in spleens and tumors from 
tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD86
+
 mature cDC was, together with the 
MFI of CD86, analyzed by flow cytometry. Data from four independent experiments are presented as 
column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-
FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); **p<0.01, ***p<0.001; control groups vs. 
treatment groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
Next, we analyzed the expression of the regulatory molecule B7-H1 on cDC in WT, 
respectively B7-DC in B7-H1 KO tumor-bearing mice. In spleens of WT mice, no 
significant difference in the frequency of B7-H1+ cDC was seen between treated and 
control animals (Fig.3.2.5.5 A). For the expression of B7-H1 molecule on cDC in WT 
tumors, similar values were found between the treatment groups and the control 
group (Fig.3.2.5.5 B). By comparing treatments and control of B7-H1 KO spleens, no 
significant difference in B7-DC expression on cDC was observed (Fig.3.2.5.5 C). 
Analyzing the B7-H1 MFI on cDC in WT spleens, no significant difference was 
determined for the treatment groups compared to the control group (Fig.3.2.5.5 D). In 
WT tumors, we found no statistically significant difference in B7-H1 MFI of cDC 
between treated mice and control mice (Fig.3.2.5.5 E). However, in spleens of B7-H1 
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KO mice, a significantly higher B7-DC MFI was found in the group of IFNα treatment 
compared to control (Fig.3.2.5.5 F). 
 
 
Fig.3.2.5. 5 Quantification of B7-H1/B7-DC expression on cDC in spleens and tumors from 
tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of B7-H1/B7-DC
+
 cDC together with the MFI 
of B7-H1/B7-DC was analyzed by flow cytometry. Data from four independent experiments are 
presented as box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; 
tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05; control group vs. treatment groups; 
one-way (A,B,C,D,F) ANOVA) 
 
After we had analyzed the population of cDC, we then took a detailed look at the 
pDC population. By comparing the frequencies of pDC out of all leucocytes between 
spleens of WT and B7-H1 KO tumor-bearing mice, no significant difference was 
found between both mouse strains in all four groups (Fig.3.2.5.6 A). As we looked at 
the single groups of WT and B7-H1 KO in more detail, no significant difference in the 
ratio of pDC was seen between the treatment groups and control, in splenocytes from 
both the WT and B7-H1 KO tumor-bearing mice (Fig.3.2.5.6 B,D). 
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In tumors of WT mice, the percentages of pDC in the control showed no significant 
difference compared to the treatment groups (Fig.3.2.5.6 C). 
The analysis of the frequencies of mature pDC revealed highly significant increases 
in the spleens of B7-H1 KO tumor-bearing mice compared to WT spleens throughout 
all four groups (Fig.3.2.5.6 E). Between the control and treatment groups in WT 
spleens, a significant decrease in percentage of mature pDC was found in the group 
of IFNα+5-FU compared to the control group (Fig.3.2.5.6 F). We observed no 
significant difference in the percentages of mature pDC between the control and 
treatment groups of B7-H1 KO (Fig.3.2.5.6 H). 
In tumors of WT mice, no significant difference was seen for the frequencies of 
mature pDC between the treatment groups and the control (Fig.3.2.5.6 G). 
 
 
Fig.3.2.5. 6 Quantification of pDC and their maturation status in spleens and tumors from 
tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequencies of pDC and mature pDC were analyzed by 
flow cytometry. Data from four independent experiments are presented as column bar graphs and box 
plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; tumors: n = 7 for co, n = 
4-6 for IFNα; 5-FU; IFNα+5-FU);  *p<0.05; control group vs. treatment groups; two-way (A,E) and one-
way (B,C,D,F,G,H) ANOVA) 
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The analysis of CD80 molecule expression on mature pDC revealed a tendency of 
higher percentages in spleens of WT mice compared to spleens of B7-H1 KO tumor-
bearing mice throughout all treatment groups and the controls (Fig.3.2.5.7 A). 
Between the single groups of either WT or B7-H1 KO spleens in comparison, no 
significant difference in the ratio of CD80+ mature pDC was determined between 
treatment groups and control, in both the WT and B7-H1 KO mice (Fig.3.2.5.7 B,D).  
For WT tumors, no significant change in percentages of CD80+ mature pDC was 
observed between the treatments and the control (Fig.3.2.5.7 C). 
When examining the MFI of CD80 molecule on mature pDC, the comparison of the 
groups of WT and B7-H1 KO spleens (Fig.3.2.5.7 E), as well as the comparison of 
the single groups of either WT or B7-H1 KO spleens, no significant difference 
between treatment groups and the control (Fig.3.2.5.7 F,H) was revealed. 
The MFI of CD80 on mature pDC of WT tumors showed no significant difference 
between the single treatment groups and the control group (Fig.3.2.5.7 G). 
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Fig.3.2.5. 7 Quantification of CD80 expression on mature pDC in spleens and tumors from 
tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD80
+
 mature pDC together with the MFI of 
CD80 was analyzed by flow cytometry. Data from four independent experiments are presented as 
column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-
FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU);*p<0.05, **p<0.01; control group vs. 
treatment groups; two-way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
In addition to the molecule CD80, we analyzed the expression of CD86 molecule on 
mature pDC. In the analysis of WT and B7-H1 KO spleens in comparison, no 
significant difference in the frequency of CD86+ mature pDC was recognized in all 
four groups (Fig.3.2.5.8 A). By looking at WT and B7-H1 KO spleens separately, 
similar ratios of CD86+ mature pDC were found when we compared treatments to the 
control, in spleens from both groups of WT and B7-H1 KO tumor-bearing mice 
(Fig.3.2.5.8 B,D). 
In WT tumors, no significant difference in percentages of CD86+ mature pDC was 
registered between the treatment groups and the control (Fig.3.2.5.8 C). 
Furthermore, the values of the measured MFI of CD86 of mature pDC showed no 
significant difference between the groups of WT and B7-H1 KO spleens (Fig.3.2.5.8 
E). In groups of WT and B7-H1 KO spleens in detail, no significant difference in the 
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values of CD86 MFI was observed between the treatment groups compared to the 
control, in both of the tumor-bearing mouse strains (Fig.3.2.5.8 F,H). 
The CD86 MFI of mature pDC in WT tumors showed no significant difference 
between the treatment groups and the control (Fig.3.2.5.8 G). 
 
 
Fig.3.2.5. 8 Quantification of CD86 expression on mature pDC in spleens and tumors from 
tumor-bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of CD86
+
 mature pDC together with the MFI of 
CD86 was analyzed by flow cytometry. Data from four independent experiments are presented as 
column bar graphs and box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-
FU; tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); control group vs. treatment groups; two-
way (A,E) and one-way (B,C,D,F,G,H) ANOVA) 
 
In this part of the experiment, we examined the B7-H1 expression on pDC in WT 
mice, and the B7-DC expression on pDC in B7-H1 KO tumor-bearing mice. The 
frequency of B7-H1 expression on pDC in WT spleens showed no significant 
difference between the control and treatment groups (Fig.3.2.5.9 A). In tumors of WT 
mice, the frequencies of B7-H1
+
 pDC were similar between the treatment groups and 
the control (Fig.3.2.5.9 B). In spleens of B7-H1 KO mice, no significant difference in 
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the ratio of B7-DC+ pDC was determined in the comparison of treatment groups to 
the control group (Fig.3.2.5.9 C). 
The analysis of B7-H1 MFI of pDC revealed no significant difference in values 
between the treatment groups and the control in both spleens and tumors of WT mice 
(Fig.3.2.5.9 D,E). For the B7-DC MFI of pDC in B7-H1 KO spleens, similar values 
were determined for the treatment groups compared to the control (Fig.3.2.5.9 F). 
 
Fig.3.2.5. 9 Quantification of B7-H1/B7-DC expression of pDC in spleens and tumors of tumor-
bearing WT and B7-H1 KO mice with and without treatment (co). 
Mice were treated with IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. Untreated mice were used as control. Four weeks after surgery, the mice were killed and 
the organs were eviscerated. Single-cell suspensions of spleens and tumors were stained with 
fluorescence labeled specific antibodies. The frequency of B7-H1/B7-DC
+
 pDC together with the MFI 
of B7-H1/B7-DC was analyzed by flow cytometry. Data from four independent experiments are 
presented as box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; 
tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); control group vs. treatment groups; one-way 
(A,B,C,D,F) ANOVA) 
 
To summarize the results seen in the analysis of the DC populations, no significant 
differences were found in the comparison of WT and B7-H1 KO spleens from tumor-
bearing mice. Between the different treatments compared to the control of either WT 
or B7-H1 KO spleens, occasional significant differences were observed. 
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3.3 Effects of chemo (5-FU) - and immunotherapy (IFNα) on cytokine 
concentration in blood serum of tumor-bearing WT and B7-H1 KO 
mice 
 
In order to investigate the in vivo effect of 5-FU and IFNα treatment on systemic 
cytokine production in tumor-bearing WT and B7-H1 KO mice, we treated them with 
either IFNα, 5-FU or the combination of IFNα+5-FU on Day 5, 7 and 9 after Panc02 
implantation. One group was kept untreated and used as the control. After a period of 
four weeks the mice were killed, the serum samples collected and analyzed for the 
presence of Transforming growth factor beta (TGF-ß), Interleukin-1 beta (IL-1ß), 
Interleukin-2 (IL-2), Interleukin-6 (IL-6) and Vascular endothelial growth factor 
(VEGF) using Luminex approaches. We compared the determined cytokine 
production between WT and B7-H1 KO mice as well as between different treatment 
groups for WT or B7-H1 KO mice separately.  
 
For TGF-ß, there was no significant difference measured between untreated control 
WT and B7-H1 KO tumor-bearing mice (Fig.3.3.1 A). Moreover, we did not find any 
significant differences between control and therapy groups for both the WT and B7-
H1 KO mice (Fig.3.3.1 B,C). 
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Fig.3.3. 1 Quantification of TGF-ß in serum samples of WT and B7-H1 KO tumor-bearing mice 
with and without treatment (co). 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα, 5-FU or the combination of 
IFNα+5-FU. Four weeks after the surgery, blood was collected prior to killing of the mice. After clotting 
and centrifugation, the serum was processed by Luminex approach. The amount of TGF-ß was 
measured and analyzed using Bio-Plex Manager 4.0. Data from four independent experiments are 
presented as box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; 
tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); control group vs. treatment groups; T-test 
(A) and one-way (B,C) ANOVA) 
 
Assessing the cytokine IL-1ß, significantly lower amounts of IL-1ß were found in the 
untreated control B7-H1 KO compared to WT tumor-bearing mice (Fig.3.3.2 A). In the 
analysis of the WT groups, no significant difference was seen between the treated 
and control groups (Fig.3.3.2 B), whereas in B7-H1 KO mice, the concentration of IL-
1ß was significantly increased in IFNα and IFNα+5-FU groups as compared with the 
control (Fig.3.3.2 C). 
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Fig.3.3. 2 Quantification of IL-1ß in serum samples of WT and B7-H1 KO mice with and without 
treatment (co). 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα, 5-FU or the combination of 
IFNα+5-FU. Four weeks after the surgery, blood was collected prior to killing of the mice. After clotting 
and centrifugation, the serum was processed by Luminex approach. The amount of IL-1ß was 
measured and analyzed using Bio-Plex Manager 4.0. Data from four independent experiments are 
presented as box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; 
tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05; control group vs. treatment groups; 
T-test (A) and one-way (B,C) ANOVA) 
 
The comparison between untreated control WT and B7-H1 KO tumor-bearing mice 
showed no significant difference in the concentration of IL-2 (Fig.3.3.3 A). Looking at 
WT alone, a significant increase of IL-2 concentration was measured in the samples 
of IFNα+5-FU treated animals as compared with WT control (Fig.3.3.3 B). However, 
in B7-H1 KO significantly higher amounts of IL-2 were seen in the group of 5-FU 
compared to the control (Fig3.3.3 C). 
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Fig.3.3. 3 Quantification of IL-2 in serum samples of WT and B7-H1 KO mice with and without 
treatment (co). 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα, 5-FU or the combination of 
IFNα+5-FU. Four weeks after the surgery, blood was collected prior to killing of the mice. After clotting 
and centrifugation, the serum was processed by Luminex approach. The amount of IL-2 was 
measured and analyzed using Bio-Plex Manager 4.0. Data from four independent experiments are 
presented as box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; 
tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05, **p<0.001; control group vs. 
treatment groups; T-test (A) and one-way (B,C) ANOVA) 
 
For the IL-6 cytokine, no significant difference in the concentration was found 
between untreated control WT and B7-H1 KO tumor-bearing mice (Fig.3.3.4 A). A 
significant increase of the IL-6 amount was found in the WT animals treated with 
IFNα+5-FU as compared to the control (Fig.3.3.4 B). However, in the B7-H1 KO 
mice, a significant increase was found in the 5-FU group compared to the control 
(Fig.3.3.4 C). 
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Fig.3.3. 4 Quantification of IL-6 in serum samples of WT and B7-H1 KO mice with and without 
treatment (co). 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα, 5-FU or the combination of 
IFNα+5-FU. Four weeks after the surgery, blood was collected prior to killing of the mice. After clotting 
and centrifugation, the serum was processed by Luminex approach. The amount of IL-6 was 
measured and analyzed using Bio-Plex Manager 4.0. Data from four independent experiments are 
presented as box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; 
tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05, **p<0.01; control group vs. 
treatment groups; T-test (A) and one-way (B,C) ANOVA) 
 
 
The last parameter we determined was VEGF. Between untreated control WT and 
B7-H1 KO tumor-bearing mice, a significantly lower amount of VEGF was found in 
B7-H1 KO mice compared to WT mice (Fig.3.3.5 A). Moreover, in WT samples, 
continued decreased levels were found between control, IFNα, 5-FU and IFNα+5-FU, 
with the lowest measured amounts of VEGF in the  IFNα+5-FU sample (Fig.3.3.5 B). 
However, in B7-H1KO mice, no significant difference in VEGF concentration was 
determined between control and treatment groups (Fig.3.3.5 C). 
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Fig.3.3. 5 Quantification of VEGF in serum samples of WT and B7-H1 KO mice with and without 
treatment (co). 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα, 5-FU or the combination of 
IFNα+5-FU. Four weeks after the surgery, blood was collected prior to killing of the mice. After clotting 
and centrifugation, the serum was processed by Luminex approach. The amount of VEGF was 
measured and analyzed using Bio-Plex Manager 4.0. Data from four independent experiments are 
presented as box plots with SEM ((spleens: n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU; 
tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05, **p<0.01, ***p<0.001; control group 
vs. treatment groups; T-test (A) and one-way (B,C) ANOVA) 
 
 
Taken together, in this experiment series where we analyzed in vivo cytokine 
production, we observed a significant difference in the cytokine production of IL-1ß 
and VEGF between WT and B7-H1 KO tumor-bearing mice, with lower 
concentrations of both cytokines in the B7-H1 KO mice. 
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3.4 Role of B7-H1 expression on the functional phenotype of MDSC 
and on the sensitivity of splenocytes to MDSC mediated 
suppression 
 
3.4.1 Effect of B7-H1 expression on the functional phenotype of MDSC 
In this first phase of this experiment series, we examined whether the presence of 
B7-H1 molecule has an effect on the functional phenotype of MDSC. To achieve this, 
we isolated MDSC from tumors of WT and B7-H1 KO mice using the MACS 
procedure and analyzed them with the help of flow cytometry. Their functional status 
was determined by assessing the iNOS and Arginase production from total MDSC as 
well as from their two subsets, granulocytic and monocytic MDSC. 
 
The gating strategy for myeloid derived suppressor cells (MDSC) is shown in 
Fig.3.4.1.1. The FACS data (dot-plot, histogram) represent one typical result out of 
three independent experiments. 
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Fig.3.4.1. 1 Gating strategy for MDSC in tumors of untreated tumor-bearing WT and B7-H1 KO 
mice using flow cytometry. 
Leukocytes were gated using FSC/SSC dot plot. Afterwards, we gated on CD45
+
 cells and further on 
the cell population of Gr-1
+
CD11b
+
 MDSC was marked. Then the two subsets of MDSC, granulocytic 
and monocytic MDSC were gated according to the expression of Ly-6G and Ly-6C. For the functional 
status, the iNOS
+
 and Arginase
+
 subsets were determined from all MDSC as well as from both subsets 
using histograms. All positive gates were set according to FMO controls. 
 
First we determined the frequency of MDSC out of all leukocytes. A significantly 
lower percentage of MDSC was observed in tumors of B7-H1 KO mice compared to 
tumors of WT mice (Fig.3.4.1.2). 
 
 
Fig.3.4.1. 2 Quantification of MDSC in tumors of untreated tumor-bearing WT and B7-H1 KO 
mice. 
Four weeks after Panc02 implantation, the mice were killed and their organs were eviscerated. Single-
cell suspensions of tumors were stained with specific antibodies. The frequency of MDSC was 
analyzed by flow cytometry. Data from three independent experiments are presented as box plots with 
SEM (( n = 15 for WT, and n = 5 for KO);**p<0.01;T-test) 
 
Next, we looked at the percentages of iNOS+ cells out of total MDSC in WT and B7-
H1 KO tumor-bearing mice. As one can see in Fig.3.4.1.3, no significant change in 
frequencies of iNOS
+
 MDSC was seen between WT and B7-H1 KO tumor-bearing 
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mice. The iNOS MFI from MDSC showed no significant change in values between 
both the WT and B7-H1 KO mice. 
 
 
Fig.3.4.1. 3 Quantification of iNOS
+
 cells of the total MDSC in tumors of untreated tumor-
bearing WT and B7-H1 KO mice. 
Four weeks after Panc02 implantation, the mice were killed and their organs were eviscerated. Single-
cell suspensions of tumors were stained with specific antibodies. The frequency of iNOS
+
 cells, 
together with the MFI for iNOS, was analyzed by flow cytometry. Data from three independent 
experiments are presented as box plots with SEM (n = 15 for WT, and n = 5 for KO; T-test) 
 
The analysis of WT tumors revealed no significant difference in the percentages of 
Arg+ MDSC out of total MDSC as compared to those from B7-H1 KO tumors. When 
analyzing the MFI of Arg, no significant changes in values were detected between 
the samples of WT compared to samples of B7-H1 KO tumor-bearing mice 
(Fig.3.4.1.4). 
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Fig.3.4.1. 4 Quantification of Arg
+
 cells of total MDSC in tumors of untreated tumor-bearing WT 
and B7-H1 KO mice. 
Four weeks after Panc02 implantation, the mice were killed and their organs were eviscerated. Single-
cell suspensions of tumors were stained with specific antibodies. The frequency of Arg
+
 cells, together 
with the MFI for Arg, was analyzed by flow cytometry. Data from three independent experiments are 
presented as box plots with SEM (n = 15 for WT, and n = 5 for KO;T-test) 
 
Furthermore, we analyzed the granulocytic (gMDCS) and monocytic (mMDSC) 
subsets of MDSC. Significantly lower percentages of gMDSC out of the total Gr-1+ 
CD11b+ population were seen in B7-H1 KO tumors compared to tumors of WT mice. 
For the mMDSC out of the total MDSC, a tendency towards higher frequencies was 
determined in B7-H1 KO mice compared to WT mice (Fig.3.4.1.5). 
 
 
 
 
MDSC
WT KO
0
10
20
30
40
50
**
%
 o
f
le
u
k
o
c
y
te
s
iNOS
+
cells
WT KO
0
20
40
60
80
100
%
 o
f
to
ta
l
M
D
S
C
iNOS
WT KO
0
200
400
600
800
M
F
I 
o
f
M
D
S
C
Arg
+
cells
WT KO
60
70
80
90
100
110
%
 o
f
to
ta
l
M
D
S
C
Arg
WT KO
0
500
1000
1500
2000
M
F
I 
o
f
M
D
S
C
 
 Results 
 
  
 
160 
 
 
Fig.3.4.1. 5 Quantification of granulocytic and monocytic MDSC out of the total MDSC in 
tumors of untreated tumor-bearing WT and B7-H1 KO mice. 
Four weeks after Panc02 implantation, the mice were killed and their organs were eviscerated. Single-
cell suspensions of tumors were stained with specific antibodies. The frequencies of granulocytic and 
monocytic MDSC were analyzed by flow cytometry. Data from three independent experiments are 
presented as box plots with SEM (( n = 15 for WT, and n = 5 for KO);*p<0.05;T-test ) 
 
Afterwards, we measured the frequencies of iNOS+ and Arg+ cells out of gMDSC. 
The analysis of iNOS+ cells showed a clear tendency towards lower percentages for 
iNOS+ gMDSC in tumors of B7-H1 KO mice compared to WT tumors. The MFI of 
iNOS from gMDSC showed no significant difference between WT and B7-H1 KO 
tumor-bearing mice. For the Arg production, no significant difference was determined 
between WT and B7-H1 KO mice. The MFI of Arg on gMDSC revealed no significant 
difference between both the WT and B7-H1 KO tumor-bearing mice (Fig.3.4.1.6). 
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Fig.3.4.1. 6 Quantification of iNOS
+
 and Arg
+
 cells out of granulocytic MDSC in tumors of 
untreated tumor-bearing WT and B7-H1 KO mice. 
Four weeks after Panc02 implantation, the mice were killed and their organs were eviscerated. Single-
cell suspensions of tumors were stained with specific antibodies. The frequencies of iNOS
+
 and Arg
+
 
cells, together with the MFI for iNOS and Arg, were analyzed by flow cytometry. Data from three 
independent experiments are presented as box plots with SEM (n = 15 for WT, and n = 5 for KO; T-
test) 
 
In B7-H1KO mice, the ratio of iNOS+ cells within the mMDSC population was 
significantly lower compared to the WT mice. Beyond that, the iNOS MFI of mMDSC 
was significantly lower in B7-H1 KO mice compared to WT mice (Fig.3.4.1.7). 
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Fig.3.4.1. 7 Quantification of iNOS
+
 cells out of monocytic MDSC in tumors of untreated tumor 
bearing WT and KO mice. 
Four weeks after Panc02 implantation, the mice were killed and their organs were eviscerated. Single-
cell suspensions of tumors were stained with specific antibodies. The frequency of iNOS
+
 cells, 
together with the MFI for iNOS, was analyzed by flow cytometry. Data from three independent 
experiments are presented as box plots with SEM ((n = 15 for WT, and n = 5 for KO); *p<0.05;T-test) 
 
Taken together, this phase of the experiment series revealed a lower frequency of 
MDSC in B7-H1 KO tumor-bearing mice compared to WT mice. Furthermore, we 
detected a shift in the distribution of MDSC subsets, with lower ratios of gMDSC in 
B7-H1 KO tumor-bearing mice compared to WT mice. Concerning the functional 
status of MDSC, we observed a decrease in iNOS+ MDSC of B7-H1 KO compared to 
the WT tumor-bearing mice. 
 
 
3.4.2 Effect of B7-H1 expression on the sensitivity of splenocytes to MDSC 
mediated suppression 
 
In this second part of this experiment series, we examined whether the presence of 
B7-H1 makes splenocytes from tumor-bearing mice more sensitive to MDSC 
mediated suppression. For this experiment, we cocultured the MACS isolated MDSC 
from tumors of WT mice with CFSE labeled splenocytes from WT and B7-H1KO 
tumor-bearing mice.  
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The experiment was performed in the presence/absence of CD3/CD28 activation. 
After 72 hours of incubation, we harvested the cells and analyzed them using flow 
cytometry. With the help of the CFSE labeling, we determined the proliferation status 
of the CD4+/CD8+ T cell populations within splenocytes, and analyzed the inhibitory 
effect of MDSC on proliferated CD4+/CD8+ T cells of WT and B7-H1 KO tumor-
bearing mice. 
 
The gating strategy for CD4
+
 and CD8
+
 T cells is shown in Fig.3.4.2.1. Here the 
intracellular panel was used because of the better CFSE performance. The FACS 
data (dot-plot, histogram) represent one typical result out of three independent 
experiments. 
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Fig.3.4.2. 1 Gating strategy for CD4
+
/CD8
+
 T cells in cocultures of MDSC and CFSE labeled 
splenocytes using flow cytometry. 
All activated and non-avtivated lymphocytes were gated using FSC/SSC dot plot. Furthermore, the 
CD45
+ 
cells were gated, and out of those we determined the CD4
+
/CD8
+
 T cells. The proliferation 
status of CD4
+
/CD8
+
 T cell population was determined and analyzed by the intensity of CFSE staining. 
 
First, we determined the percentages of proliferated CD4+ T cells out of all CD4+ T 
cells and compared those between the cells of WT and B7-H1 KO mice. As 
expected, without prior cell activation no proliferation was seen; neither in WT nor in 
B7-H1 KO spleens. After activation, significantly higher ratios of proliferated CD4+ T 
cells were seen in both the WT and B7-H1 KO mice (Fig.3.4.2.2 B,C). Moreover, a 
significant difference was seen between WT and B7-H1 KO mice, with lower 
percentages of proliferated CD4+ T cells measured in B7-H1 KO mice compared to 
WT mice (Fig.3.4.2.2 A). 
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Fig.3.4.2. 2 Quantification of proliferated CD4
+
 T cells out of WT and B7-H1 KO splenocytes in 
culture. 
Four weeks after Panc02 implantation, the mice were killed and their organs eviscerated. Freshly 
isolated splenocytes were labeled with CFSE and cultured in the presence/ absence of CD3/CD28 
antibody for 72 hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies 
and analyzed by flow cytometry. Data from three independent experiments are presented as column 
bar graphs with SEM ((n = 15 for WT, and n = 5 for KO);**p<0.01; two-way ANOVA (A) and T-test 
(B,C)) 
 
After we examined the activation and proliferation status of CD4+ T cells, we 
analyzed whether MDSC from WT tumors could inhibit this proliferation, and if the 
splenocytes from WT and B7-H1 KO mice have different sensitivities to the MDSC 
mediated suppression. For this, we added WT MDSC to the activated splenocytes 
from either WT or B7-H1 KO mice. As one can see in Fig.3.4.2.3 B, a significant 
inhibition of proliferated CD4+ T cells in the WT spleens was achieved after adding 
MDSC to the culture. In cultures of splenocytes from B7-H1 KO mice, also a clear 
tendency towards inhibition of proliferated CD4+ T cells was measured after WT 
MDSCs were added (Fig.3.4.2.3 C). In Fig.3.4.2.3 A, the comparison between WT 
and B7-H1KO cultures is shown. The significant difference in the frequency of 
proliferated CD4+ T cells between WT and B7-H1 KO splenocytes can be seen. After 
adding inhibitory MDSC to proliferated CD4+ T cells, no significant difference in the 
percentage of inhibited cells was observed between cultures of WT and B7-H1 KO 
splenocytes (Fig.3.4.2.3 A). 
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Fig.3.4.2. 3 Effect of MDSC on proliferated CD4
+
 T cells out of WT and B7-H1 KO splenocytes in 
coculture. 
Four weeks after Panc02 implantation, the mice were killed and their organs eviscerated. Freshly 
isolated splenocytes were labeled with CFSE and cultured in the presence/absence of CD3/CD28 
antibody. WT MDSC were added to the culture. After 72 hours, the cells were stained with 
fluorescence labeled specific antibodies and the inhibitory effect of MDSC on proliferated CD4
+
 T cells 
was analyzed by flow cytometry. Data from three independent experiments are presented as column 
bar graphs with SEM ((n = 15 for WT, and n = 5 for KO);**p<0.01; two-way ANOVA (A) and T-test 
(B,C)) 
 
Afterwards, we analyzed the CD8+ T cell population. Without activation with a 
CD3/CD28 antibody, no proliferation of CD8+ T cells occurred. After activation, in 
cultures from both WT and B7-H1 KO mice, a significant increase in proliferated 
CD8+ T cells out of all CD8+ T cells was determined (Fig.3.4.2.4 B,C). As we 
compared WT and B7-H1 KO cultures to each other, no significant difference in the 
frequency of proliferated CD8+ T cells was seen between WT and B7-H1 KO mice 
(Fig.3.4.2.4 A). 
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Fig.3.4.2. 4 Quantification of proliferated CD8
+
 T cells out of WT and B7-H1 KO splenocytes in 
culture. 
Four weeks after Panc02 implantation, the mice were killed and their organs eviscerated. Freshly 
isolated splenocytes were labeled with CFSE and cultured in the presence/ absence of CD3/CD28 
antibody for 72 hours. Afterwards, the cells were stained with fluorescence labeled specific antibodies 
and analyzed by flow cytometry. Data from three independent experiments are presented as column 
bar graphs with SEM (n = 15 for WT, and n = 5 for KO);*p<0.05, ***p<0.001;two-way ANOVA (A) and 
T-test (B,C)) 
 
After adding MDSC from the WT tumors to the activated cultures, a significant 
inhibition of proliferated CD8+ T cells was observed in cultures of WT splenocytes 
(Fig.3.4.2.5 B). In the samples of B7-H1KO splenocytes, a tendency towards an 
inhibition of proliferated CD8+ T cells was seen after adding MDSC from WT tumors 
to the cultures (Fig.3.4.2.5 C). For the percentages of proliferated CD8+ T cells out of 
all CD8+ T cells, a significant difference was found between splenocytes of WT and 
B7-H1KO mice, with lower proliferation in samples of B7-H1 KO mice. After adding 
inhibitory MDSC to proliferated CD8+ T cells, no significant difference in the 
frequency of inhibited cells was observed between cultures of WT and B7-H1 KO 
splenocytes (Fig.3.4.2.5 A). 
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Fig.3.4.2. 5Effect of MDSC on proliferated CD8
+
 T cells out of WT and B7-H1 KO splenocytes in 
coculture. 
Four weeks after Panc02 implantation, the mice were killed and their organs eviscerated. Freshly 
isolated splenocytes were labeled with CFSE and cultured in the presence/absence of CD3/CD28 
antibody. WT MDSC were added to the culture. After 72 hours, the cells were stained with 
fluorescence labeled specific antibodies and the inhibitory effect of MDSC on proliferated CD8
+
 T cells 
was analyzed by flow cytometry. Data from three independent experiments are presented as column 
bar graphs with SEM ((n = 15 for WT, and n = 5 for KO); **p<0.01; two-way ANOVA (A) and T-test 
(B,C)) 
 
Summarizing our results from this part of the experiment series, we observed that 
proliferation occurred after activation of CD4+ /CD8+ T cells from tumor-bearing mice. 
Furthermore, lower frequencies of proliferated CD4+ /CD8+ T cells were found in 
splenocytes of B7-H1 KO compared to WT mice. The inhibitory effect of WT MDSC 
on proliferated CD4+ /CD8+ T cells was seen in cultures of WT mice and B7-H1 KO 
tumor bearing mice. 
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3.5 Effects of B7-H1 presence on cytokines production in in vitro 
cocultures of WT/ B7-H1 KO splenocytes and WT MDSC 
 
In this experiment, we investigated the in vitro effect of a B7-H1 presence on cytokine 
production in cocultures of splenocytes from WT and B7-H1 KO tumor-bearing mice 
and WT MDSC (suppression assay). The MACS isolated MDSC from tumors of WT 
mice were cultivated with CFSE labeled splenocytes from WT and B7-H1 KO mice as 
in 3.4. The experiment was performed in the presence/ absence of CD3/CD28 
activation. After 72 hours of incubation we collected the medium supernatants and 
analyzed those for the presence of IFNγ, IL-1ß, IL-2, IL-6, IL-10, VEGF and TGF-ß 
using Luminex approach. We compared the cytokine production of WT and B7-H1 
KO splenocytes in the presence/ absence of CD3/CD28 activation. Moreover, we 
investigated the difference in cytokines production between WT and B7-H1 KO 
proliferated cells after their inhibition with MDSC. 
 
First, we analyzed the cytokine IFNγ. In WT samples, a significantly higher 
concentration of IFNy was found after activation of the cells with CD3/CD28 antibody 
(Fig.3.5.1 B). Also in the group of B7-H1 KO, a significant increase in IFNy 
concentration was found after activation of splenocytes (Fig.3.5.1 C). By comparing 
WT to B7-H1KO groups, one can see a significantly higher value of IFNγ 
concentration in B7-H1 KO compared to WT for both the activated and non-activated 
splenocytes (Fig.3.5.1 A). 
Next, we looked at the change in cytokine concentration after adding inhibitory MDSC 
to the activated samples. In samples containing WT MDSC, we saw a tendency to 
lower concentrations of IFNγ compared to activated samples without WT MDSC in 
both groups of WT and B7-H1 KO splenocytes (Fig.3.5.1 E,F). In Fig.3.5.1 D, the 
comparison of IFNy concentration between cultures of WT and B7-H1 KO mice is 
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shown. No significant difference in the concentration of IFNy was determined when 
we compared activated WT and B7-H1 KO samples to each other. After adding 
inhibitory MDSC to activated cultures, no significant difference in the IFNy 
concentration was observed between cultures of WT and B7-H1 KO splenocytes 
(Fig.3.5.1 D). 
 
 
Fig.3.5.1 Quantification of IFNγ in supernatants from cocultures of WT or B7-H1 KO 
splenocytes (+/- activation) with and without MDSC from WT tumors. 
After 72 hours, the medium supernatant of the cocultures of CFSE labeled splenocytes and MDSC 
was collected and processed by Luminex approach. The concentration of IFNγ was measured and 
analyzed using Bio-Plex Manager 4.0. Data are presented as column bar graphs with SEM (n =2-
3;*p<0.05,**p<0.01; two-way ANOVA (A,D) and T-test (B,C,E,F)) 
 
For the cytokine IL-1ß, no significant difference in concentrations was observed 
between samples with or without activation in the WT group (Fig.3.5.2 B). In B7-H1 
KO, a tendency towards a higher IL-1ß concentration was found in samples after 
activation with CD3/CD28 antibody compared to the ones without activation 
(Fig.3.5.2 C). Analyzing the IL-1ß concentration of WT and B7-H1 KO in comparison, 
no significant difference was seen between WT and B7-H1 KO in both the activated 
and non-activated samples (Fig.3.5.2 A).  
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In the presence of inhibitory MDSC, no significant difference in IL-1ß concentration 
was seen, neither in the WT group nor in the B7-H1 KO group, compared to samples 
without MDSC (Fig.3.5.2 E,F). In the analysis of WT and B7-H1KO groups in 
comparison, one sees in Fig.3.5.2 D no significant difference in the concentration of 
IL-1ß in samples without MDSC. After adding inhibitory MDSC to activated cultures, 
no significant difference in the IFNy concentration was observed between cultures of 
WT and B7-H1 KO splenocytes (Fig.3.5.2 D). 
 
 
Fig.3.5. 2 Quantification of IL-1ß in supernatants from cocultures of WT or B7-H1 KO 
splenocytes (+/- activation) with and without MDSC from WT tumors. 
After 72 hours, the medium supernatant of the cocultures of CFSE labeled splenocytes and MDSC 
was collected and processed by Luminex approach. The concentration of IL-1ß was measured and 
analyzed using Bio-Plex Manager 4.0. Data are presented as column bar graphs with SEM (n =2-3; 
two-way ANOVA (A,D) and T-test (B,C,E,F)) 
 
Next, we determined the changes in IL-2 concentration. When looking at WT and B7-
H1 KO groups separately, significantly higher concentrations of IL-2 were found after 
activation with CD3/CD28 antibody in both the WT and B7-H1 KO groups (Fig.3.5.3 
B,C). Between WT and B7-H1 KO in comparison, no significant difference in IL-2 
concentration was seen in activated or non-activated samples (Fig.3.5.3 A). 
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After the coculture of MDSC with activated splenocytes, no change in the 
concentration of IL-2 was measured compared to cultures without MDSC; neither in 
WT nor in B7-H1 KO groups (Fig.3.5.3 E,F). As we compared WT and B7-H1KO to 
each other, we have seen again no significant difference in IL-2 concentration in 
activated cultures between WT and B7-H1 KO. After adding WT MDSC to activated 
cultures, no significant difference in the IL-2 concentration was seen between 
cultures of WT and B7-H1 KO splenocytes (Fig.3.5.3 D). 
 
 
Fig.3.5. 3 Quantification of IL-2 in supernatants from cocultures of WT or B7-H1 KO 
splenocytes (+/- activation) with and without MDSC from WT tumors. 
After 72 hours, the medium supernatant of the cocultures of CFSE labeled splenocytes and MDSC 
was collected and processed by Luminex approach. The concentration of IL-2 was measured and 
analyzed using Bio-Plex Manager 4.0. Data are presented as column bar graphs with SEM (n =2-3; 
*p<0.05,**p<0.01; two-way ANOVA (A,D) and T-test (B,C,E,F)) 
 
The analysis of the cytokine IL-6 is shown in the Fig.3.5.4. In the WT group, a 
tendency towards higher concentrations was found in the presence of CD3/CD28 
activating antibody (Fig.3.5.4 B). In the B7-H1 KO group, a significant increase in IL-6 
concentration was found after activation compared to non-activated samples 
(Fig.3.5.4 C). In WT non-activated cultures compared to B7-H1 KO, no significant 
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difference was registered. However, after activation, in cultures of B7-H1 KO 
splenocytes, significantly lower concentrations of IL-6 were measured compared to 
cultures of WT splenocytes (Fig.3.5.4 A). 
In the inhibitory presence of MDSC, the tendency towards higher concentrations of 
IL-6 was seen in WT, as well as B7-H1 KO groups, compared to samples without 
MDSC presence (Fig.3.5.4 E,F). In Fig.3.5.4 D, the comparison of IL-6 concentration 
between cultures of WT and B7-H1 KO mice is shown. No significant difference in the 
concentration of IL-6 was determined when we compared activated WT and B7-H1 
KO samples to each other. After adding inhibitory MDSC to activated cultures, a 
tendency towards lower IL-6 concentration was observed in cultures of B7-H1 KO 
compared to WT splenocytes (Fig.3.5.4 D). 
 
 
Fig.3.5. 4 Quantification of IL-6 supernatants from cocultures of WT or B7-H1 KO splenocytes 
(+/- activation) with and without MDSC from WT tumors. 
After 72 hours, the medium supernatant of the cocultures of CFSE labeled splenocytes and MDSC 
was collected and processed by Luminex approach. The concentration of IL-6 was measured and 
analyzed using Bio-Plex Manager 4.0. Data are presented as column bar graphs with SEM (n =2-
3;*p<0.05,**p<0.01; two-way ANOVA (A,D) and T-test (B,C,E,F)) 
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The comparison of activated and non-activated cultures showed no significant 
change in IL-10 concentrations in the WT group (Fig.3.5.5 B). In the group of B7-H1 
KO cells, a tendency towards higher lL-10 concentration was found after activation of 
splenocytes with CD3/CD28 antibody compared to non-activated samples (Fig.3.5.5 
C). The WT and B7-H1 KO non-activated cultures in comparison, showed no 
significant difference. However, in the activated cultures, a tendency towards higher 
IL-10 concentration was seen in the group of B7-H1 KO cells compared to the group 
of WT cells (Fig.3.5.5 A). 
After we added MDSC to activated WT cultures, the concentration of IL-10 was 
significantly higher compared to samples without MDSC (Fig.3.5.5 E). In B7-H1 KO 
cultures, no significant difference in IL-10 concentration between cultures with or 
without MDSC was determined (Fig.3.5.5 F). As we compared WT and B7-H1 KO to 
each other, first we again observed a tendency towards higher IL-10 concentration in 
activated cultures of B7-H1 KO compared to WT. After adding WT MDSC to activated 
cultures, the tendency towards lower IL-10 concentration was seen in cultures of B7-
H1 KO compared to WT splenocytes (Fig.3.5.5 D). 
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Fig.3.5. 5 Quantification of IL-10 in supernatants from cocultures of WT or B7-H1 KO 
splenocytes (+/- activation) with and without MDSC from WT tumors. 
After 72 hours, the medium supernatant of the cocultures of CFSE labeled splenocytes and MDSC 
was collected and processed by Luminex approach. The concentration of IL-10 was measured and 
analyzed using Bio-Plex Manager 4.0. Data are presented as column bar graphs with SEM (n =2-3; 
*p<0.05, **p<0.01; two-way ANOVA (A,D) and T-test (B,C,E,F)) 
 
Next, we analyzed the concentrations of VEGF, which had already been associated 
with the presence of MDSC in a tumor milieu. In samples of WT mice, no significant 
difference in the concentration of VEGF was found between cultures of WT 
splenocytes with activation compared to cultures without activation (Fig.3.5.6 B). In 
the B7-H1 KO group, a tendency towards higher VEGF concentration was measured 
in the presence of CD3/CD28 activation compared to non-activated samples 
(Fig.3.5.6 C). The comparison between WT and B7-H1 KO showed no significant 
difference in the concentration of VEGF between WT and B7-H1 KO, neither in the 
activated nor in the non-activated cultures (Fig.3.5.6 A). 
As one can see in Fig.3.5.6 E,F, significantly higher concentrations of VEGF were 
found in the presence of MDSC compared to cultures without inhibitory MDSC, in the 
cultures from both the WT and B7-H1 KO mice. Between WT and B7-H1 KO groups 
in comparison, no significant difference in VEGF concentration was seen between 
WT and B7-H1 KO in activated cultures without added MDSC. After adding inhibitory 
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MDSC to activated cultures, no significant difference in VEGF concentration was 
observed in cultures of WT compared to B7-H1 KO splenocytes (Fig.3.5.6 D). 
 
 
Fig.3.5. 6 Quantification of VEGF in supernatants from cocultures of WT or B7-H1 KO 
splenocytes (+/- activation) with and without MDSC from WT tumors. 
After 72 hours, the medium supernatant of the cocultures of CFSE labeled splenocytes and MDSC 
was collected and processed by Luminex approach. The concentration of VEGF was measured and 
analyzed using Bio-Plex Manager 4.0. Data are presented as column bar graphs with SEM (n =2-3; 
*p<0.05, **p<0.01; two-way ANOVA (A,D) and T-test (B,C,E,F)) 
 
The last parameter we analyzed was TGF-ß. In both the WT and B7-H1 KO groups 
of mice, the activation of splenocytes with CD3/CD28 antibody did not induce a 
significant change in the concentration of TGF-ß compared to the concentration in 
non-activated cultures (Fig.3.5.7 B,C). Furthermore, the comparison between B7-H1 
KO and WT cultures revealed no significant difference in the concentration of TGF-ß, 
neither before nor after activation (Fig.3.5.7 A). 
In the presence of MDSC, in the WT samples a trend towards a higher concentration 
of TGF-ß was determined (Fig.3.5.7 E). In the B7-H1 KO samples, no significant 
difference in TGF-ß concentration was found between cultures with or without MDSC 
(Fig.3.5.7 F). In the analysis of WT and B7-H1KO groups in comparison, again one 
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can see in Fig.3.5.7 D no significant difference in the concentration of TFG-ß in 
samples without MDSC. After adding inhibitory MDSC to activated cultures, no 
significant difference in TGF-ß concentration was observed between cultures of WT 
and B7-H1 KO splenocytes (Fig.3.5.2 D). 
 
 
Fig.3.5. 7 Quantification of TGF-ß in supernatants from cultures of WT or B7-H1 KO 
splenocytes (+/- activation) with and without MDSC from WT tumors. 
After 72 hours, the medium supernatant of the cocultures of CFSE labeled splenocytes and MDSC 
was collected and processed by Luminex approach. The concentration of TGF-ß was measured and 
analyzed using Bio-Plex Manager 4.0. Data are presented as column bar graphs with SEM (n =2-
3;*p<0.05 ,**p<0.01; two-way ANOVA (A,D) and T-test (B,C,E,F)) 
 
Taken together, the investigation of the cytokines revealed no significant difference 
between cultures of WT and B7-H1 KO splenocytes. Only in the analysis of VEGF 
concentration did we observe higher concentrations in the presence of WT MDSC in 
cocultures of both the WT and B7-H1 KO splenocytes. 
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3.6 Effects of chemo (5-FU) - and immunotherapy (IFNα) on tumor 
volume and metastasis rate of WT and B7-H1 KO tumor-bearing 
mice 
 
The goal of this experiment series was to examine the differences in tumor volumes 
and metastasis rates between WT and B7-H1 KO tumor-bearing mice as well as in 
WT or B7-H1 KO mice separately between different treatments. For this purpose 
Panc02 cells were implanted and the mice received different treatments of IFNα, 5-
FU or the combination of IFNα+5FU on Day 5, 7 and 9 post surgeries. Untreated 
mice were used as controls. After a period of four weeks the mice were killed, the 
tumors eviscerated and investigated. We also determined the peritoneal wall 
metastasis as well as metastasis of the colon and the liver.  
 
First, we compared the number of WT and B7-H1 KO tumor- bearing mice that 
developed visible tumors after Panc02 cell implantation. Furthermore, the tumor 
volumes of untreated WT and B7-H1 KO control mice, as well as after treatment with 
IFNα, 5-FU or the combination of IFNα+5FU, were determined.  
 
 
As one can see in Fig.3.6.1, a significantly lower number of untreated control B7-H1 
KO mice developed visible tumors compared to the control WT mice. Analyzing the 
differences in tumor volume, tumors of untreated control B7-H1 KO mice were of a 
significantly smaller volume compared to tumors of the control WT mice.  
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Four weeks after Panc02 implantation, the tumors were eviscerated, measured and the tumor rate and 
volume recorded and analyzed. Data from four independent experiments are presented as scatter plot 
or as stacked bars ((n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU);   *p<0.05, ***p<0.001; T-test 
and χ
2
-test) 
 
 
The comparison of tumor volume between WT and B7-H1 KO mice showed lower 
volumes in all four subgroups of B7-H1 KO mice compared to those groups of WT 
mice. Significantly lower volumes were found in the groups of 5-FU and IFNα+5-FU 
treatment compared to the untreated control group in WT tumor-bearing mice 
(Fig.3.6.2). 
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Fig.3.6. 1 Difference in the rate of tumor development and tumor volume between WT and B7-
H1 KO tumor-bearing mice. 
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Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα, 5-FU or the combination of 
IFNα+5-FU. Untreated mice were used as controls. Four weeks after Panc02 implantation, the tumors 
were eviscerated, measured and the tumor volume recorded and analyzed. Data from four 
independent experiments are presented as column bar graphs with SEM ((n = 9 for co, and n = 6 for 
IFNα; 5-FU; IFNα+5-FU) *p<0.05; two-way ANOVA) 
 
A clear tendency towards lower tumor rates was found in B7-H1 KO mice compared 
to WT mice after IFNα treatment. Beyond that, the analysis showed that the tumor 
volume of IFNα treated mice was significantly lower in B7-H1 KO mice compared to 
WT mice (Fig.3.6.3). 
 
 
 
 
 
 
 
 
 
 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα. Four weeks after Panc02 
implantation, the tumors were eviscerated, measured and the tumor rate and volume recorded and 
analyzed. Data from four independent experiments are presented as scatter plot or as stacked bars ((n 
= 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU); **p<0.01; T-test and χ
2
-test) 
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Fig.3.6. 2 Difference in the tumor volume between WT and B7-H1 KO tumor-bearing mice with 
and without treatment. 
Fig.3.6. 3 Difference in the rate of tumor development and tumor volume between WT and B7-
H1 KO tumor-bearing mice receiving IFNα treatment. 
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In the groups of 5-FU treated WT and B7-H1 KO mice, no significant difference in the 
rate of visible tumor development was registered between WT and B7-H1 KO tumor-
bearing mice. Instead, the tumor volume in 5-FU treated animals showed significantly 
lower volumes in the group of B7-H1 KO mice compared to WT mice (Fig.3.6.4).  
 
 
 
 
 
 
 
 
 
 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with 5-FU. Four weeks after Panc02 
implantation, the tumors were eviscerated, measured and the tumor rate and volume recorded and 
analyzed. Data from four independent experiments are presented as scatter plot or as stacked bars ((n 
= 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU);   *p<0.05;T-test and χ
2
-test) 
 
Comparing IFNα+5-FU treated WT to B7-H1 KO mice, the analysis of the tumor rate 
revealed significantly lower values in B7-H1 KO mice compared to WT mice. In the 
tumor volume of IFNα+5-FU treated animals, significantly lower volumes were 
determined for the group of B7-H1 KO mice compared to WT mice (Fig.3.6.5). 
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Fig.3.6. 4  Difference in the rate of tumor development and tumor volume between WT and 
B7-H1 KO tumor-bearing mice receiving 5-FU treatment. 
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Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα+5-FU. Four weeks after 
Panc02 implantation, the tumors were eviscerated, measured and the tumor rate and volume recorded 
and analyzed. Data from four independent experiments are presented as scatter plot or as stacked 
bars ((n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU); *p<0.05, ***p<0.001; T-test and χ
2
-test) 
 
 
 
Afterwards, we looked at the metastasis rates in WT and B7-H1 KO tumor-bearing 
mice. A significant difference in the rate of peritoneal wall metastasis was seen 
between the untreated control WT and B7-H1 KO mice, with lower rates in B7-H1 KO 
mice (Fig.3.6.6 A). In the rate of colon metastasis, a significantly lower rate was 
found in the untreated control B7-H1 KO mice compared to WT mice (Fig.3.6.6 B). 
The comparison between untreated control WT and B7-H1 KO mice for liver 
metastasis showed a clear tendency towards lower rates in B7-H1 KO mice 
compared to WT mice (Fig.3.6.6 C). 
 
Next, we compared the metastasis rates of peritoneal wall metastasis between WT 
and B7-H1 KO tumor-bearing mice who received treatment, either IFNα, 5-FU or the 
combination of IFNα+5-FU. The B7-H1 KO mice treated with IFNα developed 
significantly less often peritoneal wall metastasis compared to IFNα-treated WT mice 
(Fig.3.6.6 D). The rate of peritoneal wall metastasis in the groups of 5-FU treatment 
showed a tendency towards lower metastasis rates in B7-H1 KO mice compared to 
WT mice (Fig.3.6.6 E). In the IFNα+5FU treatment group, a tendency towards lower 
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Fig.3.6. 5 Difference in the rate of tumor development and tumor volume between WT and B7-H1 
KO tumor-bearing mice receiving IFNα+5-FU treatment. 
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metastasis rates was found in the B7-H1 KO mice compared to the WT mice 
(Fig.3.6.6 F). 
 
 
Fig.3.6. 6 Difference in the metastasis rate between WT and B7-H1 KO tumor-bearing mice with 
and without treatment. 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα, 5-FU or the combination of 
IFNα+5-FU.Four weeks after Panc02 implantation, the mice were dissected and the colon, liver and 
peritoneal wall metastasis recorded and analyzed. Data from four independent experiments are 
presented as stacked bars ((n = 9 for co, and n = 6 for IFNα; 5-FU; IFNα+5-FU);   *p<0.05, ***p<0.001; 
χ
2
-test) 
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tumor-bearing mice. We observed in the B7-H1 KO mice that both the frequency and 
the volume were significantly lower in the control as well as in all treatments 
compared to WT mice. Beyond that, the frequency of tumor metastasis was lower in 
all groups of B7-H1 KO mice compared to WT mice. 
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3.7 Effects of chemo (5-FU) - and immunotherapy (IFNα) on the 
survival rate of WT and B7-H1 KO tumor-bearing mice 
 
We used WT and B7-H1 KO tumor-bearing mice to determine the effect of the B7-H1 
regulatory molecule on the survival rate of WT and B7-H1 KO tumor-bearing mice. 
Beyond that, we examined the impact of our different treatments, compared to 
control, on the survival of tumor-bearing WT and B7-H1 KO mice. The WT and B7-H1 
KO tumor-bearing mice were divided in different treatment groups, receiving either 
IFNα, 5-FU or the combination of IFNα+5-FU at Day 5, 7, and 9 after the surgery. 
Untreated mice were used as controls. Based on the experiment setting, mice that 
survived showing no cancer signs caused by tumor growth, were killed on Day 60 
post op.  
In the untreated control group, the median survival of WT mice was 35 days after the 
implantation of tumor cells. In the B7-H1 KO tumor-bearing mice who were missing 
the regulatory molecule B7-H1, the result was undefined because all B7-H1 KO mice 
were alive and showed no signs of cancer. This resulted in aborting the experiment 
on Day 60 post op. Therefore, the difference between WT and B7-H1 KO tumor- 
bearing mice was highly significant (Fig.3.7.1 A). In the therapy group of IFNα, a 
median survival of 42 days was determined for WT mice, whereas in the same group 
of B7-H1 KO mice, the result was again undefined. This was because all B7-H1 KO 
mice were alive and showed no signs of cancer, again resulting in aborting the 
experiment on Day 60 post op. Therefore, this result was highly significant (Fig.3.7.1 
B). For the treatment group of 5-FU, a significant difference was seen between WT 
mice, with a median survival of 36 days compared to a median survival of 58.8 days 
in the 5-FU group of B7-H1 KO mice (Fig.3.7.1 C). The comparison between WT and 
B7-H1 KO tumor-bearing mice in the group of IFNα+5-FU, showed a significant 
difference between those mouse strains. In the WT mice, a median survival of 39 
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days was determined compared to an undefined parameter due to aborting the 
experiment on Day 60 post op for B7-H1 KO mice (Fig.3.7.1 D). 
 
Fig.3.7. 1 Difference in the survival rate between WT and B7-H1 KO tumor-bearing mice with 
and without treatment. 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα, 5-FU or the combination of 
IFNα+5-FU. Untreated mice were used as controls. The survival rate was recorded and analyzed. 
After Day 60, mice that survived were killed. Data from four independent experiments are presented 
as Kaplan-Meier curves ((n = 13 for co, and n = 9 for IFNα; 5-FU; IFNα+5-FU); **p<0.01, ***p<0.001; 
Log-rank test) 
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followed by the combination of IFNα+5-FU at 39 days and the  5-FU treatment at 36 
days. The lowest value was determined for the control group with a median survival 
of 35 days. In the groups of B7-H1 KO mice, the median survival was analyzed as 
undefined for the control IFNα and IFNα+5-FU treatments, caused by aborting the 
experiment on Day 60 after the Panc02 implantation. In the 5-FU treated B7-H1 KO 
mice, the median survival was registered at Day 58.5 post op. Therefore, no 
significant difference was found between the control and treatment groups of B7-H1 
KO mice (Fig.3.7.2). 
 
 
 
 
 
 
 
 
 
 
Mice were treated on Day 5, 7 and 9 after Panc02 implantation with IFNα, 5-FU or the combination of 
IFNα+5-FU. Untreated mice were used as controls. The survival rate was recorded and analyzed. 
After Day 60, the mice that survived were killed. Data from four independent experiments are 
presented as Kaplan-Meier curves ((n = 13 for co, and n = 9 for IFNα; 5-FU; IFNα+5-FU); Log-rank 
test) 
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treatment. Whereas between the single treatment groups compared to the control of 
either WT or B7-H1 KO tumor-bearing mice, no significant difference was seen. 
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3.8 Analysis of the correlation between tumor volume and specific 
immune cell populations 
 
After we analyzed several important cell populations involved in the anti-tumor 
immune response, we were also interested to see whether a relationship between the 
tumor volume and the frequency of specific immune cell populations can be found. 
Therefore, in this part of the experiment series we looked at the possible correlation 
between the analyzed tumor volume and specific cell populations, examined above 
phenotypically with FACS, using the Spearman correlation analysis. We could show 
that only for total MDSC, this correlation was of a statistical significance (Fig.3.2.6.1). 
 
 
 
 
 
 
 
 
 
 
The frequency of MDSC out of leukocytes was measured with flow cytometry, statistically analyzed 
and was set in correlation to the calculated tumor volume. Data from four independent experiments 
are presented as Spearman correlation ((tumors: n = 7 for co, n = 4-6 for IFNα; 5-FU; IFNα+5-FU); 
*p<0.05) 
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Fig.3.8 1 Correlation between tumor volume and the percentage of MDSC out of leukocytes. 
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Since a correlation between the tumor volume and the frequencies of single cell 
populations was only seen for the suppressive cell population of MDSC, this result 
underscores the importance of MDSC for the establishment and development of 
tumors.
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4. Discussion 
 
Pancreatic cancer (PDAC) remains to this day a devastating disease with low 
chances of recovery, which are often caused by its late recognition, high metastasis 
rate and poor response to therapies such as radiation or chemotherapy. Therefore, 
the development of new therapies is more than ever before of great importance. New 
therapeutic approaches, for example immune therapy, offer more opportunities for 
the treatment of pancreatic cancer.  
To make progress towards the goal of using immune therapy more effectively, a 
better understanding of the tumor immune response for PDAC is essential. 
Therefore, it is especially important to take a look at both the molecular as well as on 
the cellular level of immune regulation.  
Tumors are able to escape the action of the immune system by different 
mechanisms, for example by reducing the expression of MHC molecules or by 
shedding antigens from the outer cell membrane [127, 128]. On the molecular level, the 
immunoinhibitory molecules B7-H1 and B7-DC are involved in the process of cellular 
and humoral immune regulation caused by the PD-1-PD-L pathway, and play a 
critical role in the tumor immune escape [110, 129]. In the anti-tumor immune response, 
both parts of the cellular level, the activation arm of the immune system (CD4+/CD8+ 
T cells, DC) as well as the suppressive arm (MDSC, Treg), are important in 
understanding the detailed processes in pancreatic cancer. In this project, we 
analyzed the interplay between molecular and cellular processes in healthy mice to 
be able to better interpret our results later on in tumor-bearing mice.  
One of the important activating cells for the action of the anti-tumor immune response 
are CD4+/CD8+ T cells and their subsets. Dong et al. showed that in naïve B7-H1 KO 
mice, the absence of B7-H1 molecule increases the accumulation of CD8+ T cells in 
the liver [124]. Therefore, we analyzed them and their activation status in WT and B7-
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H1 KO healthy as well as tumor-bearing mice. Determining the subsets of 
CD4+/CD8+T cells between spleens of WT and B7-H1 KO healthy mice, significantly 
higher ratios of CD8+/CD4+ Tem and CD8+/CD4+ Tcm were seen in splenocytes of 
B7-H1 KO compared to WT healthy mice and consequently less CD4+/CD8+ Tnaive. 
Also in spleens of treated tumor-bearing B7-H1 KO mice, we found significantly 
higher frequencies of CD8+ Teff and Tem as well as CD4+ Tem and Tcm as 
compared to WT spleens. This leads us to the conclusion that in spleens of healthy, 
as well as tumor-bearing B7-H1 KO mice, the absence of B7-H1 molecule leads to 
higher ratios of CD4+/CD8+ Tem and Tcm. This is in line with the fact that the 
molecule B7-H1 inhibits activated CD4/CD8 T cells [130].This effect is important in the 
anti-tumor immune response. Generally, it was determined that CD8+ T cell 
accumulation positively correlates with the survival of patients in cancers shown in 
pancreatic cancer and other tumors like colorectal cancer [131, 132]. Also, in human 
colorectal cancer patients, Pages, Berger et al. demonstrated that a high ratio of 
tumor infiltrating memory and effector memory T cells was associated with lower 
invasiveness of the tumor [133]. This leads us to the conclusion, that our result 
represents a general effect in tumors. 
When we looked at the impact of chemo-and immunotherapy on the distribution of T 
cell subsets, we have seen significantly lower frequencies of CD4+ Tem and 
significantly higher ratios of CD8+ Tcm after applied IFNα+5-FU treatment in spleens 
of B7-H1 KO healthy mice. In spleens of tumor-bearing mice, we have also seen a 
trend towards lower frequencies of Teff and higher percentages of Tem and Tcm 
subsets after treatment with IFNα+5-FU. We observed in earlier experiments that the 
treatment with IFNα induced an increase in the number of effector memory CD8+ T 
cells and in the CD8+/CD4+ ratio in mice (Bazhin et al., unpublished data). It is widely 
known that chemotherapy not just kills tumor cells having a high rate of proliferation, 
it also rapidly affects dividing healthy cells like Teff. This could possibly explain the 
lower Teff frequencies observed by us.  
The activation status of CD4+/CD8+ T cells is also an important characteristic of these 
cells, and therefore, we also took a detailed look at the activation status of 
CD4+/CD8+ T cells by analyzing the expression of CD69 early activation marker. In 
both experiment series, using either healthy or tumor-bearing WT and B7-H1 KO 
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mice, we saw no significant difference in CD69 expression between both mouse 
strains. This is in line with observations made in a leukemia tumor model by Salih, 
Wintterle et al., who did not find significant differences in CD69 expression of 
CD4+/CD8+ T cells in the presence of the anti-B7-H1 antibody [134]. Considering the 
impact of chemo- and immunotherapy on the activation status, as expected after the 
applied IFNα and IFNα+5-FU therapy, a significant increase in the frequency of 
CD69+ cells was determined in both healthy and tumor-bearing WT and B7-H1 KO 
mice. Actually, one would expect a higher CD69 expression in B7-H1 KO mice 
compared to WT mice, since this molecule is not inhibited in B7-H1 KO mice. A 
possible explanation for this is that B7-H1 KO mice lacking B7-H1 regulatory 
molecule from birth on, contrary to blocking B7-H1 molecule with antibodies in mice 
with an already developed and mature immune system. This is due to the fact that 
the immune system of B7-H1 KO mice tries to maintain the activating/suppressive 
balance by regulation.  
Another important cell population of the activating arm of the immune cells are 
dendritic cells. DC are specialized in antigen presentation, which plays a key role in 
the initiation of primary immune responses. Several cytokines and prostaglandins are 
known to influence the maturation status of DC, for example TNF-α, IL-1ß, IL-6 or 
PGE2 [135]. Until today, it is not yet fully understood which role the molecule B7-H1 
plays in this context, since it can also be expressed by the cell population of DC [136]. 
After maturation, DC stimulate antigen-specific T cells [137]. In spleens of healthy WT 
and B7-H1 KO mice, lower ratios of cDC were found after IFNα treatment. 
Furthermore, significantly lower percentages of cDC in spleens were determined after 
treatment of tumor-bearing B7-H1 KO mice with IFNα and IFNα+5-FU. For pDC, we 
found no meaningful differences. Analyzing the maturation status of cDC and pDC, 
only in spleens of WT tumor bearing mice did we find a decrease in the ratio of 
mature cDC after 5-FU and IFNα+5-FU treatment and a decrease in mature pDC 
ratio after IFNα+5-FU treatment. This is contrary to previous studies showing that 
IFNα enhanced the maturation of DCs [138].  One possible explanation for this can be 
the different experimental setting as well as that the approach of the other group was 
performed in vitro with human cells. We also analyzed the molecules CD80 and 
CD86 on mature cDC/pDC. Between spleens of WT and B7-H1 KO tumor-bearing 
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mice, comparable results were found. This is in line with observations made by 
Brandl, Ortler et al. who also observed comparable expressions of molecules like 
CD80, CD86 or B7-DC between WT and B7-H1 KO mice [139]. This allows us to 
assume that the presence/absence of the molecule B7-H1 has no decisive impact on 
the expression of those molecules. In spleens of B7-H1 KO tumor-bearing mice, 
IFNα and 5-FU treatment led to an increase in the ratio of CD80+ mature cDC, and 
moreover, IFNα treatment also led to an increase in the percentage of CD86+ mature 
cDC. This observation is supported by the data of in vitro studies where treatment of 
immature cDC with IFNα resulted in an upregulation of surface expression of 
molecules including CD80 and CD86 [140, 141]. This underscores the activating impact 
of IFNα, at least in B7-H1 KO tumor-bearing mice. 
The molecular and cellular level of the immunosuppressive arms and the crosslinks 
between both of them is the other important aspect we need to consider to fully 
understand the tumor immunology of PDAC. Therefore, we analyzed the precise role 
the B7-H1 expression plays on cells of the immune system with the main focus on 
MDSC in the context of anti-tumor immunity in PDAC. Immunosuppressive MDSC 
(Gr-1+CD11b+ compartment) are a heterogeneous group of cells that consists of 
immature myeloid cells from the bone marrow. In pathological situations such as 
sepsis, infectious disease or cancer, the differentiation into mature cells does not 
occur, resulting in the expansion of MDSC [95]. In our project, we were especially 
interested in Gr-1+CD11b+ cells and their subsets in both a healthy and tumor 
condition, and additionally, how those cells are influenced by B7-H1 molecule 
expression. Beyond that, we compared the impact of chemo- and immunotherapy on 
this cell population. Even the absence of B7-H1 molecule on immune cells in B7-H1 
KO mice showed such a large effect that we nearly had no visible tumors. Since we 
were especially interested in the interplay between MDSC and the B7-H1 molecule, 
we therefore used the tumors of B7-H1 KO mice to analyze this cell population in 
more detail. The linkage between MDSC and the regulatory molecule B7-H1 was 
already considered as an important aspect in the tumor immune mechanisms and 
was revealed by several scientists [99], but up to now, it has not been entirely 
examined and understood. We analyzed for the first time the connection between Gr-
1+ CD11b+ cells and the molecule B7-H1, as well as the impact of chemo- and 
immune therapeutics in a healthy steady-state situation. The results revealed 
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significantly lower frequencies of Gr-1+CD11b+ cells in B7-H1 KO splenocytes after 
treatment of the culture with 5-FU compared to those of WT healthy mice. This is in 
line with our earlier observations, examining the frequency of Gr-1+ CD11b+ cells in 
freshly splenocytes of healthy, untreated WT and B7-H1 KO mice (unpublished data). 
We found significantly lower ratios of Gr-1+ CD11b+ cells in B7-H1 KO compared to 
WT healthy mice. We can suggest that the molecule B7-H1 is at least one of the 
regulators that influences the Gr-1+ CD11b+ compartment. This is also supported by 
the results seen in tumor-bearing mice, where the analysis of MDSC population 
revealed lower frequencies of total MDSC in B7-H1 KO mice compared to WT mice. 
Additionally, the comparison between spleens of WT and B7-H1 KO tumor-bearing 
mice showed significantly lower ratios of MDSC in B7-H1 KO spleens compared to 
WT mice in all treatment groups and the control. This observation is in line with other 
observations made in ovarian cancer and ret melanoma models, showing a 
consistent functional interplay between the regulatory molecule B7-H1 and MDSC 
[142, 143]. So we can assume that it could represent a general effect on a various 
number of cancers. Based on the expression of the two epitopes of Gr-1, Ly-6G and 
Ly-6C, MDSC in mice can be divided in two subsets: granulocytic MDSC 
(CD11b+LY6G+LYC6low) and monocytic MDSC (CD11b+LY6G-LY6Chigh) [99]. Youn, 
Nagaraj et al. showed that in naïve mice, the ratio between gMDSC and mMDSC 
was 3:1. More often, the gMDSC subset was increased in tumor models, whereas the 
mMDSC subset was only increased in a few tumor models [99]. Beyond that, the ratio 
between gMDSC and mMDSC is much lower in the tumor site than in lymphoid 
organs [144]. In contrast, in our experiments we showed that in tumors of B7-H1 KO 
tumor-bearing mice, the ratio of gMDSC was decreased compared to WT tumor 
bearing mice. One possible explanation for our findings could be the tumor potential 
of Panc02 cells in B7-H1 KO mice, which seems to differentiate from the tumor 
potential in tumor models analyzed by Youn, Nagaraj et al. In spleens of B7-H1 KO 
mice treated with IFNα, we saw a shift in the MDSC subset towards a higher 
proportion of gMDSC and respectively lower frequencies of mMDSC. Examining the 
impact of chemo- and immunotherapy on MDSC, in WT tumors higher frequencies of 
total MDSC were seen after IFNα+5-FU treatment compared to the control group. 
Analyzing the impact of therapy on spleens of WT and B7-H1 KO tumor-bearing 
mice, we observed no significant differences in the frequencies of MDSC between 
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the groups of WT spleens. Instead, in B7-H1 KO spleens we observed higher ratios 
of MDSC in all treatment groups compared to the control, especially after we applied 
5-FU and IFNα+5-FU treatments. These effects do not endorse the findings of 
Vincent, Mignot et al. who showed that a 5-FU treatment reduced the number of 
MDSC in the spleen and in the tumor bed of EL4 thymoma subcutaneous tumor-
bearing mice [145]. This shows us that this is not a general effect of 5-FU treatment, 
but is rather specific and dependent upon factors like the tumor model and the 
chosen treatment regimen, which explains the contrary observation. Another aspect 
we have to consider is the phagocytic activity of MDSC, which can give a possible 
explanation for our observations [146]. The chemotherapeutic agent 5-FU kills cells, 
and those cell components phagocytosed by MDSC can possibly lead to an 
expansion of this cell population. The functionality of MDSC is of particular 
importance in the context of the suppressive capacity of this cell population.  
A fact in cancer is that the activation of MDSC enhances their expression of arginase 
1 (ARG1) and inducible nitric oxide synthase (iNOS), leading to augmentation of nitric 
oxide (NO) production [95]. In spleens of WT and B7-H1 KO tumor-bearing mice, we 
found no significant difference in the frequencies of iNOS+ and Arg+ MDSC. Instead, 
in tumors of untreated tumor-bearing WT and B7-H1 KO mice, significantly lower 
ratios of iNOS+ gMDSC and mMDSC were determined in tumors of B7-H1 KO 
compared to WT tumor-bearing mice. This observation is supported by an ovarian 
cancer mouse model, where it was shown that the blockade of B7-H1 with antibodies 
resulted in an inhibition of the activity and expression of ARG I [147]. However, in 
addition to the data of Liu et al. we were the first who were able to show that also the 
production of iNOS is reduced in B7-H1 KO mice. This lets us conclude that B7-H1 
KO mice not only have less MDSC frequencies, but also that those MDSC are not as 
functional in the production of NO-synthase. Especially interesting is that already the 
blockade of B7-H1 on immune cells (in B7-H1 KO mice) is sufficient enough to see 
an effect in the functional status of MDSC as compared to the blockade of both 
immune and tumor cells with antibodies, as investigated by Liu, Yu et al. 
Several therapeutic agents have been described to influence the production of iNOS 
and arginase. Serafini, Meckel et al. examined the effect of a targeted therapy using 
phosphodiesterase-5 inhibitors, and found out that it can down-regulate ARGI and 
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iNOS in murine MDSC, resulting in an increased spontaneous anti-tumor response 
[148]. However, another group examined the influence of IFNα on myeloid suppressor 
cells in a C26-colon carcinoma tumor model, and detected that IFNα therapy led to a 
more mature phenotype of MDSC with less immunosuppressive capacity, and 
furthermore, a trend towards lower ARG activity in MDSC of tumor-bearing mice [149]. 
In our experiments we found no influence from the applied chemo- and 
immunotherapy on the production of iNOS and ARG. A possible explanation for the 
varying results described above could be the different tumor model used by the other 
scientific groups, or the different applied therapeutic agents.  
Another important aspect of antitumor response is the suppressive capacity of MDSC 
and the susceptibility of T cells to MDSC-mediated suppression. To analyze this, we 
performed the CFSE proliferation assay. As expected, proliferation of CD4+ and CD8+ 
T cells was seen after activation with CD3/CD28 activating antibody. In cultures of 
B7-H1 KO splenocytes, this activation was lower compared to cultures of WT 
splenocytes. Contrary to our results seen in B7-H1 KO mice, it was shown by Blank, 
Kuball et al. that anti B7-H1 antibody augmented the T cell expansion and 
proliferation [150]. This let us speculate that in B7-H1 KO mice, compensatory 
mechanisms try to keep the stimulatory/suppressive axis in balance resulting in a 
lower activation capacity of splenocytes. After we added WT MDSC to the cultures 
containing either WT or B7-H1 KO splenocytes, a significant suppression was seen in 
both WT and B7-H1 KO cultures. Between those, no obvious difference was 
determined. This shows the immunosuppressive capacity of MDSC on activating 
immune cells. It is also an interesting question if the absence of B7-H1 molecule on 
MDSC of B7-H1 KO mice could lead to certain effects. Unfortunately, we were 
technically not able to examine this aspect, but it would be interesting to investigate 
this point in the future. 
The second cell population of the immunosuppressive arm we examined in our 
project are Treg. Since it was shown before that B7-H1 molecule plays an important 
role in the function of Treg [151-153], we also analyzed this cell population. In our in 
vitro experiment, we observed significantly higher percentages of Treg within 
splenocytes of healthy B7-H1 KO mice in the control as well as in all treatment 
groups compared to WT. This does not correlate with previous observations that B7-
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H1 expression promotes a higher accumulation of Treg [152, 154, 155]. However, these 
results were obtained in a tumor model. In a healthy state, it is tempting to assume 
that the immune system of B7-H1 KO mice tries to keep the stimulatory/suppressive 
balance by increasing the number of Treg.  
As we had already noted several differences between WT and B7-H1 KO healthy and 
tumor-bearing mice, we were also interested in whether the expression of the 
regulatory molecules B7-H1/B7-DC can also be influenced by the action of different 
cells as well as by therapeutic agents. The regulatory molecules B7-H1 and B7-DC 
are involved in the process of cellular and humoral immune regulation caused by the 
PD-1-PD-L pathway, and play a critical role in the tumor immune escape [110, 129]. So 
far, the expression of B7-H1 in tumors was described in various types of carcinoma, 
including pancreatic cancer [116, 120]. It is known that B7-H1 expression can act as 
both an activator on DC as well as a suppressor on MDSC. Therefore, in our 
experiments the difference in regulatory B7-H1 in WT and B7-DC molecule 
expression in B7-H1 KO was analyzed in healthy and tumor-bearing mice. 
Furthermore, we determined a possible impact of chemo- and immunotherapy on the 
expression of those regulatory molecules. In splenocytes of healthy WT and B7-H1 
KO mice, for the cell population of mature cDC we found a significant increase in the 
frequency of B7-DC+ cDC in B7-H1 KO mice after the treatment of cultures with IFNα 
and IFNα+5-FU. As we looked into our in vivo experiments at splenocytes of tumor 
bearing WT and B7-H1 KO mice, a significant decrease in B7-H1 MFI of total MDSC 
was found after treatment of WT mice with IFNα+5-FU. It was shown that the 
expression of cytokines can be influenced by B7-H1/B7-DC molecule. Therefore, we 
took a detailed look at this aspect. It was observed before that several cytokines are 
known to specifically induce up-regulation of B7-H1 molecule in DCs, for example IL-
27 [122], IFNß in multiple sclerosis patients [156] as well as IFNɣ in patients with 
pancreatic cancer [120] or chronic hepatitis b [157]. Also B7-DC expression was found 
to be inducible on DCs after stimulation with cytokines like IFNɣ, IL-4 or GM-CSF 
[158]. This is partially in line with our observations, that cytokines in our experimental 
setting IFNα can modulate the expression of immunosuppressive molecules like B7-
H1/B7-DC as well as their intensity of expression per cell (MFI). To what extent 5-FU 
also has an impact on B7-H1/B7-DC expression needs to be investigated further. 
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This because 5-FU kills cells, and by inference, activates DC and MDSC and 
therefore possibly has an impact on B7-H1 molecule expression. 
To furthermore compare WT and B7-H1 KO mice, we also examined the cytokine as 
well as growth factors produced by those two mouse strains in serum samples of 
tumor-bearing mice as well as in medium supernatants from the coculture of 
splenocytes and MDSC from the proliferation assay. Due to the anti-inflammatory 
effect and the impact of those cytokines on aspects like tumor volume, we analyzed 
those cytokines in detail.  
In our work, lower VEGF concentrations were found in B7-H1 KO compared to WT 
tumor-bearing mice. This is not surprisingly since VEGF is a proangiogenic growth 
factor involved in the pathogenesis of many cancers [159, 160]. Folkman showed that 
the angiogenesis leads to the spread of tumor cells resulting in metastasis [161, 162]. 
Despite conflicting results, with no correlation to the outcome in pancreatic cancer 
patients [163, 164], in more than 90 percent of pancreatic cancer, overexpression of 
VEGF and its receptors was registered as correlating with larger tumor size, distant 
metastasis and poor prognosis [165-170]. In line with the above seen results, the 
determined lower VEGF concentrations observed in B7-H1 KO mice is advantageous 
and encourages our linkage between B7-H1 KO mice and smaller tumor volumes 
and longer survival rates discussed later on in more detail. Analyzing the impact of 
chemo- and immunotherapy on the VEGF serum concentration, in WT tumor-bearing 
mice, the highest concentration was found in the untreated control group and the 
lowest in the combined group receiving IFNα+5-FU treatment. Between the treatment 
groups and the control in B7-H1 KO tumor-bearing mice, we found no significant 
difference. Our results are partially in line with earlier observations made in human 
neuroendocrine tumors, that IFNα inhibits VEGF gene transcription [171]. Also others 
have noted before that therapeutics can have an impact on the VEGF concentration, 
for example Legros, Bourcier et al. showed that Imatinib mesylate decreases VEGF 
plasma concentration in patients suffering from myeloid leukemia [172]. This allows us 
to speculate that at least in WT mice, the combined applied therapy leads to a 
decrease in VEGF concentration, which has a positive impact on those animals. 
Another important aspect we need to consider in the context of VEGF concentration 
is that on the one hand, this cytokine has an activating impact on MDSC, but on the 
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other hand, can also be produced by MDSC [173, 174]. To further pursue the question 
whether MDSCs also have an impact on the VEGF concentration, we therefore 
examined the change in VEGF concentration in medium supernatants with and 
without the presence of immunosuppressive WT MDSC. It was shown before that 
VEGF is one of the factors able to induce MDSC expansion [173] and beyond that, 
VEGF serum levels directly correlate with the frequency of MDSC in the blood and 
spleen (reviewed in [175, 176]). Since we observed in our experiment higher 
concentrations of VEGF in the presence of WT MDSC in both supernatants of 
cultures containing WT or B7-H1 KO splenocytes, this is in line with previous 
investigations. Taken together, a feedback between VEGF concentration, the 
immunosuppressive capacity of MDSC and B7-H1 molecule can be drawn and leads 
us to several main conclusions. First, B7-H1 KO tumor-bearing mice have an 
advantage over WT mice due to lower serum VEGF levels. Second, the positive 
effect of combined chemo- and immunotherapy in WT mice resulting in lower VEGF 
concentrations and therefore less pronounced tumor-cell spread and distant 
metastasis. Third, higher MDSC ratios lead to increased VEGF concentrations. Since 
we have discussed earlier that B7-H1 KO tumor-bearing mice have less MDSC, this 
is another aspect in the prerequisite for a lower metastasis rate and a longer survival.  
Il-1ß plays an important role in tumorigenesis and development. It is known that this 
cytokine expression is augmented in most human cancers and that high plasma IL-
1ß levels are associated with a worse prognosis (reviewed in [177]). Moreover, it is known 
that B7-H1 inhibits anti-cancer immune response by the interaction with its T 
lymphocyte ligand PD-1, resulting in the impairment of cytokine production [63, 178] 
and T lymphocyte anergy and apoptosis [112, 179-181]. Our results of the analysis of the 
examined cytokine IL-1ß revealed significantly lower concentrations in serum 
samples of B7-H1 KO compared to WT tumor-bearing mice. The analysis of chemo- 
and immunotherapy impact revealed significantly higher IL-1ß concentrations in 
serum samples of IFNα and IFNα+5-FU treated B7-H1 KO mice. It was shown by Xu, 
Yin et al. that IL-1ß inhibition reduces tumor growth by limiting inflammation, and 
furthermore, by inducing the maturation of MDSC into M1 macrophages [177]. We 
showed that B7-H1 KO mice have lower IL-1ß serum concentrations, and this result 
lets us assume that it is another factor resulting in lower MDSC ratios and lower 
tumor volume in B7-H1 KO mice that was observed by us.   
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IL-6 belongs to the pro-inflammatory cytokines and is linked to poor prognosis in 
different hematopoietic and solid tumors [182, 183]. We found no significant differences 
in IL-6 serum concentrations between WT and B7-H1 tumor-bearing mice. In 
samples of WT tumor-bearing mice, the treatment with IFNα+5-FU increased the 
cytokine production of IL-6, whereas in samples of B7-H1 KO tumor-bearing mice, a 
5-FU treatment increased the concentration of IL-6. As it is known that IL-6 
concentration is triggered by IL-1ß cytokine in the tumor microenvironment [184], it is 
not surprising that in our experiment, both the concentration of IL-6 and IL-1ß are 
increased in serum samples of tumor-bearing mice.  
So far, we have discussed the changes and differences in systemic cytokine 
concentrations. As a next step, we also analyzed the medium supernatants of our 
cocultures containing activated/ non-activated splenocytes and immunosuppressive 
MDSC in detail. IFNɣ is a cytokine that promotes anti-tumor immunity and moreover 
has proinflammatory characteristics important to the action of T cells (reviewed in [185]). 
In our results, we have seen significantly higher IFNɣ concentrations after activation 
of splenocytes with CD3/CD28 in both mouse strains. The comparison of B7-H1 KO 
to WT samples showed significantly higher concentrations of IFNɣ in the 
supernatants of B7-H1 KO splenocytes. This is in line with data showing that  thevB7-
H1 blockade with antibodies and induce a significant increase in IFNɣ concentration 
in a mouse pancreatic tumor model [186]. Furthermore, after adding WT MDSC to the 
culture, a tendency towards decreased IFNɣ concentrations was determined. With 
our results we were able to demonstrate a higher IFNγ production in cultures of B7-
H1 KO splenocytes, which can at least partially explain the higher anti-tumor 
immunity of B7-H1 KO mice resulting in lower tumor volumes and longer survival 
rates. Our data also revealed the immunosuppressive effect of MDSC, explaining the 
decrease in IFNγ concentration. With our observations, we can suggest that B7-H1 
molecule plays an important role for IFNɣ production. 
Concerning IL-10, it is generally known that this cytokine has anti-inflammatory 
capacities. However, IL-10 cytokine is important for maintaining the IFNɣ/IL-10 
balance in the organism. It was observed that the presence of B7-H1 molecules is 
associated with an increase in IL-10 cytokine production [63]. Our analysis of IL-10 
cytokine concentration in medium supernatants showed however higher 
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concentrations of this cytokine after activation with CD3/CD28 antibody in samples of 
B7-H1 KO splenocytes compared to WT splenocytes. This could explain the higher 
concentration of IL-10 without an impact of the molecule B7-H1 on this result. Also in 
other diseases like infection with Plasmodium vivax malaria, significantly higher 
levels of both pro- (IFN-ɣ) and anti-inflammatory (IL-10) cytokines were observed 
[187], showing that parallel increases can be found in different pathological situations. 
Furthermore, after adding WT MDSC to the culture, in samples containing WT 
splenocytes a highly significant increase in IL-10 concentration was determined. 
Since we did not see an increase in IFNɣ concentration in the presence of MDSC, 
this would likely point out in this case that the IFNɣ/IL-10 balance plays no decisive 
role.  
 
Fig.4. 1 Differences in cytokine and growth factor concentration between WT and B7-H1 KO 
tumor-bearing mice with and without treatment 
 
From our data, one can see that such immunological players as discussed above, 
can probably be linked and influenced by each other. However, the most important 
aspect in pancreatic cancer patients is the clinical outcome. It was reported that B7-
H1 expression on tumor cells correlates with an inferior clinical outcome in various 
solid human cancers like kidney [118], breast [188], ovarian [189], bladder [190], liver [191], 
and gastric [119] cancer. Previously, it was shown in PDAC patients that high B7-H1 
expression is correlated to an unfavorable prognosis for these patients [116, 120]. In 
our survival experiment series, comparing WT and B7-H1 KO tumor-bearing mice in 
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an orthotopic Panc02 tumor model, we were able to show that B7-H1 KO tumor-
bearing mice had a significantly higher survival rate compared to WT mice, 
regardless the chosen treatment. This is also consistent with observations made in 
colorectal cancer patients, where a longer survival was determined for patients with 
lower B7-H1 expression compared to those with a higher expression of this molecule 
[192]. This shows that a longer survival due to lower/no B7-H1 molecule expression is 
not specific for one cancer type, but is valid for various tumors in patients and mice 
and can be considered as a general effect. 
The success of anti-tumor therapy is measured on a longer survival rate, and 
moreover, on parameters such as tumor size and distant metastasis rate. Therefore, 
we used an experiment series to examine the differences in tumor development, 
tumor volume and metastasis rates between our two mouse strains as well as 
between the different applied treatments. Significantly lower volumes of visible 
tumors were found in B7-H1 KO mice in the control group as well as in all treatment 
groups compared to WT mice. In a pancreatic tumor model, the blocking of either B7-
H1 or B7-DC with antibodies revealed an efficient inhibition of tumor growth [186]. In a 
murine acute myeloid leukemia model, it was shown that mice lacking B7-H1 as well 
as mice treated with a B7-H1 blocking antibody, had a significantly lower tumor 
burden and survived longer [193]. Also in other cancers like melanoma, renal-cell and 
ovarian cancer, similar results, including tumor shrinkage, were observed after 
applying a B7-H1 blocking antibody [194]. Since we and others showed that the 
absence of B7-H1 molecule leads to lower tumor volumes in several tumor models, 
we assume that it is a general effect and independent of the tumor model as well as 
of the type of blockade by the B7-H1 molecule. Especially remarkable at this point is 
that blocking B7-H1 molecules on immune cells sufficiently reveals what an important 
role immune cells have in a cancer situation. Beyond that, as expected the impact of 
chemo- and immunotherapy can also influence the tumor volume. We demonstrated 
a significantly lower tumor volume in both mouse strains after treatment with 5-FU 
and the combination of IFNα+5-FU compared to the controls. This is supported by 
the data in a hematoma 22 tumor model, where a reduction of the tumor volume was 
seen in mice after 5-FU treatment [195]. This confirms our results that treatment of 5-
Fu is able to reduce tumor volume in pancreatic cancer, but also in other cancers as 
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investigated by others. In addition, IFNα with its considered radio- and chemo 
sensitizing effect, is able to improve the impact of chemotherapy [55, 56]. 
By analyzing the metastasis rate of tumor-bearing mice, we observed lower rates of 
visible distant metastasis in B7-H1 KO compared to WT tumor-bearing mice. This 
observation was made for peritoneal wall metastasis as well as for the analysis of 
liver and colon metastasis. Also in patients with colorectal cancer, Song, Chen et al. 
reported a correlation between the overexpression of B7-H1 molecule and distant 
metastasis [192]. In other human cancers like Soft Tissue Sarcomas [196] and renal cell 
cancer [197], the B7-H1 expression in those patients was associated with distant 
metastasis and a poor prognosis. This confirms our hypothesis that the B7-H1 
regulatory molecule plays a decisive role resulting in a poor prognosis for patients 
suffering from cancer, and that this effect is not specific for pancreatic cancer seems 
to be a general observation seen in tumor patients. 
A following important question is whether a causal relationship between the tumor 
volume and different cells of the immune system can be drawn. To examine this, we 
analyzed possible correlations by evaluating the data from our different experiment 
series using Spearman correlation analysis. Only between the tumor volume and 
MDSC, was a significant correlation observed in the analysis. Previously, published 
data from animal studies also suggested a linear relationship between primary tumor 
size and MDSC [198]. Between other cell fractions like Treg, DC or T lymphocytes, 
and the tumor volume of tumor-bearing mice, no such connection was recognizable. 
This confirms once again the immunosuppressive capacity of MDSC in a tumor 
milieu and the important role of MDSC in the establishment and development of 
PDAC. 
Summarizing the results of this project, the absence of the regulatory molecule B7-
H1 seems to considerably influence tumor development and establishment, and 
furthermore, the survival rate in tumor-bearing B7-H1 KO mice. A number of different 
but related factors have to be taken into consideration. First, the decreased number 
of immunosuppressive MDSC in B7-H1 KO mice seems to have a major impact. 
Second, the higher frequency of especially CD8
+
 T cell subsets like Tem and Tcm is 
associated with the absence of the B7-H1 molecule. Third, the lower serum 
concentration of the proangeniogenic growth factor VEGF in tumor-bearing B7-H1 
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KO mice diminishes the tumor cell spread resulting in lower rates of distant 
metastases and a more favorable prognosis. Fourth, the higher IFNy and lower IL-1ß 
level in B7-H1 KO mice compared to WT mice. But most important, the lower tumor 
volume and distant metastasis rates as well as the longer survival in B7-H1 KO mice 
compared to WT mice.  
 
 
Fig.4. 2 Summarized presentation of the most meaningful results 
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5. Summary 
PDAC remains today a devastating disease characterized by a poor prognosis and 
low survival rates in patients. This is primarily due to its late recognition, high 
metastasis rates and poor response to curative therapies such as chemotherapy or 
radiation. Immune therapy could provide promising opportunities for the treatment of 
PDAC. But first, it is important to analyze the immune system of PDAC patients, 
respectively mice. In this work, we analyzed the precise role of the B7-H1 expression 
on cells of the immune system, with the main focus on MDSC in the context of anti-
tumor immunity in PDAC in both in vitro and in vivo experiments using WT and B7-H1 
KO healthy and tumor-bearing mice. Higher ratios of CD4+ /CD8+ Tem and Tcm were 
seen in splenocytes of B7-H1 KO compared to WT healthy and tumor-bearing mice. 
The analysis of the MDSC population revealed lower frequencies of total MDSC in 
spleens of B7-H1 KO compared to spleens of WT tumor-bearing mice. After the 5-FU 
and IFNα+5-FU treatment, higher ratios of MDSC were seen in B7-H1 KO spleens. In 
tumors of B7-H1 KO mice, significantly lower ratios of MDSC and a decreased ratio 
of gMDSC were observed compared to that in WT tumor-bearing mice. Furthermore, 
significantly lower ratios of iNOS+ gMDSC and mMDSC were determined in tumors of 
B7-H1 KO compared to untreated WT tumor-bearing mice. In splenocytes of tumor-
bearing WT mice, a significant decrease in B7-H1 MFI of total MDSC was found after 
treatment with IFNα+5-FU. Lower VEGF concentrations were found in serum 
samples of B7-H1 KO compared to WT tumor-bearing mice, and higher 
concentrations were found in medium supernatants in the presence of WT MDSC. 
The analysis of IL-1ß revealed significantly lower concentrations in serum samples of 
B7-H1 KO compared to WT tumor-bearing mice. For IFNɣ, significantly higher 
concentrations were found in medium supernatants containing B7-H1 KO 
splenocytes. In our survival experiment series, we demonstrated a significantly higher 
survival rate as well as a lower tumor frequency, tumor volume and distant 
metastasis rate in B7-H1 KO compared to WT mice, regardless the chosen 
treatment. Beyond that, a significantly lower tumor volume was determined after 
treatment of both mouse strains with 5-FU and IFNα+5-FU. In summary, through this 
work we characterized the immune system of WT and B7-H1 KO healthy and PDAC -
bearing mice with a main focus on the molecule B7-H1 and MDSC, as well as the 
impact of chemo- and immune therapy. 
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6. Zusammenfassung 
Charakteristisch für das Pankreasadenokarzinom (PDAC) sind eine schlechte 
Prognose und geringe Überlebensraten verursacht durch zu späte Diagnose, hohe 
Metastasierungsraten und geringes Ansprechen auf Chemotherapie oder 
Bestrahlung. Immuntherapie könnte einen neuen Therapieansatz des PDAC 
darstellen. Zunächst ist es wichtig, das Immunsystem betroffener Patienten/Mäuse 
genauer zu analysieren. In dieser Arbeit haben wir die Rolle der B7-H1 Expression 
auf Zellen des Immunsystems, besonders MDSC, im Zusammenhang mit der Anti-
Tumor-Immunität im PDAC in in vitro und in vivo Experimenten an WT und B7-H1 KO 
gesunden und tumortragenden Mäusen untersucht. Einen höheren Anteil an CD4+ 
/CD8+ Tem und Tcm gab es in Splenozyten von gesunden und tumortragenden B7-
H1 KO im Vergleich zu WT Mäusen. Niedrigere Prozentzahlen von MDSC wurden in 
Milzen von tumortragenden B7-H1 KO im Vergleich zu WT Mäusen gesehen. Nach 
5-FU und IFNα+5-FU Behandlung stieg die Anzahl an MDSC in B7-H1 KO Milzen an. 
B7-H1 KO Tumoren wiesen signifikant niedrigere Anteile von MDSC und gMDSC auf 
als WT Tumoren. Die Zahl an iNOS+ gMDSC und mMDSC war signifikant geringer in 
Tumoren unbehandelter B7-H1 KO als in WT Mäusen. Weiterhin wurde in 
Splenozyten tumortragender WT Mäuse ein signifikant geringerer B7-H1 MFI Wert 
von MDSC nach IFNα+5-FU Behandlung bestimmt. In Serumproben von B7-H1 KO 
tumortragenden Mäusen sind geringere VEGF Konzentrationen festgestellt worden 
und in Mediumüberständen waren sie höher in der Anwesenheit von MDSC. Die IL-
1ß Serumkonzentration waren signifikant niedriger in tumortragenden B7-H1 KO als 
in WT Mäusen. Zudem wurden signifikant höhere IFNɣ Konzentrationen in 
Mediumüberständen mit B7-H1 KO Splenozyten gemessen. Anhand unserer 
Survival-Experimente haben wir sowohl eine signifikant höhere Überlebensrate als 
auch niedrigere Tumorfrequenzen, Tumorvolumina und Metastasierungsraten in B7-
H1 KO Mäusen  gesehen im Vergleich zu WT, unabhängig von der Therapie. Zudem 
wurden in beiden Mausstämmen signifikant niedrigere Tumorvolumina nach 5-FU 
und IFNα+5-FU Behandlung bestimmt. Zusammenfassend haben wir in dieser Arbeit 
das Immunsystem von gesunden und PDAC tumortragenden WT und B7-H1 KO 
Mäusen, mit dem Schwerpunkt auf dem Molekül B7-H1 und MDSC sowie den 
Einfluss von Chemo- und Immuntherapie, untersucht. 
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